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Abstract
Efficient transcription of the human immunodeficiency virus type 1 (HIV-1) requires the
interaction of the viral protein Tat with the trans-activation response (TAR) stem-loop of
the long-terminal repeat (LTR) portion of nascent viral RNA. The production of viable
transcripts is enhanced dramatically by the interaction of HIV-1 Tat with the host protein
human Cyclin T1. Interaction with hCycT1 remodels Tat protein contributing a single
cysteine residue that is critical to the formation of the second of two zinc fingers (Zn2).
Here we suggest that it is the presence of this critical cysteine residue and not the
presence of arginine residues from human Cyclin T1 that imparts high affinity and
specificity to the interaction with HIV-1 TAR RNA. Crucial structural features of this
interaction remain unresolved by NMR or existing crystal structures. Specifically, the
structure of the Tat activation domain (AD), and Tat interaction with hCycT1 while
bound to HIV-1 TAR RNA remain elusive. Much of the difficulty in obtaining structural
data is a result of the notoriously difficult expression of native HIV-1 Tat caused in large
part by the high cysteine count, and poor solubility of the Tat protein. This work presents
a protocol for the expression and purification of a high affinity recombinant chimeric
protein which includes the full 101 amino acid Tat protein fused to an essential minimal
portion of CycT1m) necessary for TAR binding in sufficient purity and concentration for
structural study by nuclear magnetic resonance (NMR).The elucidation of this critical
region has the potential for profound impact in the structural based drug design of HIV-1
therapeutics.
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Introduction
The focus of this work is the recombinant expression, purification, and characterization
of a difficult to express non-membrane chimeric protein comprised of the HIV-1 Tat
regulatory protein fused to an integral portion of its in vivo host binding partner the
human protein Cyclin T1. The first portion of this work will focus on the rationale behind
the importance, design, and potential applications of this particular chimera, as well as
the cloning experiments involved in producing the chimera, the conditions found
necessary to achieve adequate yield, and the methods required for purification. The latter
portion of this work will focus primarily on characterizing binding interaction through the
use of binding assays involving the in vivo TAR HIV-1 nucleic acid binding partner of
the proteins, and the expression and purification protocol modifications necessary to
obtain highly concentrated labeled protein for structural experiments. The ultimate goal
of this work is to provide data that will aid in the process of drug discovery for the
efficacious treatment of HIV-1 by improving our structural understanding of an, as yet,
unexploited drug target the HIV-1 Tat regulatory protein.

All of the presently employed HIV therapeutics that target viral proteins target the Env
and Pol proteins that are expressed late in the viral infection cycle (1,2). Regulatory
proteins Tat and Rev are expressed early in the infection cycle, as is the accessory protein
Nef (3). Inhibitors that target proteins early in viral infection cycle have the potential to

-1-

be significantly more effective in reducing viral load (2), and may also be less prone to
the development of resistant strains.

-2-

Chapter 1 The Tat-TAR Interaction

The HIV-1 regulatory protein Trans-Activator of Transcription (Tat), at its full length, is
a 101 amino acid, two zinc finger protein that interacts with the TAR stem-loop located
within the 5’ Long Terminal Repeat (LTR) region of nascent viral RNA. After synthesis,
a nuclear localization signal facilitates transport of Tat into the nucleus (4) where, in
concert with other host proteins, Tat facilitates the production of a large number of full
length viral RNA transcripts (Figure 1-1). In the absence of Tat the nascent viral RNA
transcript is prematurely terminated and the production of viable viral RNA is
substantially reduced (5). The potential impact of the interruption of this essential
interaction on viral load makes the Tat-TAR interaction an attractive target for drug
discovery (6). As of this writing however, there are no FDA approved drugs targeting the
inhibition of this important interaction.

1.1.Tat Domains

The Tat protein consists of two exons, and five domain regions (Figure 1-2) (7). The first
three domains, from amino acids 1-48, form the Activation Domain (AD) that interacts
with the host protein human cyclin T1 comprised of a highly ordered and acidic minimal
activation region rich in proline (1-20), a cysteine rich zinc finger region (containing
seven highly conserved cysteine residues) (20-40), and a highly conserved core region
(40-48). A basic RNA Binding Domain (RBD) region (49-57) (including six arginine and
two lysine residues) (Frankel et al. 1988), and a Glutamine rich region (57-72) interact
-3-

with HIV TAR RNA (7,8). Exon 2 of the Tat protein (73-101) contains a splicing silencer
(ESS) that inhibits splicing of viral mRNA at an upstream 3’ splice site (9), and does not
play a primary role in transcription (8).

1.2.Tat-P-TEFb Interaction

In vivo Tat interacts with the human host Positive Transcription Elongation Factor b (PTEFb), which regulates transcription by RNA polymerase II (RNAP II) (10). The P-TEFb
is comprised of a Cyclin dependent kinase CDK9, and the cell cycle regulatory protein
Cyclin T1 (11,12). The Cyclin T1 protein is a 726 amino acid catalytic subunit of P-TEFb
(Figure 1-3), and contains a purported Tat/TAR-recognition motif (TRM) at amino acids
250-272 (13). However, more recently other researchers have described the TRM as
being located between residues 250 and 263 of Cyclin T1 (14). Since it is not yet clear
which of these regions is the more accurate the larger region is displayed in Figure 1-3.
Cyclin T1 protein binds at the cysteine rich Activation Domain (AD) (1-48) of the Tat
regulatory protein (14).

An intramolecular CHCC zinc finger (ZnF1) of Tat is formed by amino acids Cys22,
His33, Cys34, and Cys37 (Figure 1-4). A second intermolecular CCCC zinc finger
(ZnF2) is formed by Cys261 of Cyclin T1 in concert with three additional cysteine
residues Cys25, Cys27, and Cys30 of Tat (Figure 1-5) (15). Both of the Tat zinc fingers
are structurally dissimilar to other known zinc fingers and metalloproteins (7,8).

-4-

1.3.Recruiting P-TEFb

Acetylation of Tat Lys28 by the transcriptional coactivator p300/CREB-binding protein
Associated Factor (PCAF) facilitates the recruitment of P-TEFb (16) bringing the CDK9
catalytic subunit in close proximity for hyperphosphorylation of the C terminal domain of
RNA Polymerase II (Figure 1-6) (14,15). A large number of intermolecular hydrogen
bonds between Tat and the P-TEFb alter Tat folding on contact with the complex (8).
This interaction remodels the AD of Tat into an extended conformation with an unusually
large area of interface with Cyclin T1 (7,8).

Both Tat and Cyclin T1 bind the TAR RNA stem-loop, purportedly, at a nucleotide bulge
formed by a base triple in the stem, and at the apical portion of the stem-loop respectively
(15,17). Tat binds the nucleotide bulge thorough an arginine-rich motif (ARM) at
residues 49-57 (18). Such arginine-rich binding motifs are also found to regulate RNA
binding in several other viral regulatory proteins lending to increased conservation in this
region, and a high affinity and specific interaction (19). Binding of the P-TEFb-Tat
complex to TAR is enhanced by the interaction between Cyclin T1 and Tat in the
bridging of ZnF2 (8) with the contribution of Cyclin T1 C261 (Figure 1-5) (7,15).

1.4. Tat-TAR Structural Study

Much of what we know about the Tat-P-TEFb interaction can be attributed to the
mutational and binding assays of Garber et al. 1998 who first suspected the formation of
a zinc bridge between Tat and human Cyclin T1. Since then the crystal structure of HIV-5-

1 Tat complexed with P-TEFb reported by Tahirov et al. 2010 appears to confirm these
early conclusions. Though ground breaking work, the Tahirov et al. 2010 structure is
reported in the absence of TAR and the conformation of the Tat AD and the Tat-TAR
complex remain obscure (8). In the Tahirov structure residues 50-86 of the arginine rich
Tat RNA-binding domain are undefined, and the conformation of ZnF2 remains elusive
in the absence of residues 252-260 of Cyclin T1 (Figure 1-7) (7,8).

The first NMR structures of the TAR-arginine complex reported by Puglisi et al. 1992,
TAR as reported by Aboul-ela et al. 1995, and a 24 residue Tat peptide bound to TAR as
reported by Long et al. 1999 provided much of the original insight into this interaction
and remain our primary sources of structural detail from NMR. Yet in these as well,
crucial structural features remain unclear, specifically that of the Tat Activation Domain
and its interaction with Cyclin T1 in the binding of TAR RNA. Elucidation of these
critical regions, as might be accomplished by additional NMR or X-ray crystallography
work, that includes detailed conformations of both zinc fingers has the potential for
profound impact on structure-based drug design.

1.5.TAR -The UCU Bulge

In 1992 Puglisi et al. published the NMR structure of a 31 nucleotide portion of the HIV1 Transactivation-Response Region (TAR) RNA in complex with the arginine analog
argininamide (20). The structure revealed a UCU nucleotide bulge at the Tat protein
binding site, and a flexible six nucleotide apical loop. The highly conserved cis-acting
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RNA regulatory element TAR binds to the Tat protein at a U23-A27-U38 base triple
(Figure 1-8) (20,21). Functional groups of the pyrimidine bulge and the phosphate
backbone are repositioned during binding resulting in a conformational change that is an
essential feature of specific recognition (22). This dynamic interaction has been described
as a “ligand-induced conformational rearrangement” that occurs on a micro- to
millisecond timescale (23). The base triple itself undergoes conjugated pi bond
stabilization by interaction with the guanidinium groups of arginines within the arginine
rich basic RNA binding domain of Tat (20).

In the unbound state the helical structure of TAR is distorted by the nucleotides of the
bulge that stack within the stem. In the bound form the nucleotides of the bulge loop
outward, and allow the bases above and below the bulge to stack coaxially (21). Work
with conformationally restricted peptide mimics of Tat indicates that looping out of U23
and C24 on Tat binding induces the formation of a binding pocket that places the
guanidinium group of arginine in proximity for hydrogen bonding to functional groups of
G26 and U23 (22). Supporting this, mutation of critical nucleotides G26 or U23 has been
shown to eliminate Tat binding and recognition (20,24).

1.6.TAR - The Apical Loop

The apical region of TAR is a six nucleotide loop that, due to high flexibility, does not
lend itself readily to NMR spectroscopy. Dethoff et al. 2008 used mutational analysis,
molecular dynamics, and NMR data to conclude that the binding at the bulge and at the
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apical loop are largely independent dynamic events with the possibility of some long
range interaction between them (25). The CUGGGA nucleotide sequence of the apical
loop binds Cyclin T1 of P-TEFb producing additional conformational changes (17).
However, much of the finer detail of this interaction remains unclear (20).

We do know from mutational analysis that nucleotides G32, which loops outward, and
G34 of the apical loop are essential for Cyclin T1 binding, and that elimination, but not
substitution, of A35 diminishes binding substantially (11,26). From NMR data it is
apparent that Cyclin T1 interacts directly with U31 of the apical loop (25). Nucleotides
A35 and G34 displace one another in alternation between looped in and looped out
conformations (25). To date however, considerably more work has focused on
characterizing the dynamics of the UCU bulge than on the dynamics of the apical region
of TAR (25). Toward the goal of improving rational drug design, much remains to be
gained from additional characterization of the apical loop and the recognition of its
contribution to the structurally dynamic interaction between TAR RNA, and the Cyclin
T1 and Tat proteins.
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Figure 1-1 The HIV infection cycle.
The HIV infection cycle is comprised of nine principal events: binding, membrane
fusion, entry, reverse transcription, integration, transcription, assembly, budding, and
maturation. After synthesis, a nuclear localization signal facilitates transport of Tat into
the nucleus (4) where, in concert with other host proteins, Tat facilitates the production of
a large number of full length viral RNA transcripts.
Accessed online at: http://www.bioafrica.net/proteomics/HIVproteome.html
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A

B

MEPVDPNLEP WKHPGSQPRT ACNNCYCKKC CFHCYACFTR KGLGISYGRK
KRRQRRRAPQ DSQTHQASLS KQPASQSRGD PTGPTESKKK VERETETDPF D

Figure 1-2 The Five Domains of the HIV-1 Protein Tat.
The HIV-1 Tat protein consists of two exons, and five domain regions (A) above. The
first three domains of Tat, from amino acids 1-48, form the Activation Domain (AD) that
interacts with the cellular protein human cyclin T1, increases specificity for TAR (27),
and is comprised of a highly ordered and acidic minimal activation region rich in proline
(1-20), a cysteine rich zinc finger region (20-40), and a highly conserved core region (4048). A basic RNA Binding Domain (RBD) region (49-57), and a Glutamine rich region
(57-72) interact with HIV TAR RNA. Exon 2 of the Tat protein (73-101) contains a
splicing silencer (ESS) that inhibits splicing of viral mRNA at an upstream 3’ splice site
(9), and does not play a primary role in transcription (8). The amino acid sequence of Tat
that corresponds to each of these domains appears in B above.
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Figure 1-3 Cyclin T1.
The Cyclin T1 protein is a 726 amino acid catalytic subunit of P-TEFb, and contains a
Tat/TAR-recognition motif (TRM) at amino acids 250-272. The Cyclin T1 protein binds
HIV-1 Tat through the cysteine rich Activation Domain (1-48) (14). Reprinted from:
Retrovirology, vol. 5 Page 63, Copyright 2008 (13), with permission from J. Jadlowsky.
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Figure 1-4 An intramolecular CHCC zinc finger (ZnF1)
An intramolecular CHCC zinc finger (ZnF1) is formed by residues Cys22, His33, Cys34,
and Cys37 of the HIV-1 regulatory protein Tat. Protein Data Bank File: 3MI9 (7) Crystal
structure of HIV-1 Tat complexed with human P-TEFb. Image rendered by C. Fischer
from Protein Data Bank File: 3M19 using Insight II molecular modeling software.
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Figure 1-5 A CCCC intermolecular zinc finger (ZnF2)
A CCCC intermolecular zinc finger (ZnF2) is formed by the cysteine 261 of Cyclin T1 in
concert with three additional cysteine residues 25, 27, and 30 from the HIV-1 regulatory
protein Tat. Protein Data Bank File:3MI9 (7) Crystal structure of HIV-1 Tat complexed
with human P-TEFb. Image rendered by C. Fischer from Protein Data Bank File: 3M19
using Insight II molecular modeling software.
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Figure 1-6 HIV-1 Tat recruits P-TEFb by binding Cyclin T1.
The HIV-1 Tat protein and a portion of Cyclin T1, the Tat/TAR-recognition motif (TRM), purportedly bind
the trinucleotide bulge as well as the apical portion, respectively, of the HIV-1 TAR RNA stem-loop. The
CDK9 catalytic subunit of P-TEFb is then brought into close proximity to RNA Polymerase II facilitating
hyperphosphorylation of the RNA Polymerase II C-terminal domain (CTD). This interaction results in the
production of a high number of full length viable transcripts, and thus is an attractive target for therapeutic
intervention (14,15). The terms hCycT1, mCycT1, and hCycT1(249-280)-Tat refer to full length 726 amino
acid human Cyclin T1, murine Cyclin T1 (724 amino acids) which does not support Tat transactivation,
and the minimal chimera of residues 249-280 of human Cyclin T1 fused to 101 amino acid Tat respectively
with the latter being the experimental construct as developed by Koh Fujinaga(28). The hCycT1(249-280)Tat construct is able to activate HIV-1 transcription in murine cells which do not normally transcribe HIV1 presumably due to the absence of cysteine 261 in murine Cyclin T1 where residue 261 is tyrosine (28).
Reprinted from: Journal of Virology, vol. 76(24), Pages 12934-9. Copyright 2002 (28) with permission
from Koh Fujinaga.
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Figure 1-7 Tahirov et al. 2010 Crystal structure of HIV-1 Tat with human P-TEFb.
Tahirov et al. 2010 Crystal structure of HIV-1 Tat complexed with human P-TEFb.
RCSB Protein Data Bank: 3MI9 (7)HIV Tat protein (86 aa) in orange, Cyclin T1 (266 aa)
in pink CDK9 in green (351 aa).

The Tahirov et al. 2010 structure is reported in the absence of TAR. The conformation of
the Tat Activation Domain and the Tat-TAR complex remain obscure (8). Residues 5086 of the arginine rich Tat RNA-binding domain are undefined, and the conformation of
ZnF2 remains elusive in the absence of residues 252-260 of Cyclin T1 (in red) (7,8).
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Figure 1-8 Wild type HIV-1 TAR stem loop.
A U23-C24-U25 trinucleotide bulge is present in the stem of the HIV-1 TAR RNA (at
left).The TAR RNA binds HIV-1 Tat protein at a U23-A27-U38 base triple (20,21).
Functional groups of the pyrimidine bulge and the phosphate backbone are repositioned
during binding, and result in a conformational change that is an essential feature of
specific recognition (22).
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Chapter 2 Targeting the Tat-P-TEFb-TAR Interaction

The interaction between HIV Tat, human P-TEFb, and HIV TAR RNA is a highly
attractive target for the development of new HIV therapies that may potentially be less
prone to the development of drug resistance because of their potential to inhibit the
essential activity of Tat early in the infection cycle. The Tat-TAR interaction is critical
not only during the exponential phase of virus reproduction, when it substantially
enhances processive elongation of the full length HIV-1 mRNA, but also during the
activation of the integrated provirus that leads to mutation and drug resistant strains (29).

Current therapeutics inhibiting viral entry and formation of the provirus are not effective
at eliminating viral proteins produced early in the infection cycle from provirus already
integrated in the host genome. The neurodegenerative effects of HIV-1 are experienced in
some 50-70% of patients, and begin soon after infection as viral reservoirs are established
in the glial cells of the brain. This neurocognitive impairment persists despite effective
control of viral load (30). The viral protein Tat has been demonstrated to be a potent
neurotoxin and may play a role in this HIV-1 associated neurocognitive disease (HAND)
(30,31). Inhibitors of Tat-TAR interaction have the potential to substantially reduce viral
replication, as well as to improve neurocognitive prognosis.

Attempts to inhibit the Tat-TAR interaction have generally engaged one of three angles
of approach: anti-TAR, anti-Tat, and anti-Tat-P-TEFb. To date, compounds found to
inhibit these interactions have failed to demonstrate sufficient specificity, cell- 17 -

penetration, or stability to be effectively employed as therapeutics for the treatment of
HIV (32).

2.1.Anti-TAR Agents

The bulk of research on the inhibition of the Tat-P-TEFb-TAR interaction has focused on
anti-TAR agents, and specifically on inhibition of Tat binding at the pyrimidine bulge in
the TAR RNA stem. Agents found to disrupt the interaction can be categorized into three
classes: peptide-based, oligonucleotide-based, and small molecule inhibitors. In the
category of peptide-based inhibitors: Tat-derived natural peptides, and Tat-mimetics such
as peptoids, and D and β peptides have demonstrated some ability to inhibit the Tat-TAR
interaction with the peptide mimetics demonstrating superior resistance to enzymatic
degradation (32). Oligonucleotide inhibitors include TAR decoys such as: antisense
oligonucleotides, aptamers, and RNA interference (RNAi), and have demonstrated only
moderate efficacy in the inhibition of HIV-1 replication (32). Small molecule inhibitors
such as: arginine derivatives, quinolones, and others have also displayed some ability to
inhibit the Tat-TAR interaction, but as yet no small molecule has demonstrated the
sufficiency to warrant further consideration as a drug candidate (32,33).

2.2.Anti-Tat Agents

Small molecules, biopolymers, and antibodies have all demonstrated inhibition of HIV
replication by binding directly to Tat but, here also, with insufficient efficacy to produce
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viable drugs (32). Recently, a synthetic form of didehydro-Cortistatin A isolated from the
marine sponge Corticium simplex has shown promise in the early phases of research as an
anti-Tat drug, and has been described as a potent suppressor of viral transcription at
subnanomolar concentrations (34).

2.3.Anti-Tat-P-TEFb Agents

Targeting the Tat-P-TEFb complex is complicated by the unintended consequence of
inhibiting basal cellular transcription that ordinarily requires P-TEFb (32). Selective
disruption of the Cyclin T1 subunit of P-TEFb, while highly desirable, is therefore
difficult to achieve without unwanted side-effects. Small molecules, antibodies, protein
chimeras, intracellular inhibitors, and inhibitors of Tat co-activators of the Tat-P-TEFb
interaction have, as yet, all failed to produce feasible drug candidates (32).

2.4.Aptamers as Diagnostic Tools: A Novel Approach to TAR Interaction

Elucidation of the structural features of the TAR-Tat-P-TEFb interaction could offer a
great deal toward the facilitation of rational structure based drug design. In the absence of
structural detail however, a high-throughput approach could be used to identify drug
candidates. Our laboratory utilizes oligonucleotide aptamers in a high-throughput
approach toward identification of promising small molecule drug candidates that disrupt
interactions between ligands and nucleic acid targets. Figure 2-1 illustrates an aptamer
diagnostic tool, here called an “AlloSwitch”, in which a chimeric RNA-DNA molecule
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comprised of a “probe” strand and a “cover” strand is tethered together by a fixed
nucleotide duplex that does not change as the rest of the switch changes its conformation
(35-37).

In the absence of the target the equilibrium between the two forms of the switch favors
the Hidden (H) form at the left of the figure, where the target’s binding site is hidden by
base-pairs. The equilibrium shifts toward the right as target is added and binds the probe
segment in the Open (O) form.

The RNA probe strand is generally designed with a high degree of sequence and
structural similarity to the in vivo RNA target (or to an aptamer that binds to the same
region of the target), while the DNA cover strand is mostly complementary to the probe
strand. When the concentration of target is low, the probe and cover are annealed in the
extended “on” form, where a 5’ fluorophore is distant from, and therefore not quenched
by, a strategically placed downstream quencher. At high concentrations of target, the
open-probe form is favored and the fluorescence is efficiently quenched in this “off”
state. If a competitive inhibitor is present, the conformation of the switch molecule
reverts to the on-state indicating the presence of a potential drug candidate. Other switch
formats are being investigated in our lab (35-39).

The sensitivity of an AlloSwitch is related to the three equilibria for high-throughput
screening of drug candidates (Figure 2-2). The K1-equilibrium is controlled by the degree
of complementarity between the RNA probe strand, and the DNA cover strand. The
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greater the complementarity between the probe and cover the more the molecule becomes
“locked” in the on form, so less of the switch molecule can be turned off by target
binding (K2-equilibrium). The right combination of K1 and K2 usually gives about 90%
of the maximum possible decrease in fluorescence on binding the target. This diagnostic
tool is then able to detect and rank the affinity of drug candidates via the K3-equilibium.

2.5.Building and Testing the AlloSwitches

Designing and construction of the nucleic acid AlloSwitch requires the careful
consideration of thermodynamic, and structural factors, as well as the consideration of the
mechanics of oligonucleotide synthesis. Testing the switch requires an experimental
ligand that accurately simulates the interaction between the in vivo ligand and its nucleic
acid target. In the case of the Tat-P-TEFb-TAR interaction, a 33 nucleotide stem-loop
portion of TAR complete with pyrimidine bulge can be easily secured from available
commercial sources. Recreating the essential features of the Tat-P-TEFb interaction then
becomes the challenge that has been the focus of this work. Important consideration must
be given to the conformation that unbound Tat adopts (7,8) as well as to the fact that, unremodeled by interaction with Cyclin T1 and the completion of ZnF2, unbound Tat alone
cannot effectively mimic in vivo interaction with TAR. Hence, mimicking this interaction
in a manner that is structurally accurate requires essential features of both Cyclin T1 and
Tat to be present in the experimental target.
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Figure 2-1 An indicator for Tat-TAR Binding
(a) A Tat-TAR indicator,T1, shown in the H conformation where most of the Tat-binding
UCU bulge is hidden by base pairs, and (b) in the O-form, where the bulge is open for
binding Tat. The critical binding elements for Tat (40) are circled. RNA monomers are
shown in dark italics, DNA in regular font. The Probe and Cover strands are tethered by a
fixed duplex, F (see text). Strands are numbered 53 and do not include the Fsequences. The fluorophore =  and quencher = Q are marked. A second version of the
switch has modifications in lower-case letters that include a “balancing” stem extension,
ATCG:cgat in the O-form, which increases the stability of the double hairpin O-form.
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Figure 2-2 High-throughput screen assay format for Tat-TAR blockers.
Indicators have two stable states: H and O. Interesting competitors, X, will block
formation of the LO complex (here, L = Tat).
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Chapter 3 A Tat-Cyclin T1 Chimera

Embarking on the recombinant expression of a protein frequently presents biochemical
challenges that are unique to the specific characteristics of the protein of interest and, the
expression strain being used, and which require optimization by what can be a lengthy
empirical process. The existing literature on the expression and purification of HIV-1 Tat
protein demonstrates that Tat expression in E. coli is notoriously difficult to achieve at
appreciable yield, solubility, and in native form. This observation is often attributed to the
high cysteine content of the Tat activation domain (41). The presence of several atypical
codons in the corresponding DNA can compound this problem by stalling expression in
E. coli (42). Accommodation must be made for the atypical codons either by codon
optimization, or by providing the appropriate supplemental tRNA. The presence and
maintenance of the two zinc fingers of the Tat protein, and the corresponding secondary
structure they induce, present additional considerations for expression and purification
which appear to have hindered other work (43).

3.1.Recombinant Tat Expression

Much of the recombinant expression of Tat has been performed in mammalian cells.
Where Tat has been expressed in E. coli, it is most commonly extracted from inclusion
bodies by denaturation and refolding, and is often still hindered by problems with
insolubility, precipitation, and aggregation (43,44). Unfortunately, the process of
denaturing and refolding is a cumbersome one that, if accomplished successfully, will
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then necessitate additional assays in order to confirm the biological activity of the target
(41). A high yield of soluble protein from denaturing and refolding protocols is rare (45).
Hence, a recombinant expression protocol for adequate yield of the soluble protein in its
native form is highly desirable.

In order to facilitate the expression and purification of Tat, researchers frequently opt to
express only the first exon of the Tat protein (42,46). The second exon, which is high in
basic lysine residues, is not known to play a primary role in viral transcription (8,47,48).
Still, difficulty with oxidation, misfolding, insolubility, precipitation, aggregation, or low
yield persist even in the expression of truncated Tat in E. coli (42,43,49-52). Oxidation of
recombinant Tat has been found to produce disulfide bond formation at C27-C30, and is
suspected at C31-C34, and C22-C25 (53,54). In some cases, while working with Tat,
oxidation was of such great concern that purification and refolding were performed in an
anaerobic chamber (43). Even with the use of the anaerobic chamber protein dimers were
observed. This can perhaps be explained, however, by the absence of the Cys261 residue
contributed by CycT1 rather than by oxidation.

3.2.Human Cyclin T1

The work of Garber et al. 1998 suggested that Tat binding to TAR is mediated by Tat
interaction with human Cyclin T1 and specifically by the completion of an intermolecular
zinc finger by Cys261 of Cyclin T1(15). From an experiment mutating all cysteine and
histidine residues of Cyclin T1, with the exception of Cys261, Fujinaga et al. 2002
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concluded that Cyclin T1 binds Tat in a Zn2+ dependent manner at Cys261, and that no
other cysteine or histidine residue of Cyclin T1 between amino acids 1 to 280 was
required. This conclusion was largely based on the fact that Tat transactivation was not
supported in mutants lacking Cys261(28). However, since the structure of HIV-1 Tat
bound to HIV-1 TAR has not yet been solved, many questions remain including whether
Cys261 of Cyclin T1 is mediating the interaction of Cyclin T1 with Tat or whether it is in
fact directly responsible for binding to TAR. It is also possible that Cys261 could be
influential in both interaction between Cyclin T1 and Tat and between the Tat-P-TEFb
complex and TAR. Interestingly, it has also been suggested that TAR nucleates and
enhances the interaction between Tat and Cyclin T1 (55) perhaps involving Cys261.

Complicating an already rather nebulous image of the interaction, Richter et al. 2002
concluded that residues 252-260 of Cyclin T1 were essential for TAR interaction with
one side of the TAR RNA stem-loop and that these same residues enhanced the
interaction of Tat residue K50 with the opposite side of the stem-loop (11). Unfortunately
the 252-260 residues of Cyclin T1 are missing from the Tahirov crystal structure (Figure
1-7) (7,8). Das et al 2004 however, performed mutagenesis experiments that strongly
support a metal binding role for cysteine 261 in the formation of a ternary complex with
HIV-1 TAR (27). Also of interest are the basic residues R251 and R254 which have been
implicated by some as potential stabilizers of the Tat-P-TEFb-TAR interaction (15). That
there is, as yet, little consensus about this interaction is perhaps the only certainty.
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Because of the role zinc finger proteins are now known to play in gene transcription, it
would seem intuitive that this interaction could be highly influential in binding and
recognition between Cyclin T1-Tat and TAR and that the zinc fingers are likely to play
an important role in specificity and transactivation. Much of the existing research,
however, focuses on the importance of the arginine-rich region of Tat binding to the
nucleotide bulge of TAR, and also on arginine residues 251 and 254 of Cyclin T1 as the
modulators of TAR interaction rather than on Zn1 and Zn2. Since the original suggestion
of the importance of the two zinc fingers in this interaction by Garber et al. 1998 little has
been done to assess the effective contribution of the zinc fingers alone. A minimal
construct of Cyclin T1 eliminating or mutating R251 and R254 of Cyclin T1 and
reducing the contribution of Cyclin T1 (as much as possible) to that solely provided by
completion of Zn2 could offer important insight toward this end. Moreover, the mutation
or elimination of arginine residues in the arginine-rich region of Tat purported to bind the
TAR stem-loop bulge could also yield valuable insight.

Of the 726 residues of Cyclin T1 the first 272, encompassing the entire Cyclin domain,
were originally found sufficient to bind Tat (15,28,56). However, interaction between the
N-terminal and C-terminal region of Cyclin T1 has an autoinhibitory effect on TAR
binding that is removed in vivo by Cyclin T1 C-terminal interaction with Tat-SF1 (57).
The size and complexity of the dynamic interaction between P-TEFb-Tat-TAR suggests
that structural study of the complex would be difficult to accomplish (28), and that a
minimal construct could provide much needed structural information. With the intention
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of identifying such a minimal construct, Fujinaga et al. 2002 produced a series of
minimal chimeras of N-terminally truncated Cyclin T1 fused to the full length (101
amino acid) Tat.

Working with N-terminally GST tagged chimeras of amino acids 1 through 280 of human
Cyclin T1 fused to the 101 amino acid Tat in NIH 3T3 cells, Fujinaga et al. 2002
measured transactivation of viral RNA for a series of Cyclin T1 N-terminally truncated
variants of the construct. Predictably, the 1-280 amino acid Cyclin T1-Tat chimera was
able to produce the highest level of transactivation at greater than 250 fold increase over
baseline transactivation. However, a minimal construct of amino acids 249-281 of Cyclin
T1 fused to the full 101 amino acid Tat produced an efficient 125 fold increase in
transactivation.

Working with a minimal chimera presents the possibility of acquiring important
structural data from a construct of an appropriate length for 600-800 MHz NMR
structural determination, and so was chosen as the chimera construct for this work.
Subsequent to the work of Fujinaga, circular dichroism experiments performed on a
human Cyclin T1 construct of amino acids 1-272 demonstrated that the 20 amino acids at
the C-terminus of the construct were conformationally flexible or disordered (27).
Similarly, and as mentioned previously (Figure 1-7), residues 252-260 of Cyclin T1 were
absent from the Tahirov crystal structure (7,8), perhaps due to the flexibility and/or
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disorder observed by Das et al. 2004. Thus an even shorter construct omitting nonessential and flexible or disordered residues of Cyclin T1 could yield the important
advantage of reducing this intractable region, while providing insight into questions about
the importance of the completion of Zn2 by cysteine 261, as well as insight into the role
of residues R251 and R254 in high affinity TAR binding.

Since the Tat protein is notoriously difficult to express, purportedly due to insolubility
and a high number of cysteine residues (43), work on the recombinant production of the
chimera began by using the 249-280 hCyclin T1-Tat chimera published by Fujinaga et al.
2002 in an attempt to assess the yield obtainable from this construct.

3.3.pGEX 2TK Plasmid 249-280 hCyclin T1-Tat Chimera

The pGEX 2TK plasmid of the 249-280 human Cyclin T1-Tat chimera was generously
provided by Koh Fujinaga from Case Western University. While the details and yield
were not published, Fujinaga (personal communication) indicated that the construct had
been expressed in E. coli BL21 cells (28). Sequencing of the plasmid by Upstate Medial
University DNA Core Facility confirmed that the open reading frame of the plasmid
coded for the correct portion of human Cyclin T1followed by a 25 amino acid linker
(within which a myc tag has been placed for antibody assay), and finally the full length
(101 amino acid) Tat protein (Figure 1-2). The molecular weight of the GST-hCycT1-Tat
construct is ~ 33.5 kDa, with an extinction coefficient (without disulfide bonds) at 280
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nm of ~41250, and pI = 8.1 (Appendix 1). The Tat 101 aa portion of the sequence is
identical with the Tat 101 aa protein sequence of accession number AAB59879.1 (101 aa
Tat HIV-1 Group M Subtype B isolate ARV2/SF2) by Blast and was confirmed by
ClustalX2 alignment.

3.4.Expression of the pGEX 2TK GST hCycT1-Tat Chimera in E. coli

The pGEX 2TK (~ 5.0 kb) chimera plasmid utilizes a tac promoter which is a hybrid of
the lacUV5 and trp promoters. The tac promoter produces a tightly controlled, high-yield
expression of recombinant protein. In general, the tac promoter necessitates the use of
BL21 (non-DE3) (non-pLys) expression strain for optimal expression. The BL21(DE3)
(pLys) strain designed for use with a T7 promoter would unnecessarily tax the cells with
the production of the T7 polymerase, and reduce the yield of the target protein expression
(Novagen conversations). While some researchers suggest it is possible to use DE3
strains with plasmids utilizing a tac promoter, Figure 5-1 demonstrates clearly that yield
of recombinant protein was considerably lower when using a DE3 strain to express the
protease TEV from a pRK793 plasmid with a tac promoter.

Unfortunately, many trials of recombinant expression of the pGEX 2TK plasmid, even
when using the appropriate BL21 (non-DE3) (non-pLys) expression strain and following
in close accordance with the protocol conditions generously provided by Koh Fujinaga
(personal correspondence), produced a lower than anticipated yield (Figure 3-2) that was
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insufficient for structural work with NMR. Estimates of crude and soluble protein yield
were made using gel electrophoresis since the full length GST protein (already well
below approximately 10 mg/L) was unstable when UV absorbing surfactants were
removed. Concentration of the target after removal of the GST tag was too low for
accurate determination by NanoDrop. A great deal of time and effort was spent varying
expression conditions such as: culture temperature, IPTG concentration, media and media
additives, among many others, and in the hopes of improving yield, but these efforts were
to no avail. A variety of cell lysis techniques including sonication, microfluidizer
processing, and freeze thaw cycling also failed to provide any observable improvement in
the yield.

Investigation into the potential causes of the low expression yield observed in the BL21
(non-DE3) (non-pLys) expression strain revealed a number of significant factors.
Analysis of the DNA sequences of the Cyclin T1 and Tat portions of the chimera alone
(not including the adjoining sequence) showed that 15 of the chimera codons are atypical
in E. coli (discussed in Chapter 7, see Table 7-1), and can therefore stall expression when
corresponding tRNA are either unavailable or are in low abundance. However,
transformation of the plasmid into the Rosetta 2 E. coli expression strain (Novagen
Madison, WI), which contains an additional plasmid that codes for the production of
several rare tRNA, increased basal protein expression while making only modest
improvements in the expression of the target (Figure 3-4).

Solubility also appeared to be a limiting factor early in the expression as much of the
expressed protein remained in the insoluble fraction after cell lysis. This was somewhat
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surprising in view of the presence of the GST tag. Moreover, cleavage of the GST tag
using thrombin was highly non-specific and resulted in a further reduction in yield of the
cleaved protein after FPLC purification (Figure 3-3). The diminished yield was observed
when using a second benzamidine column to remove thrombin after cleavage, and was
worse still when using a heparin sepharose column for thrombin removal, as in an
unfortunate coincidence heparin bound Tat as well. In all trials with the pGEX 2TK
plasmid the yield of the Tat chimera was far too low for structural work with NMR with
the total yield of the full length chimera (with GST tag attached) at approximately 14
mg/L. Yield of the target after removal of the tag was predictably lower still, and the final
sample was substantially contaminated by co-purified proteins.
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249–280 human Cyclin T1-----------------------

PN RLKRIWNWRA CEAAKKTKAD DRGTDEKTSE
Spacer------myc------Spacer-------

QTMPEQKLIS EEDLAMEFLE IDPVD
HIV-1 Tat (1-101) ---------------------------------------------------

MEPVDPNLEP WKHPGSQPRT ACNNCYCKKC CFHCYACFTR KGLGISYGRK
Proline rich domain

Cysteine rich domain

Arginine-rich-

-------------------------------------------------------------------

KRRQRRRAPQ DSQTHQASLS KQPASQSRGD PTGPTESKKK VERETETDPF DLX
(basic) domain

RGD containing C-terminal domain

Figure 3-1 Sequence of the pGEX 2TK GST Chimera
The sequence of the pGEX 2TK GST Chimera: shown in green for amino acids 249-280
of human cyclin T1, in cyan for a myc antibody recognition sequence (which, together
with 12 surrounding residues shown in black, constitute a spacer between the cyclin T1
domain and Tat) , and in magenta for the 101 amino acid full length HIV-1 Tat protein;
key residues are underlined. Blocks of residues are aligned in groups of ten according to
the numbering schemes for cyclin T1 and Tat. A residual leucine remains at the Cterminal of the Tat sequence as an artifact of the cloning process and X indicates the stop
codon that terminates translation. The three features are recombinantly expressed as a
single GST tagged construct The presence of the myc tag permits recognition of the
chimera by anti-myc antibodies. The spacer portion of the contruct lends sufficient
flexibility for the chimera to form a high-affinity complex with TAR RNA. The GST tag
coding region upstream from the cloned insert and positioned at the N-terminus of the
recombinant protein. The GE pGEX-2TK GST plasmid contains the GST tag sequence in
the generic form prior to cloning. The GST sequence is not shown.
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Figure 3-2 Expression of the pGEX 2TK GST hCycT1-Tat chimera

The expression of the pGEX 2TK GST hCycT1-Tat chimera in BL21 (non-DE3) (nonpLys) in LB media. Red arrow indicates the full ~33.5 kDa GST tagged chimera. From
left to right:

(L) ladder

(UN) uninduced

(IN) induced with 1 mM IPTG at 0.6 OD600 and harvested after 6 hours

(SE) soluble extract

(IE) insoluble extract
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Figure 3-3 Cleavage of full purified GST- hCycT1-Tat chimera

Cleavage of the full purified GST hCycT1-Tat chimera after three hours of incubation
with thrombin at room temperature (RT) from left to right:
6 U Thrombin/mg

12 U Thrombin/mg Tat

18 U Thrombin/mg Tat

Full GST tagged Chimera

Red arrow indicates location of cleaved chimera. The thrombin protease 37,000 kDa was
present at concentrations too low for visible detection on the gel stained with GelCode
Blue coomasie protein stain (this section of the gel omitted).
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Figure 3-4 Expression of pGEX 2TK GST-hCycT1-Tat in Rosetta 2 cells
Expression of pGEX 2TK GST-hCycT1-Tat full chimera
in Rosetta 2 cells (Novagen Madison, WI). From left to right:
ladder

uninduced

induced

soluble

insoluble

FPLC purified fraction

Note that the full length chimera and the tag-free chimera (not shown) run at a higher
molecular weight than predicted. This artifact was observed consistently throughout all
gel electrophoresis experiments, and is likely due to preferential SDS loading and the
high number of cysteine residues present in the Tat chimera.
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Chapter 4 Re-engineering the hCycT1-Tat Chimera Plasmid

When re-engineering the chimera plasmid the first task was to increase the expression
yield and to improve the solubility of the native hCycT1-Tat chimera. To this end a
multitude of plasmid attributes were considered for their potential to impact the final
yield of the active purified protein. For example, in some cases the expression yield can
be improved by an alternate inducible promoter, which provides more tightly regulated
expression while mitigating the buildup of toxic recombinant proteins in the cell. Once an
adequate expression level is achieved, the final yield can be improved by increasing the
solubility of the target protein. One approach to improving solubility is the addition of
“solubility enhancing” tags or fusion proteins encoded by the plasmid, and expressed at
either the N-terminus or the C-terminus of the recombinant protein.

For many downstream applications the fusion tag may remain on the protein of interest
without confounding the assay. With respect to the binding assays and structural work
that the purified chimera is intended for, the frequently cumbersome fusion tag must
often be removed. As a general rule, each step added to the purification process has the
unintended effect of reducing yield. With this in mind, optimizing the cleavage sequence,
and employing a highly specific protease enzyme to cleave solubility enhancing tags can
contribute substantially to recombinant protein yield by cleaving as much of the tag from
the target as possible while minimizing non-specific cleavage.
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The second important task in re-engineering the chimera plasmid was to truncate the
human Cyclin T1 portion of the chimera. By omitting the flexible region of Cyclin T1
and removing the arginine residues suspected of influencing the affinity of TAR binding
the contribution of Cyclin T1 Cys261 may be assessed. Specifically, the role of Cyclin T1
in the binding of such a truncated construct is likely to be solely attributable to Cys261 of
Zn2. By including only residues 257-280 of human Cyclin T1, the arginine residues R251
and R254 could be removed while still allowing a few additional residues following
Cys261 to afford conformational stability and flexibility.

4.1.Selection of an Appropriate Vector

When selecting a vector the size of the insert, copy number, promoter, selection marker,
cloning sites, and other additional attributes of the vector must be thoroughly considered
with respect to downstream applications (58). Commercially available plasmids can
accommodate inserts approaching 15 kb in size. The chimera DNA insert is
comparatively small, at less than 500 base pairs, and can be readily accommodated by
most commercially available plasmids. Since the recombinant protein being expressed is
considered toxic to E. coli in high concentrations, a low copy number plasmid, rather
than a high, is a prudent choice (59,60).
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4.2.Solubility Enhancing Tags

The initial expression of the glutathione S-transferase (GST) tagged chimera produced a
low yield with a high proportion of the target protein in the insoluble fraction. Hence, the
primary objective in re-engineering the chimera was to exchange this fusion protein, in
the hopes of improving both expression and solubility of the chimera. Oddly, while the
GST tag (24 kDa) is often characterized as solubility enhancing, improved solubility as a
direct result of the inclusion of the GST tag is rarely observed (61-63). In fact, GST
tagged proteins are frequently expressed at even lower levels, and in less soluble form
than their untagged counterparts (63). A comparison by Braun and LaBaer 2003 reports
the solubility achieved with GST in their own work, and the work of two other research
groups, Hammarstrom et al. 2002, and Shih et al. 2002, at 50%, 48%, and 38% solubility,
respectively (64,65). Thus, the true advantage of including the GST tag may lie in the
ability to purify the protein by affinity chromatography, rather than in any predictable
effect on solubility.

Some of the more commonly employed solubility enhancing tags are: maltose-binding
protein (MBP) (43 kDa), thioredoxin (Trx) (11 kDa), calmodulin-binding protein (CBP)
(4 kDa), cellulose-associated protein (CAP) (17 kDa), NusA (54 kDa), and SUMO (11.5
kDa) (64,66,67). However, little is known about the mechanism by which solubility is
achieved with the use of these fusion proteins (68).
Selecting an optimal solubility enhancing tag remains an empirical process that, using
traditional methods, can be prohibitively time consuming. Recent advances in highthroughput technology have facilitated parallel cloning, and rapid screening techniques
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that expedite this process. As a general rule, larger solubility enhancing tags tend to
produce higher expression yields of more soluble proteins, to improve folding, and also
to reduced proteolysis of the target (66,69). However, larger tags tend to complicate
structure determination necessitating their removal, and reducing yield as an inevitable
and undesirable consequence. Folding, function, crystallization, and NMR experiments
can all be hindered by the presence of solubility enhancing tags. Thus, keeping the fusion
tag at a low molecular weight, and/or removing the tag entirely after purification are part
of a repertoire of conventional strategies that can be used to deliberately design target
proteins to facilitate downstream applications.

4.3.Gateway® Cloning of hCycT1-Tat into pDEST HisMBP

The fusion protein MBP has demonstrated exceptional efficiency at enhancing both the
total expression and the solubility of many target proteins (68). Hammarstrom et al. 2002,
Shih et al. 2002, and Braun and LaBaer 2003 reported solubility of target proteins fused
to MBP at 70%, 60%, and 90% respectively, far better than these researchers observed
with the same targets tagged by GST. In some cases MBP has specifically exhibited the
ability to influence proper folding of the target by acting as a molecular chaperone (68).
These observations suggested that the MBP fusion protein was an attractive candidate for
improving the overall expression yield of the Tat chimera.

One potential drawback to the use of MBP is problematic affinity purification where
MBP often does not bind well to amylose resin, or where the target protein interferes with
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MBP binding (70-72). The difficulties of MBP affinity purification can be circumvented
by the use of a double-affinity fusion system such as that developed by Pryor and Leiting
(1997). Addition of a 6 histidine (His6) tag to the C-terminus of MBP permits metal
chelating affinity purification, and by employing both tags simultaneously solubility and
purification are enhanced beyond what would be achieved by employing either of the
tags independently. Building on the work of Pryor and Leiting (1997), the David Waugh
Lab designed a similar pDEST-His6MBP plasmid for use in the Gateway Cloning
method. In this construct the His6 tag is placed at the N-terminus of MBP. We chose this
route for production of the MBP tagged hCycT1-Tat chimera. The pDEST HisMBP
plasmid (#11085) was deposited with, and secured from, Addgene for the construction of
the hCycT1-Tat pDEST His-MBP. A tac promoter in the pDEST His-MBP plasmid
generates a low copy number, and is well-suited to expression of the (possibly) toxic
chimera.

4.4.Gateway® Cloning Technology
Gateway® Technology exploits the recombination properties of the bacteriophage lambda
by introducing att recombination sites flanking the sequence of interest. In the presence
of the proprietary Clonase™ enzyme the desired sequence, with flanking att sequences, is
recombined into a donor plasmid containing the appropriately complementary att
recombination sequences. On recombination the desired sequence is inserted into the
donor plasmid in a directional manner replacing the ominous control of cell death (ccd)
gene and providing stringent selection. Subsequently, and in the presence of the
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proprietary enzymes, the insert may be transferred by recombination into a number of
commercially available destination plasmids with a variety of attributes that can be
tailored to alternate downstream applications. The entire protocol may be accomplished
in a few hours with the insert remaining in frame, and appropriately oriented, and without
the need for a ligation step (73).

4.5.Cloning Protocol

A nine step procedure was followed for the production of the pDEST His-MBP hCycT1Tat vector:
1. Introduce AfeI Blunt-end Restriction Sites into the pGEX 2TK hCycT1-Tat
plasmid by Site Directed Mutagenesis
2. Cleave pGEX 2TK hCycT1-Tat plasmid
3. Isolate insert from agarose gel
4. PCR amplify insert with N1 and C primer
5. Purify insert with N1 and C attachments from agarose gel
6. PCR amplify N1 C insert with N2 and C primers
7. Purify insert with N1, N2, and C by agarose gel
8. BP reaction to pDONR221 entry vector (Appendix 7)
9. LR reaction to pDEST HisMBP vector (Appendix 7)
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4.6.Introduction of AfeI Blunt-end Restriction Sites

Prior to cloning the DNA fragment into the pDEST HisMBP plasmid (Figure 4-1), and
beginning with the Cyclin T1 residue 257, the insert was excised from the pGEX-2TK
(GE Healthcare Biosciences Pittsburg, PA) plasmid leaving blunt end restriction sites
necessary for Gateway® cloning. Two flanking AfeI restriction sites were introduced to
the chimeric sequence by site directed mutagenesis (Stratagene La Jolla, CA) (Figure
4-2) (Appendix 6). Primer X online software was used to design the mutagenic primers
(Figures 4-3, 4-4). The AfeI restriction site AGC/GCT (serine/alanine) cleaves between
the cytosine and guanine residues of the DNA. As an artifact of this procedure the
chimeric sequence will have an alanine added to the N-terminus and a residual serine
added to the C-terminus of the protein. After site directed mutagenesis the inserts were
analyzed by agarose gel electrophoresis (Figure 4-5), excised, purified, and sequenced.
The correct placement of the mutations was confirmed by sequencing from the Upstate
Medical University DNA Core Facility, and analyzed with Serial Cloner software.

4.7.Addition of the att and TEV sites by PCR

After excising the insert the att recombination sites must be added by polymerase chain
reaction (PCR) at each end in order to facilitate recombination into the entry vector. At
this point a tobacco etch virus (TEV) protease cleavage site was introduced 3’ of the 5’
att recombination site (Figure 4-6). The TEV protease is a highly specific protease that
provides efficient cleavage of the MBP fusion tag (74). Introduction of the TEV cleavage
site will facilitate MBP removal from the chimera at the amino acid sequence
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ENLYFQ/G with a single residual glycine amino acid artifact that when added to the
alanine artifact produced by the introduction of the AfeI restriction sites will leave 2
residual amino acids at the N-terminus. Following the 101 amino acid Tat sequence, a
single additional serine residue will follow a residual leucine that remains at the Cterminus as an artifact of the cloning process (Figure 4-11).

Following the work of Austin et al. 2009 for the construction of a pDEST HisMBP
plasmid with a TEV cleavage site, three primers were employed to produce the insert:
primer N1, primer C, and primer N2 in a two sequential PCR reactions. In the first
reaction the forward primer N1 contains a 5’ region coding for the restriction sequence of
TEV (Figures 4-6) followed by 20 nucleotides of the coding passenger DNA. The reverse
primer, Primer C, has a 5’ region encoding the attB2 recombination site followed by 21
nucleotides of the 3’ coding region of the passenger DNA (Figure 4-7). Here an
excessively long forward primer is obviated by a second PCR reaction in which the first
PCR amplicon becomes the primer for the second PCR amplicon N2 (Figure 4-6) (75).
Primer C, the reverse primer, is used in both reactions. Primer N2, the forward primer for
the second PCR reaction, encodes the attB1 recombination site followed by 19
nucleotides of the coding TEV protease site. The three primers can be employed in a
single PCR reaction to obtain a final insert with flanking attB1 and attB2 recombination
sites, and a TEV protease site, or the reaction can be done in series amplifying first with
Primer N1 and C, purifying the PCR product, and then amplifying a second time with
Primer N2 and C.
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The reaction was performed in both single step (not shown), and two step reactions with
only the later successfully producing the appropriate insert. Concentrations of the primers
were consistent with those used by Austin et al. 2009 (Table 1). The PCR thermal cycler
settings were as follows: initial melt 5 min at 95°C; 35 cycles of 95°C for 30 s, 55°C for
30 s, and 72°C for 60 s then hold at 4°C. After agarose gel electrophoresis (Figures 4-7,
4-8) PCR products excised, and then purified with the Pure Link™ PCR clean-up kit
(Invitrogen, Carlsbad CA).

4.8.Gateway® Cloning Donor Vector

After PCR the inserts were purified, and introduced by recombination into the donor
vector pDONR221 (Invitrogen Carlsbad, CA). The hCycT1-Tat gene was transferred
from the attB flanked PCR product into the attP flanking donor vector by recombination
in what is called a “Gateway® BP reaction” (referring to the joining of the attB and attP
sites) (Figure 4-9) by incubating equimolar amounts of attB-PCR product and donor
vector with BP Clonase overnight at 25°C (Invitrogen Carlsbad, CA) in TE buffer at pH
8.0. At the end of the BP reaction Proteinase K solution was added and the reaction was
incubated for 10 minutes at 37ºC. The pDONR221 vector was then transformed into
OmniMAX™ 2-TIR chemically competent E. coli. The negative selection gene ccdB of
the pDONR221 plasmid was replaced by recombination of the attB flanked PCR product
and only successful recombinants survived on LB plates with 50 ug/ml kanamycin (73).
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4.9.Gateway® Cloning Destination Vector

Once the hCycT1-Tat gene was transferred into the pDONR221 donor vector the target
gene was then transferred by LR recombination reaction into the expression or
“destination” vector (more details of the recombination reactions will be described in
connection with Fig. 6-10). The attP recombination sites of the pDONR221 vector
recombined with the attB sites of the PCR insert to form attL sites that recombine into the
attR sites of the destination vector during the LR reaction. The pDONR221 plasmid DNA
(150 ng/ul in TE, pH 8.0) was incubated with 150 ng/ul of pDEST HisMBP in TE, pH
8.0 overnight at 25ºC. At the end of the LR reaction Proteinase K solution was added and
the reaction was incubated for 10 minutes at 37ºC (73). The pDEST His-MBP hCycT1Tat vector was then transformed into chemically competent Rosetta Gami B (Novagen
Madison, WI) E. coli (Figure 4-8). The pDEST HisMBP hCycT1-Tat plasmid was
sequenced at Upstate Medical DNA Core Facility, and the correct sequence and the
reading frame of the insert were confirmed (Figures 4-10 and 4-11).
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Figure 4-1 pDEST-HisMBP Plasmid.
Addgene#:11085. Deposited by The David Waugh Lab.
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BamHI (803)
AfeI (829)
NcoI (948)
EcoRI (953)
AvaI (959)
ClaI (966)

HindIII (1176)
AvaI (1209)
AfeI (1288)

pGEX 2TK hCycT1 249-280 Tat 101@1@2 with AfeI
1351 bp

mutations

Figure 4-2 Introduction of AfeI restriction sites by site directed mutagenesis.

The location for introduction, by site directed mutagenesis, of two AfeI blunt-end
restriction sites to the pGEX 2TK plasmid flanking the hCycT1-Tat chimera DNA
sequence. The AfeI sites were placed such that the 5’ site cleaved the insert prior to the
codon corresponding to residue 257 of the 249-280 portion of Cyclin T1 and the 3’
restriction site was placed after the codon corresponding to a single residual leucine
residue past the 101 amino acid Tat sequence that remains as an artifact of the cloning
process.
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Primer pair 1
*****
Forward: 5' CCAACAGGCTCAAACGCAGCGCTAATTGGAGGGCATGCGAG 3'
Reverse: 5' CTCGCATGCCCTCCAATTAGCGCTGCGTTTGAGCCTGTTGG 3'
*****
GC content: 58.54%

Location: 754-794

Melting temp: 77.2°C

Mismatched bases: 5

Length: 41 bp

Mutation: Substitution

5' flanking region: 18 bp

Forward primer MW: 12678.36 Da

3' flanking region: 18 bp

Reverse primer MW: 12535.25 Da

Figure 4-3 Two PCR primers for the introduction of the 5’ restriction sites.
Using PrimerX software two primers were designed
to add the same AGC/GCT blunt end restriction site to the 5’ end of the insert (Serial
Cloner)
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Primer pair 1
******
Forward: 5'
GACAGATCCGTTCGATTTGAGCGCTGTCGAGAGAGCGGCCGCATC 3'
Reverse: 5'
GATGCGGCCGCTCTCTCGACAGCGCTCAAATCGAACGGATCTGTC 3'
******
GC content: 60.00%

Location: 1211-1255

Melting temp: 78.1°C

Mismatched bases: 6

Length: 45 bp

Mutation: Substitution

5' flanking region: 19 bp

Forward primer MW: 13903.14 Da

3' flanking region: 20 bp

Reverse primer MW: 13783.08 Da

Figure 4-4 Two PCR primers for the introduction of the 3’ restriction sites.
Using PrimerX software two primers were designed to add the same AGC/GCT blunt end
restriction site to the 3’ end of the insert (Serial Cloner)
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Figure 4-5 Agarose gel electrophoresis of the PCR products for AfeI sites
Agarose gel electrophoresis analysis of the PCR products for the addition of AfeI bluntend restriction sites by site directed mutagenesis at sites 5’ and 3’ of the hCycT1-Tat
insert. Gel electrophoresis at 0.7% agarose 140 V. From top to bottom:
1 – forward primer for 3’ mutation

2 – reverse primer for 3’ mutation,

3, 4, 5 – pGEX 2TK plasmid with 5’ AfeI sites,
6,7,8 – pGEX 2TK plasmid with both 5’ and 3’AfeI sites.
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Figure 4-6 Diagram of the sequential PCR reaction for the att flanked insert.
Diagram of the sequential PCR reactions for the production of the HisMBP hCycT1-Tat
chimera insert with flanking att, and internal TEV protease sites.
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Table 1 Set-up of the PCR reactions for primers N1, N2, and C
Set-up of the sequential PCR reactions for primers N1, N2, and C for the production of
the HisMBP hCycT1-Tat chimera insert.
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Primer N1 – 5’ - GAG AAC CTG TAC TTC CAG GGT GCT AAT TGG AGG GCA
TGC GA – 3’
Primer C - 5’ - GGG GAC CAC TTT GTA CAA GAA AGC TGG GTT ATT AGC
TCA AAT CGA ACG GAT CTG T – 3’
Primer N2 – 5’ - GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC GGA GAA
CCT GTA CTT CCA G – 3’

Figure 4-7 Nucleotide Sequences of N1, C, and N2 primers
Sequences of N1, C, and N2 primers for addition of the TEV protease site, and the attB1,
and attB2 flanking recombination sequences for Gateway® cloning. For the N1 and N2
primers sequences in blue include the sequence for addition of the TEV protease site. For
primer N1 the sequence in black complements the antisense strand of the Tat chimera
insert after cleavage by AfeI. For primer C the sequence in green includes the sequence
for the addition of the attB2 site, and the portion in black complements the sense strand.
The primer N2 sequence in red includes the sequence for addition of the attB1 site, while
the sequence in blue is the same as the TEV protease sequence in N1 (with the exception
of the final three nucleotides), and complementary to the antisense strand after the first
PCR reaction with N1 and C.
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Figure 4-8 Agarose gel electrophoresis of PCR products for the N1 and C primers
An agarose gel electrophoresis analysis of the PCR products for the N1 and C primers
adding the TEV protease site and the flanking att B2 recombination site to the hCycT1Tat chimera DNA insert. Gel electrophoresis 0.7% agarose 0.5 X TBE 140 Volts. From
top to bottom:
1 – ladder 1 kb

2 - negative control primers only (no template DNA)

3 – positive control (kit template DNA and primers)
5 – primer N1, primer C, and Tat chimera insert reaction (20 ul).
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4 – empty
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Figure 4-9 Agarose gel electrophoresis of PCR products for the N2 and C primers
An agarose gel electrophoresis analysis of the PCR products for the second round of
PCR with the N2 and C primers adding the attB1 and attB2 sites, respectively to the Tat
chimera DNA insert after the first round of PCR with N1 and C primers. Gel
electrophoresis 0.7% agarose 0.5 X TBE 140 Volts. From top to bottom:
1 – ladder 1 kb

2 – negative control primers only (no template DNA)

3 – positive control (kit template DNA and primers)

4 – empty

5 and 6 – primer N1, primer C, and Tat chimera insert reaction (20 µl)
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Figure 4-10 Gateway cloning BP and LR reaction
Gateway cloning BP and LR reactions for the production of the pDEST HisMBP (257280) hCycT1-Tat (101) chimera expression plasmid. In the BP reaction (top) the att
flanked insert is recombined into the pDONR221 entry vector. In the LR reaction
(bottom) att sites of the donor vector recombine with att sites on the pDEST-HisMBP
expression plasmid.
* According to Life Technologies Corporation the letters B, P, L, and R refer to bacterial, phage, left, and right respectively.
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Figure 4-11 Diagram of the pDEST-HisMBP hCycT1-Tat chimera.

Schematic diagram of the pDEST-HisMBP hCycT1-Tat chimera plasmid. The chimera
insert is flanked by attR sites compatible with the Gateway® Cloning recombination
system. The tightly regulated tac promoter is upstream from the dual HisMBP tag which
facilitates purification, and enhances solubility of the Tat chimera. The straight portions
between the Tat (orange), myc (yellow), and hCycT1 (red), are linker regions that
provide the chimera with the flexibility to adopt secondary structure.
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Figure 4-12 pDEST HisMBP 257-280 hCycT1-myc-Tat Protein Sequence

The final translated protein sequence of the HisMBP 257-280 hCycT1-Tat chimera
confirmed with DNA sequencing by the Upstate Medical University DNA Core Facility
and translated by Serial Cloner software. The sequence begins with glycine and alanine
(artifact residues of the cloning process) at the N-terminus of the protein. The 257-280
portion of Cyclin T1 appears underlined in green, followed by a spacer region which
contains the myc tag (underlined in blue). The 101 amino acid Tat sequence is followed
by residual amino acids leucine and serine which remain (as artifacts of the cloning
process) at the C-terminus.
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Chapter 5 A Preliminary Cyclin T1-Tat Chimera

Once the construction of the pDEST HisMBP hCycT1-Tat chimera was complete, a
suitable expression strain was selected. Choosing an appropriate strain for the production
of a heterologous protein is essential to achieving high yield, adequate solubility, and
proper folding. Due to rapid growth rate, low cost, and the extensive amount of genetic
information available E. coli strains are regularly chosen for the production of
recombinant proteins. In order to achieve the high yield required for structural study of
the hCycT1-Tat chimera the chosen strain would first be required to accommodate the
tightly controlled tac promoter of the pDEST-HisMBP plasmid.

5.1.The tac Promoter

When expressing recombinant proteins from plasmids with tac promoters it is generally
best to select a non-DE3 non-pLysS expression strain (Novagen conversation).
Researchers often propose that a DE3 strain can be used with plasmids utilizing tac
promoters (42,76). However, here we show that the expression of the pRK793 plasmid
(Appendix 8) for production of the TEV protease enzyme (HisMBP-TEV[S219V]) (74) in
Rosetta Gami B (Novagen, Madison, WI) (Figure 5-1), a non-DE3 strain of E. coli, provides
a substantial increase in target expression, as well as a moderate increase in basal expression,
over the Rosetta Gami B DE3 strain. This observation can likely be attributed to the fact that
the DE3 prophage expresses T7 RNA polymerase which, when utilizing a tac promoter,
unnecessarily taxes the cells and should be avoided as tac expression systems employ the
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native E. coli RNA polymerase. It is also important to note that the pLysS plasmid often
provided with DE3 strains produces T7 lysozyme which regulates T7 RNA polymerase
reducing basal expression, but is also unnecessarily taxing in, and obviated by, the use of
plasmids with tac promoters.

5.2.Codon Usage

The next important consideration in the recombinant expression of the chimera is the
presence of codons that are atypical in E. coli. Using the UCLA Rare Codon Calculator
(http://nihserver.mbi.ucla.edu/RACC/) it was estimated, prior to sequencing, that the
cleaved chimera sequence contains at least 15 rare codons that are known to hinder
expression in E. coli by the stalling and premature termination of translation,
incorporation of incorrect amino acids, and by frameshifts that contribute to low
expression yield (77) (Table 7-1). Of the rare codons known to be present, 11 are rare
arginine codons. There are also two occurrences of a rare leucine codon, and two
occurrences of a rare proline codon.

The presence of rare codons in recombinant expression can be addressed by codon
optimization, where an equivalent E. coli codon is substituted for the atypical codon, or
by the use of expression strains that contain additional plasmids coding for the atypical
tRNAs such as Rosetta Gami B (Novagen, Madison, WI).
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5.3.Disulfide Bonds

In E. coli the formation of disulfide bonds is compartmentalized in the periplasm.
Subsequently, the reduction of disulfide bonds is accomplished through the thioredoxin,
and glutathione/glutaredoxin pathways in the cytoplasm. Mutation of the thioredoxin
reductase (trxB), and glutathione reductase (gor) genes allow disulfide bond formation in
heterologous protein to take place in the cytoplasm of E. coli by destabilization of the
reduction mechanism (78). Substantial increases in active protein yield have been
observed in expression strains with both the trxB and gor mutations with the result being
attributed to improved folding where disulfide bond formation in the cytoplasm is
facilitated (79). Strains possessing the dual mutation are commercially available.

The high number of cysteine residues in the Tat chimera and the presence of two zinc
fingers alone suggest that an environment favorable to disulfide bond formation during
expression could potentially augment expression yield. In support of the potential
importance of disulfide bond formation, dramatically inhibited Tat activity has been
observed in the presence of strong reducing agents leading to speculation about the
presence of disulfide bonds in the active protein (44,80,81). Though no such disulfide
bonds were reported by Tahirov et al. 2010 in the published structure of Tat complexed
with P-TEFb, the conformation of the active site of Tat remains unknown, as does the
conformation of Tat when bound to TAR. Moreover, a number of zinc finger proteins
have been shown to demonstrate redox sensitivity (82) as well as behavior consistent
with that of redox sensory proteins that may alternate conformation between zinc bound
states and disulfide bond formation between cysteine residues.
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5.4.Outer Membrane and Lon Proteases in E. coli

The outer membrane protease T (OmpT) of E. coli is a member of the omptin family of
integral membrane peptidases implicated in the pathogenicity of several gram-negative
bacteria. This highly specific endopeptidase cleaves between two basic amino acids, and
demonstrates resistance to extreme denaturing conditions (83). In E. coli OmpT has been
implicated in protein degradation (84). Expression strains containing an OmpT mutation
inactivating this endopeptidase have demonstrated higher yields of heterologous proteins.

The Lon protease of E. coli is a highly conserved ATP dependent protease that degrades
misfolded, or mutant proteins, and a few specific regulatory proteins (85). In the
expression of recombinant proteins it is desirable to choose an expression strain with the
Lon protease inactivated by mutation in an effort to prevent possible degradation of the
target protein.

5.5.Lactose Permease

In E. coli lactose is utilized under the control of the lac operon system where lacY
facilitates the transport of lactose into the cell, and lacZ cleaves lactose (86). In E. coli
protein expression strains containing the lacZY deletion mutation, protein expression
levels may be adjusted (called “tuning”) throughout all cells in a culture by regulating
IPTG concentration at induction. Proteins with solubility issues occasionally exhibit
improved solubility with reduced concentrations of IPTG that theoretically allow the
protein more time to fold properly. Therefore, in difficult to express proteins it may be
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advantageous to employ this mutation. However, when using such strains auto-induction
media may not be used as strains with the lacZY mutation do not produce the required
allolactose.

5.6.Rosetta Gami B Strain (Novagen, Madison WI)

The commercially available Rosetta Gami B Strain of competent cells (Novagen,
Madison, WI) provides a combination of attributes that are well suited to the expression
of the recombinant Tat chimera. Rosetta Gami B cells carry an additional plasmid
accommodating the expression of six rare codons. This strain, bearing the trxB and gor
mutations, may also improve protein folding and the yield of soluble protein in proteins
containing disulfide bonds. Both the OmpT and the Lon proteases have been removed by
mutation from the Rosetta Gami B expression strain. Finally, this strain has a “tunable”
expression feature, as a result of the lacZY mutation, presenting another potential
mechanism for improved folding and solubility.

During the initial expression attempts with the GST tagged chimera virtually no
expression was observed in either BL21 DE3 pLysS or BL21 non-DE3 non-pLysS, and
very low expression was achieved with the Rosetta 2 (Novagen, Madison, WI) cells that
contain a plasmid accommodating expression of atypical codons. After carefully
considering the combination of attributes afforded by the strain, the characteristics of the
recombinant protein being expressed, and the initial observations during expression of the
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GST tagged chimera, the Rosetta Gami B cells were selected for the first attempts at
expression of the HisMBP-hCycT1-Tat chimera.
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Position

Codon

Amino Acid

5

AGC

Arginine

18

CGA

Arginine

59

CTA

Leucine

61

CCC

Proline

70

AGG

Arginine

91

AGA

Arginine

100

AGG

Arginine

104

AGA

Arginine

106

CGA

Arginine

107

CGA

Arginine

108

AGA

Arginine

120

CTA

Leucine

124

CCC

Proline

129

CGA

Arginine

135

CCC

Proline

144

AGA

Arginine

Table 2 Rare codons and their position in the hCycT1-Tat chimera.
Rare codons in red and green are not accommodated by the Rosetta Gami B strain.
This fact will not prevent expression entirely as these rare tRNA are present in E. coli
albeit in lower amounts.

- 66 -

1

2

3

4

5

250
150
100
75
50
37
25
20
15
10

Figure 5-1 Expression of the HisMBP TEV pRK793 plasmid
The expression of the HisMBP TEV pRK793 plasmid (Appendix 8) (for recombinant
expression of the Tobacco Etch Virus protease S219V mutant) in Rosetta Gami B DE3
versus non-DE3 strains. From left to right:
1 – ladder

2 – Rosetta Gami B DE3 uninduced

3 – Rosetta Gami B non-DE3 uninduced

4 – Rosetta Gami B DE3 induced

5 - Rosetta Gami B non-DE3 Induced
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Chapter 6 Optimizing Protein Expression Yield

Optimizing the yield of recombinant protein expression is an empirical process that
requires a dual pronged approach. First the overall crude protein expression yield must be
optimized, and second the fraction of the expressed protein available in soluble form
must be maximized. Care must be taken to avoid aggregation and precipitation after
cleaving solubility enhancing tags, and when the target protein is present in solutions at
both low and high concentrations. With an eye toward downstream applications, buffer
compatibility with purification and assay requirements and long-term storage conditions
must be optimized.

Control over the final soluble expression yield may be exerted at many points throughout
the expression, purification, and storage of the protein. The choices of expression strain,
growth media, and growth conditions, as well as a long list of potentially helpful
techniques and additives that can be employed along the way results in a daunting
number of possible combinations of varying efficacy. Predicting which of these
techniques will be most effective for a particular protein is rarely possible, and empirical
determination can be extremely costly and time-consuming. Hence, wherever possible
high-throughput methods of assessing the efficacy of yield and/or solubility enhancing
techniques are highly desirable.

While the subject of choosing an expression strain has been discussed previously, it is
worth noting here that even within a specific transformed strain target protein expression
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levels of some colonies may surpass that of others. Thus, it is often advantageous to
screen multiple colonies of the same transformed strain for the purpose of comparing
expression yields. In an assay called a Double Colony Selection (DCS) several colonies
from a single transformation are assessed for recombinant target expression yield. The
colony with the highest yield is then cultured overnight, plated, and in a second round of
selection several colonies are again compared by yield of the target protein. In some
cases this procedure can substantially increase the yield of recombinant expressions.
Periodically re-transforming, and screening the expression strain to be sure that the
plasmid is not lost is also an important step in maintaining high yields of protein
expressions.

Once the transformed strain has been optimized, the next step is to optimize the growth
conditions by providing appropriate nutrients in the form of growth media, and additives
where necessary, and by controlling the growth conditions of temperature, aeration, and
pH of the growth environment. Many different media formulations are available with a
variety of nutrients and additives that may improve both the yield, and the efficiency of
the expression protocol.

6.1.Growth Media

The appropriate selection of growth media is necessary for achieving maximal growth
rate and cell yield. While E. coli are able to synthesize many of the nutrients they require,
the production of soluble, stable, and functional recombinant proteins is best achieved
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with the addition of trace metals, minerals, and vitamins to the growth medium (87). The
basic components of E. coli growth media include water, an amino acid nitrogen source
such as tryptone, a carbon source in the form of a fermentable sugar (such as glucose),
yeast extract (an additional nitrogen source), sodium chloride to regulate the osmotic
environment, and phosphate to provide a source of phosphate for growth and also to
buffer the growth media. Where a specific strain is growing aerobically at a fixed
temperature, both growth rate and yield of cells are dependent on the carbon source (88).
Supplementation of the E. coli medium with appropriate nutrients increases the quantity
of E. coli cells. Both plasmid and recombinant protein yield are directly proportional to
the quantity of E. coli cells.

Another important condition in the optimal growth of E. coli is the maintenance of near
neutral pH. While sensitivity to low pH is somewhat lower than sensitivity to high pH,
which can cause cell death, the optimal pH range for E. coli growth is 5.5 to 8.5 (87).
Without proper aeration E. coli produce acetic acid which lowers the pH of the culture,
and inhibits cell growth. Agitation of the culture during cell growth increases aeration of
the culture, as does the use of a baffle bottom flask. In addition, many media formulations
employ buffers such as potassium phosphate to maintain an optimal pH range during cell
growth.
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6.2.LB Media

Lysogenic Broth (LB) also known as Luria-Bertani is a commonly used media formula
for the growth of E. coli cell cultures. Originally, the formula was supplemented with the
addition of 1 mg/ml glucose, but such supplementation is no longer common in
contemporary LB formulas. Sezonov et al. 2007 found that steady-state growth of E. coli
ended when the culture reached an OD600 of 0.3, and that the growth of the cell culture
was limited by availability of carbon sources which E. coli catabolized, not from sugars,
but from available amino acids (89). The use of LB media is generally an appropriate
choice for recombinant expression of a protein of interest, and tends to produce low basal
expression of other E. coli cellular proteins.

6.3.Rich Media

Achieving high cell yield and cost effective and efficient recombinant protein production
can be enhanced in some expression systems with the use of rich media. Accumulation of
acetic acid, a byproduct of glucose metabolism that inhibits cell growth, can be reduced
with the use of alternative carbon sources such as glycerol, and also by media with
buffering capacity. Many recipes for rich media contain trace metals, trace minerals, and
vitamins, as well as proprietary ingredients in commercial formulations which often have
animal sources (87). As with most other aspects of recombinant protein expression
protocols, the usefulness of any particular media formulation must be determined
empirically. One of the potential disadvantages of the use of rich media is an increase in
basal expression which can hinder purification.
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6.4.Turbo Broth™
One proprietary media formulation, Turbo BrothTM (AthenaES Baltimore, MD), claims to
achieve 4 to 5 times higher E. coli cell yields than that achieved in LB media alone. This
rich media substitutes glycerol for glucose as a carbon source, and is supplemented with
trace minerals, vitamins, inorganic compounds, and amino acids. The addition of
potassium phosphate maintains the culture pH at 7.2 ± 0.2. Although not quantitatively
compared, by visual comparison the induced protein yield of the HisMBP-hCycT1-Tat
chimera appears considerably higher with the use of Turbo BrothTM when compared to
LB media (Figure 6-1). Predictably however, the basal expression of other E. coli cellular
proteins also appears to have been considerably increased.

6.5.Auto-induction Media

Auto-induction media contains the carbohydrates lactose, and glucose. Initially E. coli
use the limited amount of glucose available in the formula as an energy substrate
typically until mid or late log phase. When the glucose has been depleted the E. coli then
use lactose converting it to allolactose with the enzyme β-galactosidase. The lac repressor
is released from the DNA by allolactose initiating the expression of the recombinant
protein. The advantages of using this formula are that it is not necessary to monitor the
culture to determine the induction point, increased cell mass is generally observed, and
that optimal initiation of expression tends to increase protein yield (90). However,
because of the lacZY mutation the Rosetta Gami B cells will not produce allolactose, and
therefore this strain cannot be used for protein expression in auto-induction media.
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6.6.Minimal Media

For structural study of proteins using nuclear magnetic resonance (NMR) isotopically
labeled proteins must be expressed in E. coli. In particular, heteronuclear single quantum
coherence (HSQC) requires the protein of interest to be 15N labeled. Isotopic labeling of
the protein with 15N is typically achieved by growing E. coli in M9 media (Appendix 9)
containing 15NH4Cl as the sole nitrogen source. The M9 media is supplemented with
glucose, trace metals, vitamins, and other minerals, but in general E. coli incorporating
15

N tend to grow more slowly in minimal media. Some proteins can be expressed

sufficiently with little effort in minimal media, while other less tractable targets can prove
problematic. A multitude of minimal media formulas have been developed to improve
labeled protein yields in minimal media, and a number of commercial and proprietary
formulas are marketed for use in exceptionally difficult expressions. Commercial
formulas such as BioExpress® (Cambridge Isotope Laboratories, Inc. Andover, MA),
however, can be quite costly (at present in excess of $700 per liter) depending upon the
number of isotopes incorporated.

6.7.Growth Phases of E. coli

The growth of E. coli can be described in four phases: lag phase, log phase, stationary
phase, and death phase. When the optical density at 600 nm of a solution of E. coli in
growth media is plotted as a function of time each of these four phases can be seen to
occur in succession. When the culture is first inoculated the rate of growth is typically
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during the initial lag phase as the E. coli acclimate to fresh media and antibiotics. During
the second phase, the logarithmic phase or “log” phase, E. coli reproduce exponentially.

It is at the mid-point of this log phase that induction of recombinant protein expression
will generally produce optimal yield. During the log phase the E. coli are said to be
“healthy” as the medium is not yet depleted of nutrients, nor yet full of the toxic
byproducts of E. coli metabolism. Recombinant protein expression is a process which is
heavily taxing to the cell, and which sequesters many cellular resources. Moreover, many
recombinant proteins are toxic to E. coli. Thus, the induction of expression when the E.
coli are most fit and reproducing rapidly will generally produce the highest yield. As
nutrients are depleted, byproducts contaminate the medium, and crowding occurs. At this
point cells enter the stationary phase. In the stationary phase cell density is maintained at
a steady state. During the final “death phase” the effects of the nutrient depleted medium
and the buildup of the toxic waste byproducts of metabolism combine causing cell death
observable as a decrease in culture density.

6.8.Growth Curves for the Tat Chimera in Various Media

Figures 6-2, 6-3, and 6-4, show the growth curves for the pDEST HisMBP hCycT1-Tat
chimera in Rosetta Gami B cells (RBG) in LB, Turbo, and BioExpress® media. Figure 65 shows the growth curve for the double colony selection mutant (DCS) in BioExpress®
media. In each of the growth curves below we see that optimal induction should occur
between OD600 of 0.6 to 0.8.The mid-point of the mid-log phase for the growth curves of
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the Rosetta Gami B (RGB) in LB, Turbo Broth™, and BioExpress®, and for the double
colony selection (DCS) was approximately OD600 0.7.

When Tat chimera expression by RGB transformed with pDEST HisMBP-hCycT1-Tat
was compared in LB, Turbo Broth™, and BioExpress® media, as anticipated, the highest
recombinant protein expression was found in the Turbo Broth™ rich media (Figure 6-7).
Tat chimera expression by DCS in BioExpress® media was compared to expression by
RGB in BioExpress® media. The specifically selected DCS mutant demonstrated higher
expression than RGB in samples taken four hours after induction (Figure 6-7), but lower
levels of expression than RGB in samples taken after 18 hours. This could be due to
protein degradation which is commonly observed in lengthy expression protocols, and
which for some reason the DCS mutant may be more susceptible to. The yield achieved
for both RGB and DCS in the BioExpress® media was comparable to that achieved in
LB (Figure 6-7), a promising result when considering the low levels of recombinant
expression typical of minimal media when compared to nutrient rich media.

6.9.Comparison of Construct, Strain, and Media Changes

There was no consistent observable overexpression of the GST-hCycT1-Tat chimera in
BL21 with either the DE3 pLysS, or non-DE3 non-pLysS strains. This observation is
most likely due to the approximately 14% atypical codons which would not be
accommodated by these strains. When the GST chimera was expressed in Rosetta 2
(Novagen) cells a low level of expression was observed in 1 L of LB induced at OD600
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=0.7

with 1.0 mM IPTG and after 6 hours of growth at 28º C (Figure 6-8 A). By visual

comparison of the samples in SDS PAGE, expression of the HisMBP chimera construct
in Rosetta Gami B in 1 L of Turbo Broth™ was clearly and substantially increased over
that of the original GST construct and protocol (Figure 6-8 B)
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Figure 6-1xpression of the HisMBP Tat Chimera in LB and Turbo Broth
A. Expression of the HisMBP-hCycT1-Tat chimera in LB media
: 1 – Ladder

2 – Uninduced

3 – Induced.

B. Expression of the HisMBP-hCycT1-Tat chimera in Turbo BrothTM
: 1 – Ladder

2 – Uninduced

3 – Induced

Both samples from one liter cultures induced at OD600 0.7 and grown at 28°C for 7 hours.
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Figure 6-2 Growth Curve of Rosetta Gami B in LB Media
The growth curve of pDEST HisMBP hCycT1-Tat in Rosetta Gami B cells in LB media
at 37°C.
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Figure 6-3 Growth Curve of Rosetta Gami B in Turbo Media
The growth curve of pDEST HisMBP hCycT1-Tat in Rosetta Gami B cells in Turbo
media at 37°C.
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Figure 6-4 Growth Curve of Rosetta Gami B in BioExpress® Media
The Growth curve of pDEST HisMBP hCycT1-Tat in Rosetta Gami B Cells in
BioExpress® Media at 37°C.
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Figure 6-5 Growth Curve of Double Colony Selection in LB Media
The growth curve of pDEST HisMBP hCycT1-Tat in Rosetta Gami B cells Double
Selection Mutant in LB media at 37°C.
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Figure 6-6 Growth Curve of Double Colony Selection in BioExpress® media.
The growth curve of pDEST HisMBP hCycT1-Tat in Rosetta Gami B cells Double
Selection Mutant in BioExpress® media at 37°C.
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Figure 6-7 Small Scale Media and Strain Comparison in Various Media
Small scale (6 ml) media and strain comparison in various media with induction at OD600
=0.7. From left to right:
1 – ladder

2 – uninduced Rosetta Gami B (RGB) in LB

3 – induced RGB in LB after 4 hours

4 – induced RGB in LB after 18 hours

5 – uninduced RGB in Turbo BrothTM
6 – induced RGB in Turbo BrothTM after 4 hours
7 – induced RGB in Turbo BrothTM after 18 hours
8 – uninduced RGB in BioExpress® minimal media
9 – induced RGB in BioExpress® minimal media after 4 hours
10 – induced RGB in BioExpress® minimal media after 18 hours
11 – uninduced double colony selection (DCS) in BioExpress® minimal media
12 – induced DCS in BioExpress® minimal media after 4 hours
13 – induced DCS in BioExpress® minimal media after 18 hours
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A

B

Figure 6-8 Comparison of GST Chimera and HisMBP Chimera Constructs
Comparison of protein expression with the original GST chimera construct and protocol
and in the re-engineered HisMBP construct with revised expression strain and protocol.
A. Original GST-hCycT1-Tat chimera in Rosetta 2 cells expressed in LB induced at
OD600=0.7 with 1.0 mM IPTG after 6 hours at 28°C (as per original protocol from
K. Fujinaga (Appendix 10)).
B. HisMBP-hCycT1-Tat chimera in Rosetta Gami B cells expressed in Turbo
Broth™ induced at OD600 =0.7 with 1.0 mM IPTG after 6 hours at 28°C.
Samples from 1 ml of 1 L induced culture resuspended in 100 ul 1 X SDS.
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Chapter 7 Optimizing Recombinant Protein Solubility

Once a high rate of recombinant protein expression is achieved the next set of challenges
entail avoiding proteolytic degradation of the nascent target protein, achieving a
sufficient yield of soluble and active protein, and removing the solubility enhancing tag
in preparation for downstream applications. While proteolytic degradation can generally
be mitigated substantially by the introduction of protease inhibitors to the working
solutions, solubility can be considerably less tractable.

The majority of published work addressing techniques shown to improve the solubility of
recombinant proteins focuses on the notoriously difficult expression of membrane
proteins. Receiving considerably less attention, however, are the 80% of non-membrane
proteins which are poor subjects for structural assays primarily due to insolubility (91).
Mammalian and other proteins are frequently poorly expressed in bacteria where the
absence of post-translational modification and differences in the folding environment
introduce formidable challenges to recombinant expression (92). In eukaryotic proteins
multiple domains, and the requirement of cofactors, and protein partners tend to hinder
recombinant expression efforts (93). In fact, the production of many of the recombinant
proteins that would make attractive subjects for research is often abandoned because of
the time and expense involved in their pursuit. The introduction of high-throughput
protein expression and purification methods is a valuable addition to the field, with the
advantage of permitting the screening of a multitude of variable expression, purification,
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and storage conditions simultaneously. Unfortunately, this equipment is not yet widely
available, and most laboratories still rely on more traditional empirical methods.

7.1.Denaturing and Refolding Recombinant Proteins

In many cases high expression levels of the recombinant protein are observed in the crude
extract, but the protein can present in misfolded and inactive forms that aggregate in
insoluble inclusion bodies. Rescuing the active form of the protein from insoluble
inclusion bodies may or may not be possible, and can involve complicated denaturing
protocols utilizing chaotropic agents or acids, followed by difficult refolding procedures
into what the researcher hopes will be suitable buffers. Many problematic proteins do not
readily refold into active conformations by known in vitro folding techniques (94), and
high yields of soluble recombinant protein from denaturing and refolding protocols are
rarely observed (45). Where refolding is possible, confirming that the form achieved is
the proper native and active form of the protein generally requires additional assays that
can also be challenging. Moreover, confirming the proper conformation may be
complicated by a lack of available structural information for the protein of interest. Thus,
wherever possible obviating such complicated denaturing and refolding techniques is
highly desirable.
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7.2.Increasing Recombinant Protein Solubility

Yield of the purified soluble and active protein may potentially be improved by a plethora
of measures, among them: changes in expression conditions such as post-induction
temperature, and IPTG concentration, as well as the strategic addition of a variety of
potentially solubility enhancing compounds to the growth media. It is also possible to
introduce a number of techniques during cell lysis, purification, concentration, and
storage procedures that can further enhance solubility, and ultimately improve the final
yield of the active protein. Commonly, a multitude of techniques are evaluated
empirically, and combined in a single protocol in order to achieve adequate yield of the
protein of interest.

7.3.Reducing the Expression Rate

One simple approach to improving the soluble yield of the target protein is to reduce the
expression rate in order to allow additional time for proper folding of the native and
thermodynamically favored state. Reducing the concentration of the inducing agent
(IPTG in this case), and/or decreasing the temperature of the culture post-induction
reduces the expression rate of the recombinant protein and frequently results in an
increase in the yield of the soluble protein. A range of concentrations of the inducing
agent, and temperatures post-induction should be evaluated to determine the optimal
conditions for enhanced solubility. Weaker promoters and lower copy number plasmids
can also be employed to reduce the expression rate of the recombinant proteins.
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7.4.Increasing the Expression of Chaperone Proteins

In vivo protein folding can occur over a timescale ranging from milliseconds to days.
During the folding process protein folding intermediates often have exposed hydrophobic
surfaces that promote self-association and the formation of aggregates that lead to
insoluble inclusion bodies and precipitation (95). Proteins known as chaperone proteins
assist in the process of folding nascent proteins and in refolding improperly folded
proteins.

In overexpression systems the high concentration of newly formed protein can
exacerbate self-association leading to the increased formation of insoluble proteins and
inclusion bodies. Moreover, the limited availability of chaperone proteins to assist in the
folding and refolding of the newly synthesized proteins will also result in a higher
fraction of insoluble protein in the form of inclusion bodies (45,94). Whenever possible,
expression of these chaperone proteins should be increased concomitant with
overexpression of the target protein in order to accommodate the increased folding
requirements of the highly concentrated nascent protein.

In the cytoplasm of E. coli Trigger Factor, and the DnaK and GroES complexes are
chaperone proteins that assist in the folding, refolding, and the prevention of aggregation
in newly synthesized proteins (45). However, which chaperone protein is capable of
enhancing the solubility of a particular recombinant protein of interest may differ
depending upon characteristics of the target that are usually unknown at the time when
optimization begins (94). Once again the empirical determination of optimal expression
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conditions by multiple trials with a variety of chaperone proteins, and solubility
enhancing media additives remains a necessary and time consuming process.

7.5.Ethanol

When employed as a media additive, ethanol mimics the heat-shock response in E. coli
and has demonstrated efficacy in increasing the expression of heat-shock proteins that
function as molecular chaperones in E. coli (92,94-96). Media supplemented with as little
as 1% ethanol demonstrated enhanced heterologous protein expression in E. coli (96-98).
Georgiou and Valax 1996 reported that 3 % ethanol added to the growth medium
increased the heat-shock response and the production of chaperone proteins GroES/EL
and DnaK/J and demonstrated a synergistic effect on protein expression. Interestingly,
the enhancing effect of the addition of ethanol on solubility was prominent at the postinduction temperature of 30ºC, but was markedly reduced at 37 ºC and at 42 ºC (95).

During expression of the HisMBP-hCycT1-Tat chimera the addition of 1% ethanol to the
growth medium approximately 30 minutes prior to induction, and the reduction in culture
temperature from 37ºC to 28ºC for 7 hours of expression produced a substantial increase
in solubility of the recombinant chimera (Figure 7-1). Here the introduction of ethanol
prior to the induction of expression allows some time for the accumulation of chaperone
proteins prior to expression of the target, and appeared to have little detrimental effect on
the growth rate of the culture (data not shown).
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However, other work indicates a high yield of soluble protein can also be achieved with
the introduction of ethanol prior to inoculation. Barroso et al. 2003 attributes the
observed high target solubility in the presence of ethanol to the accumulation of
stoichiometric intracellular concentrations of chaperone proteins prior to induction, and
the expression of most rather than only some chaperone proteins though the continuous
synthesis of heat-shock transcription factor 32 (99). The heat-shock transcription factor
32 controls the induction of some 20 heat-shock genes. The requirement of sequential
interaction of nascent proteins with several chaperone proteins is reported by Gragerov et
al. 1992, observing extensive aggregation in heat-shock transcription factor  deficient
mutants, and reporting the effects of four heat-shock proteins on the deficient mutant
(100).

Where the growth rate of the culture prior to induction is not prohibitively negatively
impacted by the addition of ethanol it may be advantageous to include ethanol in the
growth media as early as possible, and also at concentrations greater than 1%. Since the
addition of 1% (v/v) ethanol at 30 minutes prior to induction produced adequate yield of
the soluble protein, the alternatives of introducing ethanol prior to inoculation, and higher
concentrations of ethanol were not evaluated. However, the synthesis of heat-shock
proteins accelerates rapidly with temperature shift, and is believed to reach steady state
within 20 minutes (101). Thus it is possible that introducing ethanol prior to inoculation
may offer no further improvement in solubility over that observed with the introduction
of ethanol 30 minutes prior to induction.
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Increasing the concentration of ethanol could increase the concentration of the soluble
fusion chimera. However, at some point high concentrations of ethanol will produce
diminishing returns for example: where the growth of the culture is taxed by toxic effects
of ethanol, and where translocation of recombinant proteins may be inhibited as observed
by Chaudhuri et al. 2006 at concentrations of ethanol in excess of 2.5% (102). The
efficacy of ethanol in enhancing the solubility of any recombinant protein, its point of
introduction into the expression protocol, and the concentration employed must be all
determined empirically and specifically for each protein target.

7.6.Osmolytes

Osmolytes are small chemically diverse organic metabolites that are made and
accumulate in the intracellular medium of cells in response to osmotic stress (103-105).
Proteins are purportedly stabilized and protected from denaturants in the intracellular
milieu by organic osmolytes that force folding, despite harsh conditions, by interaction
with the protein backbone (103,106). Osmolytic interaction with the protein backbone is
described as a highly unfavorable “solvophobic” interaction that raises the Gibbs free
energy of the denatured state substantially more than it raises the Gibbs free energy of the
native state and in this manner stabilizes the folded form of the protein (103,105). Such
stabilization of folded proteins is highly desirable for structural study. Moreover,
osmolytes may prove useful in influencing the proper folding of proteins in vivo as well
as in vitro, potentially as therapeutics in the treatment of misfolding diseases such as
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cystic fibrosis (106), or as stabilizers of protein therapeutics which are notoriously
hindered by difficulties with stability and long-term storage (107).

Naturally occurring osmolytes can be grouped into three categories: polyols, amino acids,
and the combinations of methylamines, methylsulfonium, and urea (103,108). This
diverse group of compounds can be employed to improve solubility, and stability at many
different points throughout expression, purification, concentration, and storage of
recombinant protein protocols. Here the inclusion of the polyols ethylene glycol during
cell lysis, and glycerol throughout purification and storage of the fusion chimera
appeared to improve the yield of soluble recombinant protein. In the absence of these
compounds low amounts of protein were observed in the soluble extract, and the protein
tended to be lost to precipitation during IMAC purification, and subsequent
concentration.

7.7.Additional Solubility Enhancing Compounds

A number of additional co-solvents are well known to positively influence the solubility
of proteins in solution; among these salts are highly influential and their effects on
solubility were well described by Hofmeister as early as 1888. Detergents, while most
often utilized to improve the solubility of membrane proteins, are not infrequently found
to improve the solubility of non-membrane proteins as well. While detergents often help
to prevent protein aggregation, above relatively low threshold concentrations many
detergents tend to form high molecular weight aggregates that are prohibitively difficult
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to remove, can absorb at 280 nm, and are often incompatible with downstream
applications. When possible, it is desirable to avoid the use of detergents.

7.8.Salts

In general the solubility of a protein is dependent upon dissolved salts, pH, temperature,
and the polarity of the solvent. When working with recombinant proteins the pH is
generally kept as close to a biological (pH 7.4) as possible, the buffer is polar, and the
temperature is commonly kept low to prevent degradation. The salt concentration of the
solution, however, can be modulated to increase the solubility of the protein consistent
with the phenomenon known as “salting in” in which the solubility of a protein increases
as salt is added to the solution. In salting in the addition of salt ions shield the ionic
charges of the protein preventing the aggregation and precipitation of the protein
molecules. Increasing the salt concentration past the optimal solubility range however,
will produce the opposite “salting out” effect whereby the solubility of the protein
decreases as the salt ions and protein molecules compete for molecules of solvent (109)
(Figure 7-2).

7.9.The Hofmeister Series

The Hofmeister Series, published in 1888, ranks the effect of ions on protein stability.
Kosmotropes are anions of high charge density and have a favorable effect on protein
stability. Chaotropes are cations of low charge density and also tend to stabilize protein
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structure (Figure 7-3). Though these observations generally hold to be true independent
of the protein being studied the underlying basis for this is not well understood, and
despite extensive study of this perplexing phenomenon the mechanisms of stabilization
remains elusive. So elusive is this mechanism, in fact, that researcher Barry W. Ninham,
professor emeritus of the Australian National University who has spent much of his
career studying the phenomenon described it as an area of research that is “rediscovered
every 10 years” only to be abandoned when it is discovered to be a “Sisyphean task” that
he maintains is daunting in its complexity (110).

7.10. Timasheff and Thermodynamics in Protein Stability

Some light was shed on the subject however, nearly one hundred years after the
introduction of the Hofmeiser Series when Timasheff and colleagues demonstrated that
osmolytes, several other compounds, and ions are preferentially excluded from the
immediately surrounding environment of the protein. This exclusion effectively produces
a “preferential” hydration zone surrounding and stabilizing the folded state of the protein
(105,111-118). The work of Timasheff provided the thermodynamic basis for the ranking
of the effect of inorganic salts on solubility by Hofmeiser, and suggested that the
solubility enhancing effects of these inorganic salts were dependent upon solutedependent differences in the preferential interaction of proteins with solvent and cosolvents in solution (119).
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The predictable effect of the Hofmeiser Series of ions on the thermodynamic stability of
the native state can be used to influence solubility, crystallization, aggregation, and the
stability of proteins. Clearly, a better understanding of stabilization mechanisms has
tremendous potential for the advancement of protein therapeutics where preventing
aggregation and maintaining stability are constant challenges, and in structural study
where the formation of crystals for x-ray crystallography is so notoriously difficult.
While elucidating the intricacies of the mechanism behind the observed effect of the ions
in the Hofmeiser series is beyond the scope of this text, the properties and trends of the
co-solvents aforementioned and their effects on solubility have been considered and
employed throughout the expression, purification, and storage protocols of the fusion
chimera in order to achieve adequate yield for structural work.

The challenges and complexities of elucidating the mechanisms of protein solubility and
stability notwithstanding, the author looks forward to progress in this regard. Advances in
proteomics, data generated from high-throughput empirical methods of determining
solubility and stability, and bioinformatics might be used to compile databases which aid
in the determination of these mechanisms.
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Figure 7-1 Expression of HisMBP Tat Chimera in LB media.
Analysis by SDS PAGE of small scale (25 ml) expression of the pDEST HisMBP
hCycT1-Tat in LB media. Induced with 1 mM IPTG at OD600 0.7 expressed at 28 ºC for 7
hours. s:
1 – Ladder

2 – Uninduced 1% EtOH

3 – Uninduced no EtOH

4 – Induced 1% EtOH

5 – Induced no EtOH

6 – Soluble 1% EtOH

7 – Soluble no EtOH

8 – Insoluble 1% EtOH

9 – Insoluble no EtOH

Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine
buffer. Run condition: 200V, 50 minutes.
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Figure 7-2 The effects of increasing salt concentration on protein solubility.
Salt concentration can be modulated to increase the solubility of protein consistent with
the phenomenon known as “salting in” in which the solubility of a protein increases as
salt is added to the solution. In salting in the addition of salt ions shield the ionic charges
of the protein preventing the aggregation and precipitation of the protein molecules.
Increasing the salt concentration past the optimal solubility range however, will produce
the opposite “salting out” effect whereby the solubility of the protein decreases as the salt
ions and protein molecules compete for molecules of solvent (109). Reprinted from Color
atlas of biochemistry Koolman, J. and R.H. Rohm Copyright (2005) (120) with
permission from Jan Koolman.
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.

Figure 7-3 The Hofmeister Series of Ions

Reprinted from “Experimental System II: Concentrated Aqueous Solutions & The
Hofmeister Series” with permission from Darryl Eggers. Accessed online at:
http://www.chemistry.sjsu.edu/deggers/new_page_3.htm
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Chapter 8 Protein Extraction

Structural determination of a protein of interest requires highly concentrated and purified
protein, in native conformation. After expression the target protein must be selectively
isolated from other cellular proteins, as well as from the cell membrane, and other
cellular debris. Throughout this process, and from lysis to storage, the factors affecting
solubility discussed previously must be consistently considered in order to maintain the
stability of the protein in solution. With each process added to the protocol in an effort to
improve purity, some of the yield is inevitably sacrificed. Optimization of each process in
the purification, and the minimization of the number of steps overall, will produce the
most efficient and reproducible protocol for high yield recombinant protein production.
After many attempts an efficient and reproducible protocol was developed for the
expression the HisMBP Tat chimera (Appendix 11).

8.1.Cell Lysis

The cell culture of the fusion chimera in Turbo media was induced with 1 mM IPTG at
OD600= 0.7, expressed overnight at 28ºC in 1% ethanol, and then harvested by
centrifugation. The pellets were washed in ice cold PBS, and then resuspended in 4 ml of
ice cold lysis buffer (pH 7.4) per gram of wet cell pellet weight. The lysis buffer
consisted of Tris 20 mM, NaCl 0.5 M, ZnCl2 10 uM, imidazole 20 mM, BME 5 mM,
ethylene glycol 20% (v/v), HALT protease inhibitor cocktail EDTA Free (Pierce
Rockford, IL) 10 ul/ml, arginine 50 mM, and lysozyme 10 mg/ml.
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8.2.Lysis Buffer Design

Many different formulations of the lysis buffer were evaluated. The original protocol
received from Koh Fujinaga for the GST tagged chimera specified PBS, but after several
trials with PBS, HEPES, and Tris, Tris proved to be the most effective buffer for the
HisMBP fusion chimera. Since phosphate ions are known to chelate metal ions; in the
interest of maintaining the integrity of the two zinc fingers in the HisMBP fusion
chimera, PBS was replaced. Trials with HEPES buffer failed to maintain protein stability
during FPLC purification. This is likely due to difficulties related to the use of secondary
amines in buffers and the reduction of nickel ions during IMAC purification.

With respect to the use of reducing agents, in initial trials with the HisMBP fusion
chimera TCEP was used in the hopes of providing more stable and complete reduction,
and less interference with protein quantitation measurements at 280 nm. However, TCEP
is inactivated by PBS buffers, and in addition, Bigalke et al 2011 observed that Tat
protein precipitates slowly in the presence of TCEP. Replacing TCEP with BME
provided improved solubility of the chimera during cell lysis and purification, as well as
during concentration, and storage. Improved solubility was apparent from consistent and
increasing concentration measurement by Nanodrop, when using BME as opposed to
decreasing concentration observed in samples during processing when TCEP was used
instead.
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After several trials of varying salt concentration, the relatively high 0.5 M concentration
of NaCl proved to be both recommended (GE Life Sciences) and necessary to maintain
the stability of the protein during FPLC purification. Since the yield and purity achieved
with sodium chloride was sufficient for downstream applications, other salts were not
evaluated. However, based on the Hofmeister series and the work of Wei et al. 1998, and
Frankel et al. 1988 the use of potassium chloride in lieu of sodium chloride could provide
additional stability and might make a worthwhile substitution where additional stability is
required (17,43).

A low 10 µM concentration of ZnCl2 was maintained throughout purification and storage
as a precautionary measure to preserve the integrity of the two zinc fingers. Imidazole is
present in the lysis buffer at a relatively low 20 mM concentration for the purpose of
preventing nonspecific binding to the nickel column during IMAC FPLC purification
later in the protocol. The inclusion of ethylene glycol in lysis buffers is generally present
as a cryoprotectant, while here it may have the added benefit of being an osmolyte that
tends to improve both the solubility and the stability of the target. The HALT protease
inhibitor cocktail (Pierce Rockland, IL) provides seven different protease inhibitors, and
effectively inhibited protease related degradation. The EDTA free formula of HALT was
necessary to prevent EDTA chelation of the zinc ions from the fusion chimera.

8.3.Arginine

Arginine is a potent aggregation suppressor that purportedly prevents aggregation by
masking the hydrophobic surface of the protein and prohibiting protein-protein
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interaction, specifically such aggregation as can occur due to heating, dilution, and partial
unfolding (121,122). Arginine has been shown to have a solubilizing effect on proteins
within insoluble inclusion bodies (123). Protein aggregation in low concentration
environments, while somewhat less intuitive, is frequently a concern during the early
stages of purification. Arginine is present in the lysis buffer at a concentration of 50 mM.
However, evaluating the effect of arginine on solubility was difficult due to its removal
during FPLC purification to prevent interference with downstream applications.

It should be noted that many other co-solvents were explored, and were not found to be
particularly helpful to any substantial degree. The high number of potentially useful cosolvents, and the length of time required to complete each expression do not lend
themselves readily to comparison. In the interest of time several factors were often
changed between trials and comparison of the effects of any one component was often
impractical. The appropriate combination of co-solvents determined to achieve adequate
yield may differ markedly from those required to achieve optimal yield, and it is possible
that some of the buffer components were redundant in nature, or even antagonistic rather
than complimentary. Notably however, the addition of osmolytes did appear to have the
most profound effect on enhancing solubility of the fusion chimera when expression
levels were compared in SDS PAGE analysis (Figure 7-1).

8.4.Cell Wall Disruption

A variety of lysis techniques such as sonication, freeze-thaw, liquid homogenization, and
mechanical methods are all commonly used methods of rupturing the cell wall of E. coli.
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While all but mechanical means were tried in the lysis of the chimera, sonication
provided the most consistent and high yield of soluble fusion protein. Sonication breaks
down the cell wall by delivering pulses of sonic waves. The sonication process does
cause the temperature of the cell solution to become elevated, so several short pulses are
typically alternated with equally short intervals at reduced temperature to maintain the
low temperature of the solution.

After collecting the cells by centrifugation at 2,500 rpm for 25 minutes at 4°C, the cell
pellet was held on ice in 4 ml of lysis buffer per liter for 15 to 20 minutes to begin
degradation of the cell wall. The protein extraction reagent B-PER (4 ml/L of culture)
(Thermo Fisher Scientific, Inc. Rockford, IL), a non-ionic detergent solution, was added
for the final 10 minutes on ice. The cells were then lysed by sonication for several 25
second bursts alternated with 25 seconds on ice until the solution color changed slightly
becoming somewhat darker and semitransparent. It is important to avoid overheating the
solution thereby degrading the target protein, and also to avoid producing foam during
sonication which exposes the protein to air and can lead to aggregation and the formation
of inclusion bodies.

8.5.Nucleic Acid Precipitation

Nucleic acids were precipitated with 4% (v/v) polyethyleneimine (PEI) by vortexing
lightly followed by a brief hold. In addition to removing nucleic acids, PEI may also
improve solubility. The cationic polymer PEI prevents the aggregation, and oxidation, of
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proteins, and chelates the metal ions required by proteases to degrade proteins. The
solution was then centrifuged at 21,000 rpm for 30 minutes at 4°C to separate the soluble
proteins from the cellular debris. The soluble protein was decanted from the insoluble
pellet, and the solution was syringe filtered with a 0.2 uM GD/X filter (Whatman
Piscataway, NJ) prior to Immobilized Metal ion Affinity Chromatography (IMAC)
purification.

- 104 -

Chapter 9 FPLC Purification of the Tat Chimera

The term chromatography, from the Greek for “color-writing”, refers to a group of
techniques used to separate mixtures. Separation by chromatography was first described
by Friedlieb Ferdinand Runge in his 1855 work “Der Bildungstrieb der Stoffe,
veranschaulicht in selbstständig gewachsenen Bildern” on early paper chromatography.
Runge’s work is often considered the precursor to the invention of chromatography
(124). The invention of column chromatography is most often credited to M.S. Tswett in
1903 (published in 1905), but unfortunately due to the political climate in Russia, and the
criticism of other researchers who were unable to reproduce his results, Tswett’s work
went largely unrecognized for many years after his report (125,126). In 1952 Martin and
Synge received the Nobel Prize jointly for their invention of partition chromatography.

9.1.Column Chromatography

In column chromatography solutions are partitioned into mobile and stationary phases,
and particles are separated on the basis of retardation from the mixture based on their
relative affinity for each of these phases. A hollow cylindrical column is packed with
absorbent material that constitutes the stationary phase, and in biochemical applications is
usually a solid or a gel material. The column material is then wetted with the solution that
will serve as the mobile phase for the separation. The mixture being separated, the
analyte, is applied to the top of the wet column, and travels through the column propelled
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by gravity, and is then separated by exploitation of the differences in the particles being
separated, and their relative affinities for of the column material, or stationary phase.

9.2.Liquid/Column Chromatography

Liquid/column chromatography refers to all forms of chromatography in which the
mobile phase, the analyte, is a liquid, and in which the stationary phase is linked to an
inert matrix. Proteins are most often separated and purified with liquid/column
chromatography by exploiting particle differences such as size, hydrophobicity, charge,
and by the presence or absence of metal binding residues.

9.3.Fast Performance Liquid Chromatography (FPLC)

Prior to the 1970s protein separations by liquid/column chromatography were propelled
through columns by gravity in lengthy procedures that frequently produced poor
separation. In the late 1970s the addition of pressure during separation, provided by
nearly pulse-free pumping systems, led to the development of high performance liquid
chromatography. The improved separation was achieved by greatly decreasing particle
size, dramatically increasing the surface area of the solid phase. Thus, solutes equilibrate
more rapidly between the solid and mobile phases effecting higher resolution of solutes
having similar interactions with the solid phase. Higher pressures are required to maintain
reasonable flow rates for the mobile phase through the small particles. Fast performance
liquid chromatography (FPLC) is similar to high performance liquid chromatography
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except that the wetted surfaces of the column, detectors, and tubing are made from glass
or fluoropolymers to avoid denaturing proteins on the metal surfaces common in HPLC.
This requires lower pressures for FPLC, and particle sizes that are larger than for HPLC
to accommodate reasonable flow rates.

During FPLC the solvent velocity is controlled by pumps that control the flow rate of the
mobile phase of proteins through one of four types of columns: size-exclusion, ionexchange, reverse-phase, and affinity. As the name implies, size-exclusion
chromatography separates proteins from solutions on the basis of the size of the protein
and its speed of migration through porous silica beads of variable size. Ion-exchange
column chromatography separates proteins by differences in the net charge of the protein
and its affinity for charged column material in high and low salt mobile phases. Reversephase chromatography separates proteins based on differences in their hydrophobicity,
and therefore by the protein’s affinity for the stationary phase. Finally, affinity
chromatography exploits the affinity of specific residues of the target protein for a
specific ligand or column material that is affixed to the matrix of the stationary phase.

In the experiments that follow the ÄKTA FPLC explorer system and the Unicorn 4.11
system control software (Amersham Pharmacia Biosciences, Uppsala Sweden) were used
for all protein purifications of the Tat fusion protein chimera. After many trials an
efficient and reproducible protocol was developed for the purification of the HisMBP Tat
Chimera (Appendix 12).
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9.4.Purification of the GST Chimera by Column Chromatography

Affinity chromatography was used to purify the original GST tagged construct by
exploiting the affinity of the fusion tag for the GSTrap FF 5 ml column (GE Healthcare
Biosciences Pittsburg, PA). The low expression level and poor solubility of this original
construct produced a predictably low yield of the full length protein in the initial
purification round. Additional issues arising from removal of the GST tag with thrombin
protease compounded the problem and reduced the yield still further. Much of the full
length target remained uncleaved after incubation with thrombin at temperatures ranging
from 7-15°C and over periods of 2 to 24 hours (data not shown) Poor cleavage was
observed in both on column trials and in solution. The low efficiency of thrombin
cleavage was likely due, in part, to the fact that the optimal temperature for thrombin
cleavage is 22°C (127). However, since high temperatures can adversely affect the native
conformation of the target protein, and appeared to be causing precipitation (as evidenced
by decreasing concentration measurements of absorbance at 280 nM over time by
Nanodrop) higher temperatures were avoided.

Predictably, on column cleavage trials were less effective at removing the GST tag from
the full chimera than were the trials in solution (data not shown). In this case the low
expression level of the full chimera makes it unlikely that cleavage was hindered by high
concentrations of the substrate, as is frequently the problem in on column cleavage
protocols. Steric occlusion, concentration issues, and the restricted movement of proteins
affixed to the stationary phase are issues known to hinder on column cleavage attempts.
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For this reason cleavage of solubility enhancing tags with both the target protein and the
protease free in solution is the generally preferred method.

In addition to the problem of incomplete cleavage, was the problem of non-specific
cleavage for both the on-column and in-solution trials. Size-exclusion chromatography
with the Superdex 75 100/300 (GE Healthcare Biosciences Pittsburg, PA) column failed
to adequately separate the tag-free chimera from the GST tag, the uncleaved full chimera,
and the non-specifically cleaved fragments despite what should have been sufficient
differences in molecular weight for adequate separation. Attempts to separate the proteins
by charge with ion-exchange chromatography were also poorly resolved, and several
proteins co-purified. When affinity chromatography was used to remove the GST tag,
yield of the final target was very low and the solution was also contaminated with several
co-purified proteins. Ultimately, the cleaved chimera was inseparable from the full length
GST fusion construct, and from a number of non-specifically cleaved fragments, even
after the addition of a several polishing steps.

9.5.Affinity Chromatography with the HisMBP Tagged Chimera

Re-engineering the chimera not only improved the overall expression yield and solubility
dramatically, but the HisMBP tagged chimera proved considerably more tractable
throughout purification (Figure 9-1). The full chimera was purified by affinity
chromatography utilizing the affinity of the His6 tag for the nickel residues of the HisTrap
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HP column (GE Healthcare Biosciences Pittsburg, PA). An adequate yield and purity was
readily achieved and reproducible.

9.6.Buffer Selection

Selecting appropriate buffers for all aspects of the purification proved challenging.
Phosphate buffered saline (PBS) was the initial buffer used for the GST tagged chimera
in the inherited protocol (Appendix 10). However, concerns over the chelating of metal
ions by PBS with specific regard to the maintenance of the zinc molecules within the two
zinc fingers of the chimera, and also concerns over the incompatibility of PBS with the
reducing agent tris(2-carboxyethyl)phosphine) (TCEP) led to a change in the buffering
component.

Trials with the buffer HEPES at 20 mM were unsuccessful as the full chimera
prematurely eluted from the HisTrap HP column. This premature elution could be related
to the fact that as a Qiagen technical article reports “Buffers with secondary or tertiary
amines may reduce nickel ions” (128). While Qiagen recommends that such buffers as
Tris, HEPES, and MOPS can be used with nickel columns at concentrations below 100
mM, trials with a 20 mM concentration of HEPES were unsuccessful. Ultimately, a Tris
buffer of 20 mM and pH 7.4 produced the adequate and reproducible yield required.
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9.7.Reducing Agents

The reducing agent dithiothreitol (DTT) is known to remove metal ions, as are most
chelating agents including: ethylenediaminetetraacetic acid (EDTA), and sodium citrate.
As much as possible, all agents known to remove metal ions were avoided in order to
preserve the integrity of the two zinc fingers of the Tat chimera. Many trials were
conducted with the reducing agent TCEP because it is often suggested that it does not
interfere with concentration measurements made at 280 nM, and because, while more
expensive, it is known to be a strong and reasonably stable reducing agent. Interestingly
however, Bigalke et al. 2011 observed the slow precipitation of Tat in the presence of
TCEP. When TCEP 0.3 mM was replaced by 5 mM BME, the stability of the chimera
was noticeably improved in the form of higher and more stable final concentrations of
both the full and the cleaved chimera (52).

The importance of the electrochemical environment in the successful expression and
purification should not be underestimated as, in general, with the purification of Tat most
of the concern has been over keeping the chimera reduced (43). Observations suggest that
there may be a point of diminishing returns at which high concentrations of reducing
agent may denature the chimera perhaps by disturbing the zinc fingers, or by altering
some other as yet unknown feature. The use of reducing and/or chelating agents such as
EDTA and DTT may be the cause of at least some of the dimerization and aggregation
reported in other work on Tat. Moreover, in vivo the actual conformation of proteins in
general may be somewhat more dynamic than currently contemplated (129).
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9.8.Salt

The FPLC purification of the Tat chimera was successful when using a 0.5 M sodium
chloride concentration in both the binding and elution buffers, and since this was
consistent with GE Healthcare Biosciences recommendations for the HisTrap HP column
higher concentrations were not explored. It is worth noting, however, that Frankel, Bredt
et al. 1988 found an even higher 0.7 M potassium chloride concentration was needed to
maintain the solubility of Tat alone (86 amino acid construct), and so such higher
concentrations during purification might be worth investigating (43). It was necessary to
lower the salt concentration considerably later on while cleaving the tag from the chimera
with TEV protease, and during binding assays. Thus, the improved solubility provided by
increasing the salt concentration may prove unsustainable for downstream applications. It
may be useful, however, to employ higher salt concentrations when attempting to use
spin columns to concentrate the Tat chimera which has proved to be somewhat
problematic.

9.9.Glycerol

The osmolyte glycerol was present in all FPLC buffers during purification in order to
enhance the solubility of the chimera. A concentration of 5% glycerol was sufficient to
maintain solubility of the chimera throughout the FPLC purification, including after
removal of the solubility enhancing tag and did not appear to hinder TEV cleavage. The
concentration of glycerol was increased to as much as 20% when storing the purified
protein long term, as at this point glycerol also serves as a cryoprotectant. When
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conducting binding assays the glycerol was removed from the solution by dialysis or by
buffer exchange using Vivaspin® 20 20 ml 5,000 MWCO centrifugal concentrator
columns (GE Healthcare Bio-Sciences AB Uppsala, Sweden) to prevent any potential
interference by glycerol in the binding interaction.

9.10. Imidazole

A low concentration of 20 mM imidazole was present in both the lysis and the binding
buffer in order to maintain consistency between the two buffers while loading the crude
protein extract onto the column, and during the column wash. This low concentration of
imidazole serves to prevent non-specific binding of proteins to the column. A wash buffer
of 60 mM was employed in several trials to remove any low affinity binding proteins, but
no further improvement in purification was observed with this increased concentration.
Subsequent washes were performed with the 20 mM imidazole binding buffer. An elution
gradient of up to 500 mM imidazole was used to elute the full His6 tagged chimera from
the HisTrap HP column. The full chimera typically eluted from the column when 66% of
the 500 mM imidazole elution buffer, and 33% of the 20 mM imidazole binding buffer
was reached. Alternatively, the full chimera can be successfully eluted with 100% 500
mM imidazole with acceptable purity.
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9.11. Sodium Azide

The anti-microbial agent sodium azide was added to the binding and elution buffers at
0.02% to prevent degradation of the protein by contaminating microorganisms during the
several days from cell lysis through purification, dialysis, and downstream assays when
the protein could not be frozen.

9.12. Protocol

Following the protocol outlined in Figure 9-2, the syringe filtered cell lysate was applied
to the HisTrap HP column using a 50 ml Superloop at a flow rate of 0.2-0.4 ml/min. or
slower. The column was then washed with binding buffer for five column volumes (50
ml) at a flow rate of 0.4-0.6 ml/min. or until a stable baseline was achieved. After
allowing ample time to wash at the stable baseline the full length chimera was eluted by
setting a gradient exchanging the 20 mM binding buffer on pump A for the 500 mM
elution buffer on pump B over 30 minutes at a flow rate of 2 ml/min (Figure 9-3).

9.13. Results

With this protocol 40 mg of the 60 kDa full chimera were purified from 17 grams of wet
cell pellet harvested from one liter of Turbo media which was induced at OD600 = 0.7
with 1.0 mM IPTG and expressed overnight at 30°C. Figure 9-4 shows the uninduced,
induced, soluble, and insoluble fractions of the expression prior to FPLC purification, as
well as the purified fractions, and the loading and elution flow through waste solutions.
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Lanes 10 through 14 are purified fractions A1 though A5 of the full chimera and
correspond to the fractions indicated in the chromatogram in Figure 9-3. Lanes 11 and 12
of Figure 9-4 show the highly concentrated fractions of the 60.8 kDa full chimera.
Additional bands between 100 and 150 kDa may be dimers of the full chimera and seem
to be more prevalent in concentrated fractions.

Lanes 6, 7, and 8 (Figure 9-4) are samples of the loading flow through materials that did
not bind to the column. The highly concentrated ~60 kDa band here appears to indicate
that the column was overwhelmed by the highly concentrated recombinant chimera.
Lane 9 is a sample of materials eluted from the column prior to the peak (X1) and
indicates that a fair amount of protein was eluted prior to the observance of the peak. This
is likely to be an artifact of the AKTA system and indicates that wherever possible
fraction collection should begin slightly in advance of the appearance of the peak. The
highly concentrated fractions A1 though A5 were pooled and then dialyzed into a low
imidazole buffer for cleavage of the HisMBP tag, and its subsequent removal by
reapplication to the HisTrap HP column.
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Figure 9-16 The HisMBP Tat chimera expressed in the Rosetta Gami B
The HisMBP Tat chimera expressed in the Rosetta Gami B strain in LB media and FPLC
purified. Induction at 0.7 OD with 0.8 mM IPTG. Incubation at 30°C post induction for 7
hours before harvest. From left to right:
1 – ladder

2 – uninduced

3 – induced

4 – soluble

5 – insoluble

6 – full chimera

Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine
buffer. Run condition: 200V, 50 minutes.
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Figure 9-2 Recombinant protein purification flow chart.
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FPLC Chromatogram
Elution of Full Length Chimera

Figure 9-3 FPLC Chromatograph of the elution of the full chimera.
The sharp peak starting in fraction A2 eluted approximately one column volume after reaching the full
500 mM imidazole concentration. The SDS Page analysis of fractions X1 through A5 can be seen in
Figure 9-4. The UV remains elevated after the peak due to 280 nm absorbance by the 500 mM imidazole
elution buffer.
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Full Tris Trial BME 6/8/1
O/N expression in Turbo

1 2 3 4 5 6 7 8 9 10 11 12 13 14

1 – Ladder
2 – Uninduced
3 – Induced
4 – Soluble
5 – Insoluble
6 – Flow Thru X1
7 – Flow Thru X2
8 – Flow Thru X3
9 – Elution Flow Thru X
10 – Full Length A1
11 – Full Length A2
12 – Full Length A3
13 – Full Length A4
14 – Full Length A5
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Figure 9-4 SDS PAGE of the Tat Chimera Expression and Purification
The SDS PAGE analysis of the overnight expression and purification of the full chimera
in Turbo media. The expression and FPLC purification fractions of the full chimera (60.8
kDa), s from left to right:
1 – ladder

2 – uninduced

3 – induced

4 - soluble

5 – insoluble,

6 – loading flow thorough

7 – loading flow through

8 – loading flow through

9 – elution flow through X1

10 – full chimera A1

11 – full chimera A2

12 – full chimera A3

13 – full chimera A4

14 – full chimera A5

Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine
buffer. Run condition: 200V, 50 minutes.
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Chapter 10 Removal of the Fusion Tag

While fusion tags are often necessary to facilitate expression of recombinant proteins at
high yield, they also may confound downstream applications, particularly applications
that explore binding interactions, biological activity, and structural detail. Removal of the
solubility enhancing tag can introduce an entirely new set of challenges, not the least of
which is maintaining the solubility of the recombinant protein after this important
solubility enhancing component has been removed.

Choosing a protease enzyme that is highly specific and cleaves only at a rare series of
amino acids is a helpful means of preventing non-specific cleavage of the target. Some
proteases such as thrombin are notorious for cleaving non-specifically (74,130).
Moreover, non-specific cleavage can be exacerbated by long incubation periods, high
temperatures, excessive concentrations of proteolytic enzyme, and a variety of other
factors specific to the chosen enzyme.

In some cases non-specific cleavage by thrombin can be mitigated by the prompt removal
of the enzyme with affinity purification using benzamidine columns, and perhaps more so
by removal with heparin sepharose columns (130). However, in the case of the GSThCycT1-Tat chimera, non-specific cleavage was still observed even with prompt removal
of thrombin by benzamidine, and in an unfortunate coincidence the Tat chimera also
bound to heparin rendering this manner of protease removal useless (131,132).
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When developing a new recombinant protein expression and purification protocol one
should carefully consider the available protease enzymes and choose an enzyme that is
specific, efficient, cost effective, and compatible with downstream applications whenever
possible. The efficiency of the cleavage can be an extremely important, albeit somewhat
less obvious, consideration in achieving a high yield of recombinant protein after
purification.

10.1. Cleavage of HisMBP Tag with TEV

Having inherited the pGEX 2TK chimera plasmid with a thrombin protease site for the
purpose of cleavage of the original GST tag, and after many disappointing attempts to
isolate the tag-free chimera, the highly specific protease TEV was chosen to be the
protease enzyme for cleavage of the HisMBP tag from the re-engineered chimera. The
protease sequence ENLYFQ/G was introduced into the chimera sequence between the
MBP tag and the hCycT1 portion of the chimera in order to facilitate tag removal (Figure
4-6). This peptide sequence is readily cleaved by the highly active and highly specific
cysteine protease TEV from the tobacco etch virus.

Unfortunately, wild type TEV is auto-inactivated rapidly in vivo and catalytic activity is
diminished markedly and in direct proportion to the concentration of the enzyme
(74,133). Self-cleavage of the enzyme and the multiple fragments that result complicate
purification, as well as the removal of the enzyme from the cleavage reaction. Further,
the activity of the enzyme continues to diminish during storage (74). Autoproteolysis
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takes place between Met218 and Ser219 of the TEV enzyme and may be an
intramolecular event (74). Kapust et al. 2001 mutated the TEV enzyme with the
substitution S219V, and found that self-cleavage was eliminated and the mutated enzyme
was some 100 fold more stable (74).

10.2. Results: Cleavage of the MBP Tag with GST Tagged TEV

The initial attempts to remove the MBP tag from the fusion chimera employed a GSTHis6 tagged TEV protease (~ 50 kDa), which was generously donated by Michael
Cosgrove, Upstate Medical University, NY. However, incubation of 1 mg of the enzyme
per 20 mg of the fusion chimera produced precipitation with nutation during incubation,
and appeared to produce incomplete cleavage after 24, and 48 hours at room temperature
even without nutation (Figure 10-1). Predictably, at 14°C the reaction was even less
efficient leaving considerably more of the full fusion chimera uncleaved after 24, 48, and
even 72 hours (Figure 10-2).

In order to optimize the yield of CycT1m-Tat, a TEV protease that was more efficient,
especially at lower temperatures, was required. Kapust et al. 1999 compared the
solubilizing effects of three fusion tags: maltose-binding protein (MBP), glutathione Stransferase (GST), and thioredoxin (TRX), and found MBP to be, by far, the more
effective solubilizing fusion partner (68). Further, Kapust et al. 1999 compared the
solubility of GST tagged TEV to that of MBP tagged TEV, and found that less than 20%
of the GST-TEV was soluble as opposed to greater than 60% of the MBP-TEV (68).
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Having observed such poor solubility in the recombinant expression of TEV, Kapust et
al. 2001 constructed a plasmid for the recombinant expression of MBP-His6TEV(S219V)-Arg in an effort to simultaneously improve both the stability of the enzyme
and the solubility (74). Fortunately, the pRK793 plasmid was deposited with Addgene
(Cambridge, MA) from which it was purchased for a nominal fee. In this interesting
construct the MBP tag is self-cleaved from the recombinant enzyme after expression, and
the protease can then be purified by affinity for either its remaining N-terminus His6 or
by the C-terminus Arg tag (74).

10.3. Expression of His6-TEV(S219V)-Arg Protease in E. coli

Following the work of Tropea, Cherry et al. 2009 the pRK793 plasmid was expressed
consistent with the published protocol with an exception (Appendix 13). The expression
strain used by Tropea et al. 2009 is the BL21 (DE3) CodonPlus-RIL(134). Though it is
not uncommon to recommend the use of a DE3 expression strain with a plasmid
containing a tac promoter (135), the DE3 strain is designed for the T7 promoter system
and expresses T7 RNA polymerase. When working with the tac promoter the native E.
coli RNA polymerase is used, and so production of T7 RNA polymerase places an
entirely unnecessary stress on the cell (Novagen personal conversation). Since so much
conflicting information on this exists the two cell lines were compared in the recombinant
expression of the TEV enzyme from the pRK793 plasmid with a tac promoter (Figure 103). Here the expression is compared in the Rosetta Gami B cell line for both the DE3
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Rosetta Gami B cells and the non-DE3 Rosetta Gami B cells. Comparison of lanes four
and five clearly indicates that the non-DE3 cell line produces a substantially higher
concentration of the TEV protein in the crude induced cell extract, as well as a slight
increase in basal expression levels.

When performing a large scale expression of TEV the Rosetta 2 expression strain
(Novagen, Madison, WI) was used. This strain of E. coli is similar to the Rosetta Gami B
strain but does not provide the folding accommodation for disulfide bond formation in
the cytoplasm, which was not required here. Three liters of LB media containing 100
ug/ml ampicillin, 30 ug/ml chloramphenicol, and 0.2% glucose were inoculated with 25
ml of an overnight culture of Rosetta 2 (non-DE3) cells containing the pRK793 plasmid.
The culture was grown at 37°C until OD600 ~0.5 when the temperature was reduced to
30°C and the culture was induced with 1 mM IPTG. The TEV protein was expressed for
6 hours post induction. On harvesting the 3 liter culture yielded 23.4 g of wet cell pellet
weight which was slightly above the range of 30-40 g per 6 L reported by Tropea, Cherry
et al. 2009 (134).

The MBP-His6-TEV(S219V)-Arg5 was purified by affinity chromatography with a
HisTrap HP nickel column. The Tropea et al. 2009 protocol contains an additional gel
filtration polishing step at this point. Since the appropriate column was not available the
gel filtration step was omitted. From the 23.4 g of wet cell pellet weight the 41 mg of
purified MBP-His6-TEV(S219V)-Arg5 recovered were of sufficient concentration and
purity for downstream applications (Figure 10-4). The FPLC fractions were pooled, and
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concentrated with Vivaspin® 20 20 ml MWCO 5,000 columns (GE Healthcare BioSciences AB Uppsala, Sweden).

10.4. Determination of Optimal Cleavage Conditions

In order to determine the optimal concentration of the His6-TEV protease for cleavage of
the HisMBP Tat chimera six different concentrations of the protease were incubated
overnight at either room temperature or 4°C (Figure 10-5). Ratios of milligrams to
milligrams 100:1, 50:1, 25:1, 12.5:1, 6:1, and 1:1 are compared with full cleavage in all
room temperature samples, and nearly complete cleavage in only the 1:1 sample at 4°C.

In Figure 10-5 the lowest concentration ratio of the His6-TEV(S219V)-Arg5 to target to
achieve efficient cleavage of the HisMBP chimera appeared to be between 50:1 and 25:1
in the room temperature trials. Using the midpoint concentration of 37.5:1, cleavage
reactions were compared at room temperature, and at 15°C at intervals of one hour for
between 1 to 5 hours (Figure 10-6). Here the goal was to achieve the greatest amount of
cleavage in the shortest amount of time, with the least amount of enzyme, and at the
lowest incubation temperature possible. All cleavage reactions in this comparison
achieved efficient cleavage, and so the ratio of 37.5:1 mg/mg, the temperature of 15°C,
and the incubation time of at least one hour were set as the cleavage conditions for the
remaining experiments.
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Full length fusion chimera 60.8 kDa
GST-His6 TEV ~50 kDa
KKdAK~VTEVTE TE

MBP 42 kDa

Cleaved chimera 17.5 kDa

Figure 10-1 Cleavage of the fusion chimera with GST-His6-TEV protease
The cleavage of the full fusion chimera with GST-His6-TEV protease at a ratio of 1:20
milligrams of protease to substrate at room temperature (RT). Cleavage reactions from
left to right:
1 – GST-His6-TEV control

2 – Full fusion chimera control

3 – Cleavage reaction 48 hours

4 – Cleavage reaction 24 hours

Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine
buffer. Run condition: 200V, 50 minutes.
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Full length fusion chimera 60.8 kDa
GST-His6 TEV ~ 50 kDa
MBP 40 kDa
kkkkkkkkk
ttttttttttttTETEVTTEVTEV

Cleaved chimera 17.5 kDa

Figure 10-2 Cleavage of the full fusion chimera with GST-His6-TEV
The cleavage of the full fusion chimera with GST-His6-TEV protease at a ratio of 1:20
milligrams of protease to substrate with incubation at 14°C. Cleavage reactions from left
to right:
1 – cleavage reaction 28 hours

2 – cleavage reaction 48 hours

3 – cleavage reaction 72 hours
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine
buffer. Run condition: 200V, 50 minutes.
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Figure 10-3 Comparison of expression conditions for the pRK793 plasmid
A comparison of the expression conditions for the pRK793 plasmid for the recombinant
expression of His6-TEV(S219V)-Arg5 in E. coli DE3 vs. non-DE3 cell lines. Expression
samples from left to right:
1 – ladder

2 – uninduced Rosetta Gami B DE3

3 – uninduced Rosetta Gami B non-DE3

4 – induced Rosetta Gami B DE3

5 – induced Rosetta Gami B non-DE3
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine
buffer. Run condition: 200V, 50 minutes.
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Figure 10-4 PAGE analysis of FPLC fractions for His6-TEV(S219V)-Arg5.
The FPLC purification fractions of His6-TEV(S219V)-Arg5, lanes from left to right:
1 – ladder

2 - empty

3 – A1

4 – A2

5 – A3

6 – A4

7 – A5

8 – A6

9 – A7

10 – A8

11 – A9

12 - concentrated TEV 1

13 – concentrated TEV 2

14 – concentrated TEV 3

Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine
buffer. Run condition: 200V, 50 minutes.
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1 – Empty
2 – Ladder
3 – FPLC Fraction
4 – FPLC Fraction
5 – FPLC Fraction
6 – FPLC Fraction
7 – FPLC Fraction
8 – FPLC Fraction
9 – FPLC Fraction
10 – FPLC Fractio
11 – FPLC Fractio
12 – Concentrated
13 – Concentrated
14 – Concentrated

His-TEV Cleavage
Concentration & Temperature O/N

1 2 3 4 5 6 7 8 9 10 1112131415
kDa
200kDa
150
100
75

1 – Ladder
2 – Full Length MBP tagged chimera
3 – His-TEV
4 – Cleavage 100/1 RT
5 – Cleavage 100/1 4ºC
6 – Cleavage 50/1 RT
7 – Cleavage 50/1 4ºC
8 – Cleavage 25/1 RT
9 – Cleavage 25/1 4ºC
10 – Cleavage 12.5/1 RT
11 – Cleavage 12.5/1 4ºC
12 – Cleavage 6/1 RT
13 – Cleavage 6/1 4ºC
14 – Cleavage 1/1 RT
15 – Cleavage 1/1 4ºC

50
37
25
20
15
10

Figure 10-5 Conditions comparison for His6-TEV(S219V)-Arg5
Comparison of cleavage with increasing concentrations of the His6-TEV(S219V)-Arg5
protease at room temperature (RT) and 4°C incubated overnight with the HisMBP Tat
chimera from left to right:
1 – ladder

2 – full MBP chimera

3 – His6-TEV(S219V)-Arg5

4 – 100:1 RT

5 – 100:1 4°C

6 – 50:1 RT

7 – 50:1 4°C

8 – 25:1 RT

9 – 25:1 4°C

10 – 12.5:1 RT

11 – 12.5:1 4°C

12 – 6:1 RT

13 – 6:1 4°C

14 – 1:1 RT

15 – 1:1 4°C

Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine
buffer. Run condition: 200V, 50 minutes.
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Temperature & Time

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

1 – Ladder
2 – Full Length MBP tagged c
3 – His-TEV
4 – His-TEV after MWCO 10,
5 – Cleavage 37/1 RT 1 hour
6 – Cleavage 37/1 15ºC 1 hou
7 – Cleavage 37/1 RT 2 hours
8 - Cleavage 37/1 15ºC 2 hou
9 – Cleavage 37/1 RT 3 hours
10 - Cleavage 37/1 15ºC 3 ho
11 – Cleavage 37/1 RT 4 hou
12 – Cleavage 37/1 15ºC 4 ho
13 – Cleavage 37/1 RT 5 hou
14 – Cleavage 37/1 15ºC 5 ho
15 – His-TEV after MWCO 10

kDa
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Figure 10-6 Comparison of cleavage ratio of 37.5:1 for His6-TEV(S219V)-Arg5
Cleavage reactions at a concentration ratio of 37.5:1 mg/mg for both room temperature
(RT) and 15°C at intervals of 1 hour from 1 to 5 hours from left to right:
1 – ladder

2 – full MBP tagged chimera

3 – His6-TEV(S219V)-Arg5

4 –FPLC purified His6-TEV(S219V)-Arg5 (control)
5 – cleavage reaction RT (1 hour)

6 – cleavage reaction 15°C (1 hour)

7 - cleavage reaction RT (2 hours)

8 – cleavage reaction 15°C (2 hours)

9 – cleavage reaction RT (3 hours)

10 – cleavage reaction 15°C (3 hours)

11 – cleavage reaction RT (4 hours)

12 – cleavage reaction 15°C (4 hours)

13 – cleavage reaction RT (5 hours)

14 – cleavage reaction 15°C (5 hours)

15 –FPLC purified His6-TEV(S219V)-Arg5 (control) with additional purification by
10,000 MWCO spin column.
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Chapter 11 FPLC Purification of CycT1m-Tat

Once the HisMBP tag has been sufficiently cleaved from the full chimera the tag and the
His6-TEV protease can be removed from the solution by affinity chromatography with
the HisTrap HP column. In contrast to the first round of purification, in this step the His6
tagged proteins that bind to the column will be the unwanted cleaved tag and protease;
the desired target (cleaved chimera, CycT1m-Tat) will be captured in the flow through.
Since a reasonable degree of purity is achieved in the first purification step of the full
chimera, and the concentration of His6-TEV is low relative to the chimera, the bulk of
material bound to the column will be the cleaved HisMBP tag.

Isolating the chimera in this manner can be challenging. Purifications with a Tris based
buffer and using the reducing agent BME tended to produce a more focused UV peak in
the chromatogram (Figure 11-1) with the concentrated cleaved protein visible by SDS
PAGE (Figure 11-2). In earlier trials with a PBS based buffer and the reducing agent
TCEP the peak was either absent or less focused (data not shown), yet the fairly pure and
concentrated cleaved target was present and was observed by SDS PAGE. Since the
cleaved target is present in solution and does not bind to the column theoretically a peak
should not necessarily be anticipated as the target simply passes through and is not
focused in any manner.

In general, when performing FPLC purification one should collect as many fractions
throughout the process as possible regardless of the visible absorption recorded by the
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chromatogram. Each fraction should be analyzed by SDS PAGE before assessing the
purification or attempting to concentrate the target protein. Proper selection of the
fractions will help to reduce dilution of the final sample, and prevent contamination by
any undesirable co-purified proteins.

11.1. Results

Figure 11-1 is the FPLC chromatogram for the purification of the cleavage reaction
solution with a HisTrap HP column. The peak at 15 ml was collected in fractions A2 and
A3 and contained the concentrated CycT1m-Tat. An SDS PAGE analysis (Figure 11-2)
of the cleavage reaction demonstrates nearly complete cleavage of the chimera in lane 2
of the gel. The A2 and A3 FPLC fractions corresponding to the UV peak in the
chromatogram in Figure 11-1 appear to be highly concentrated and of greater than ~80%
purity. In the final yield approximately 6.5 mg of CycT1m-Tat were recovered in 8 ml
after purification from a 1 liter culture, 17 g of wet cell pellet weight, and 40 mg of the
full chimera. The chromatogram peak at 35 ml corresponds to the elution of the HisMBP
tag and the His6-TEV protease from the HisTrap HP column in the full strength 500 mM
imidazole elution buffer.

Notably, CycT1m-Tat migrates at nearly 25 kDa despite a true molecular weight of 17.5
kDa, and a doublet of CycT1m-Tat was often apparent. Proteins frequently do not
migrate to their calculated positions due to preferential SDS loading at hydrophobic
regions. It has also been suggested that the SDS loading capacity of a protein may be

- 133 -

related to the protein structure, secondary or tertiary, and here the protein may not have
been completely denatured by the presence of SDS (136). Finally, observations of
similarly anomalous migratory behavior are well documented in proteins with a high
number of basic residues, such as are present in the Tat chimera (137,138).

The appearance of the doublet of CycT1m-Tat could indicate the presence of two species
of the target in different oxidation states, as while it might be reasonable to suspect a
truncated form of the target as the source of the doublet, a single molecular weight
species at 17.5 kDa was later confirmed by matrix-assisted laser desorptionionization/time-of-flight (MALDI-TOF) experiments on the same sample (data not
shown).

All fractions from the final purification of CycT1m-Tat were analyzed by SDS-PAGE to
ensure that some fraction of the target was not lost in the waste material nor was it
binding to the column. Fractions from the cleaning of the column at the end of the
procedure were also analyzed, and no proteins were observed in the gel for these washes
(Figure 11-2). Finally, a control containing the His6-TEV in a concentration equivalent to
that of the cleavage solution was run on the gel (Figure 11-2 lane 13) to assess whether
this low concentration of the enzyme would be visible, and the enzyme is not apparent in
the gel at this concentration.
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11.2. Buffer Exchange and Concentration

At the end of the purification procedure the buffer must be exchanged based on either
downstream applications, or storage requirements. Removing the imidazole is necessary
for accurate measurement of protein concentrations since imidazole absorbs at 280 nM.
Downstream binding assays are confounded by the presence of high salt concentrations
such as the 0.5 M NaCl in the FPLC binding buffer, and so the buffer was exchanged for
a lower salt concentration solution free from the presence of imidazole. If storage is the
next step the glycerol concentration will likely be increased, but for binding and other
assays glycerol and perhaps BME may need to be removed.

Buffer exchange worked well with the use of a dialysis membrane and where little
change the in concentration took place, but was considerably more complicated when
both concentration and buffer exchange were attempted simultaneously. When the salt
concentration was lowered and the glycerol was removed during concentration with
Vivaspin® 5,000 MWCO columns (GE Healthcare Bio-Sciences AB Uppsala, Sweden)
the protein appeared to aggregate. Though the precipitation was not visibly apparent, the
concentration of the retentate decreased, when measuring absorbance at 280 nm by
Nanodrop, rather than increased with each successive spin even when using a refrigerated
centrifuge. Measurements of washes from pipetting up and down on the membrane
indicated that at least some of the protein had precipitated onto the membrane. The
addition of arginine may be helpful toward mitigating this aggregation, but could also
interfere with downstream applications such as NMR. The empirical determination of
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appropriate conditions for highly concentrated solutions of CycT1m-Tat could prove
daunting, and here also high throughput methods would definitely be desirable.

11.3. Storage of CycT1m-Tat

When storing proteins a number of factors can affect the stability and biological activity
of the protein and must be considered. Degradation of stored proteins can result from
changes in temperature, protease activity, and the presence of some heavy metals.
Another frequent concern is damage caused by oxidation. Aggregation and precipitation
can result from changes in concentration, pH, ionic composition, and changes in
temperature. Freeze thaw damage caused by extremes of temperature can also degrade
proteins. During storage important cofactors of the protein can also be lost that can
compromise the integrity of the protein such as the zinc atom from each of the zinc
fingers. In general, the chimera was stored in 20% glycerol in 20 mM Tris, 0.2 M NaCl,
10 uM ZnCl2, 5 mM BME, and pH 7.4 at -80°C in the interest of circumventing as much
of the damage from storage as possible. Samples of the chimera stored in these conditions
for several months and then run in SDS PAGE analysis appeared as a single band at the
same molecular weight as when freshly purified.
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FPLC Chromatogram
Cleaved Tat and Final Elution

Figure 11-1 FPLC chromatogram of CycT1m-Tat
The FPLC chromatogram of the elution of CycT1m-Tat. The chimera with HisMBP tag
removed flows through the HisTrap HP column without binding to it and is collected in
the flow through solution. A peak at 15 ml was collected in fractions A2 and A3 and
contained the concentrated (from the first round of purification) and purified CycT1mTat.
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Cleaved Full Tris BME
1 2 3 4 5 6

7 8 9 10 1112 13 14

1 – Empty
2 - Ladder
3 – Cleavage Rea
4 – Cleaved Tat A
5 – Cleaved Tat A
6 – Waste Elution
7 – Waste Elution
8 – NaCl wash
9 – H2O wash afte
10 – NaOH wash
11 – Isopropanol w
12 – Binding buffe
13 – NaOH wash
14 – TEV 1/37.5 C
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Figure 11-2 SDS PAGE of cleavage reaction and FPLC fractions and washes.
The SDS PAGE analysis of the cleavage reaction solution and the FPLC fractions and
wash solutions from left to right:
1- ladder

2 – cleavage reaction

3 – CycT1m-Tat A2

5 – waste 1

6 – waste 2 (MBP, His6-TEV)

4 – CycT1m-Tat A3

7 – NaCl wash

9 – NaOH wash

10 – isopropanol wash

12 – second NaOH wash

13 – His6-TEV 37.5:1 dilution control.

8 – water wash

11 – binding buffer wash

Note: His6-TEV at 25 kDa in 6 runs at a molecular weight that is nearly indistinguishable
here from that of CycT1m-Tat. Distinguishing the protease from the chimera is addressed
by western blot in the following chapter.
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Chapter 12 Non-Quantitative Binding Assays

Once the recombinant protein purification was complete two experimental techniques
were used to confirm the correct Tat-chimera sequence. First the presence of the target
protein was confirmed by the binding of primary and secondary antibodies in a Western
blot, and second the correct molecular weight, corresponding to the appropriate target
sequence, was confirmed by matrix-assisted laser desorption-ionization/time-of-flight
(MALDI-TOF). With the use of both techniques it was possible to confirm the identity of
the chimera with a reasonable degree of certainty before moving on to additional assays.

12.1. Western Blot

Western blotting was developed by W. Neal Burnette who submitted the idea in 1981 in
an article to the journal of Analytical Chemistry (139). Ironically, the article was initially
rejected. The original technique involves the electrophoretic transfer of proteins from
SDS-PAGE (during which the proteins are initially separated vertically on the basis of
molecular weight) to nitrocellulose filters from which a specific protein can then be
detected by the binding of radioactive iodine-labeled antibodies or “probes” for the
protein of interest. Today the technique is still widely used for the detection of proteins,
and is available commercially with both radioactive and non-radioactive visualization
alternatives including fluorescently and chromogenically labeled antibodies.
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Since the chimera contains a myc antibody binding sequence between the hCycT1 and
Tat portions of the protein (Figures 3-1 and 4-11) the presence of the Tat chimera was
confirmed by first binding a primary anti-myc antibody to the sequence, and
subsequently binding a secondary chromogenic antibody to the primary antibody for
visualization by Western blot. The Novex® WesternBreeze™ Chromogenic Anti-mouse
Kit (Life Technologies Grand Island, NY) detects picogram levels of protein, and was
used with the iBlot® western blotting system (Life Technologies Grand Island, NY).

12.2. Western Blot Results

In an unfortunate coincidence the chimera and the His6-TEV protease were found to run
at nearly the same molecular weight (~25 kDa) in SDS-PAGE. However, while the His6TEV runs true to size the actual molecular weight of the chimera is ~17.5 kDa. Thus an
alternative method of distinguishing between the two proteins is essential. A Western blot
of the Positope™ positive control, full purified chimera, the cleavage reaction, and the
His6-TEV protease confirmed that the band appearing in (Figure 12-2 SDS PAGE) 5 is
His6-TEV which is not myc tagged and is therefore not present in the Western blot
(Figure 12-1 Western 5). Comparing the two bands in s four and five of Figure 12-2 SDS
PAGE it is clear that the two proteins migrate with remarkable similarity in SDS PAGE.

A second Western blot of several samples of the full chimera and CycT1m-Tat in a
variety of buffers (Tris based storage buffer, fluorescence titration buffer, and Octet
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buffer) confirms the presence and integrity of the full chimera and CycT1m-Tat samples
that were used in downstream assays (Figure 12-3 Western) (Figure 12-4 SDS-PAGE).

12.3. MALDI-TOF

The basic principle of mass spectrometry (MS) is that a moving charged particle is
accelerated in a magnetic field which causes the deflection of the particle. The degree of
deflection of the charged particles is dependent upon the mass/charge ratio. A detector
receives the deflected particle, the signal is amplified, and the mass to charge ratio is
recorded and plotted on the x axis, while the intensity of the signal is plotted on the y axis
in what is called a mass spectrum.

Developed in 1988 by Franz Hillenkamp at University of Műnster in Germany, matrixassisted laser desorption-ionization/time-of-flight (MALDI-TOF) is a highly sensitive
soft ionization technique that is able to accurately analyze intact biomolecules (Figure 125). In MALDI-TOF the sample is mixed with excess matrix and is then dried to the
MALDI plate. A laser is directed at the sample on the plate surface and ionizes the
sample by proton transfer to the sample from the matrix which absorbs the laser light.
The time that the ionized particle takes to reach the detector is known as “ion drift” and is
inversely proportional to the square root of the mass to charge ratio of the particle. When
the particle reaches the detector the signal is amplified and then recorded (140).
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This technique is particularly useful in the analysis of biomolecules because MALDITOF is a soft ionization technique that produces less fragmentation and is therefore
useful in the study of larger intact biomolecules. Other soft ionization techniques include:
chemical ionization, fast atom bombardment, and liquid secondary ionization,
Over the past 25 years use of MALDI-TOF has grown with the field of proteomics as the
technique is highly sensitive and accurate and provides reasonable resolution for
biomolecules up to several hundred kilodaltons (141).

12.4. Results: MALDI-TOF of CycT1m-Tat

Subsequent to confirming the presence of the chimera with Western blot, the appropriate
molecular weight of the protein was confirmed by matrix-assisted laser desorptionionization/time-of-flight (MALDI-TOF). The Bruker AutoFlex III MALDI TOF/TOF
Mass spectrometer in the Jahn Lab at the State University of New York College of
Environmental Science and Forestry (SUNY-ESF) was used to confirm the molecular
weight of a 20 uM sample of CycT1m-Tat in a 3,5-dimethoxy-4-hydroxycinnamic acid
(sinapinic acid) matrix.

The base peaks of the two spectra produced from two samples of CycT1m-Tat (Figure
12-4 MALDI-TOF) indicate molecular weights of 17,485.1 and 17,485.9 daltons
respectively and are within 4.4 daltons of the 17481.5 daltons predicted by the Protein
Calculator version 3.3 provided online by The Scripps Research Institute (Appendix 3).
This relatively small experimental error may be attributable to: protonation, differences in

- 142 -

isotopic abundance calculations of the calculator, and/or to calibration error for the
Bruker AutoFlex III.

12.5. Electrophoretic Mobility Shift Assay

An electrophoretic mobility-shift assay (EMSA), formerly known as a gel-retardation
assay and also known as a gel shift or band shift assay is sensitive and inexpensive
technique that was originally described by both Fried and Crothers, and by Garner and
Revzin, in 1981 (142,143). This non-denaturing electrophoresis technique permits both
the qualitative and quantitative characterization of protein-nucleic acid complexes (144).
In EMSA molecules are separated at near neutral pH on the basis of shape, size, and
charge since SDS is omitted and no negative charge is artificially imparted as it would be
in denaturing electrophoresis (145).

12.6. Characterization of the Protein-Nucleic Acid Complex

In EMSA the formation of complexes between nucleic acid and protein is evidenced by a
reduction in the distance traveled by the higher molecular weight bound complex through
the polyacrylamide gel when compared to the distance traveled by the free nucleic acid.
This so called “retardation” of the distance traveled by the nucleic acid is referred to as
“shifting” or “super-shifting” and is rendered visible by staining. The band produced by
the complex appears vertically higher or closer to the well than that of the lighter
unbound nucleic acid.
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The binding affinity of the protein-nucleic acid complex can be characterized, to a limited
degree, by the length of time that the complex travels through the gel before separating
into its primary components. In some cases the relative intensity of the bands produced
by the complexed nucleic acid versus those produced by the free nucleic acid can be
measured and used for a more quantitative analysis. However, both the formation and
stability of the complex are affected by numerous factors including: binding buffer, and
running buffer components, gel concentration, temperature, and competitor molecules.
For any particular protein-nucleic acid interaction EMSA conditions must be determined
empirically (146).

The EMSA technique is useful for nucleic acids ranging in size from short
oligonucleotides to longer and more complicated nucleic acid structures including small
circular DNA, but is limited to approximately 5,000 base pairs or less (144). Assays with
shorter oligonucleotide segments tend to be hindered by difficulties related to binding
sites positioned close to the end of the molecules, while longer nucleic acids tend to
exhibit more non-specific binding (144). With respect to protein, the EMSA technique is
effective for proteins ranging from small oligopeptides to molecular weights greater than
1,000 kDa and is useful for both crude and purified solutions (144).

12.7. Visualizing Proteins and Nucleic Acids in the EMSA
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In a traditional EMSA the protein-nucleic acid interaction is visualized by 32P labeling of
the nucleic acid, and provides a high degree of sensitivity detecting 0.1 nM or less of the
nucleic acid (144). However, new and highly sensitive staining techniques have been
developed that permit the circumvention of radioactive techniques. Chemiluminescent,
fluorescent, and immunohistochemical detection methods are commercially available,
reasonably sensitive, and stain either nucleic acids or proteins, or both.

For use in protein staining SYPRO Ruby Protein Gel Stain (Molecular Probes, Inc.
Eugene, OR) is a highly sensitive luminescent stain with two excitation maxima at
approximately 280 nM, and 450 nM, and with an emission maximum of approximately
610 nM (147). This stain can be visualized at 300 nM with a UV transilluminator. The
sensitivity of this stain is comparable to that of silver staining with a lower detection limit
between 0.25 ng and 1 ng of protein. This highly sensitive protein stain does not stain
nucleic acids, and binds to basic amino acids and the peptide backbone of the protein
(147).

The nucleic acid stain SYBR Gold (Molecular Probes, Inc. Eugene, OR) has excitation
maxima for the dye-nucleic acid complexes at approximately 495 nM, and 300 nM and
an emission maximum at approximately 537 nM. This proprietary unsymmetrical cyanine
dye exhibits a greater than 1000-fold fluorescence enhancement when bound to nucleic
acids and has a high quantum yield (~0.6) upon binding to double- or single-stranded
nucleic acid (148). While this stain is highly sensitive and useful for EMSA, it is
important to note that in general unsymmetrical cyan dyes bind the minor groove of
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nucleic acids (149) and could potentially interfere with the binding interaction of a
protein ligand.

12.8. Limitations of Electrophoretic Mobility Shift Assays

In addition to the complications already presented regarding the use of dyes that have the
potential to alter or inhibit binding interactions there are other limitations to EMSA.
Specifically, little can be gained from the assay regarding the molecular weight of the
complex, or of the location of the binding interaction. Moreover, during electrophoresis
samples are not at equilibrium, and both the ionic strength of the buffer and the so called
“caging effects” of the gel may cause certain interactions to be stabilized, while the rapid
dissociation of other interactions may prevent their detection entirely (144).

Glycerol, often added to the sample buffer for the purposes of increasing the density of
the sample for loading, often has a stabilizing effect both on the unbound protein, and on
the protein-nucleic acid complex (144,150,151) and can confound attempts at more
quantitative analysis. Because of these issues, the aforementioned complications
experienced with the positioning of small oligonucleotide binding sites, and the potential
effects of the temperature of the gel on the affinity of the complex EMSA may be more
useful in a semi-quantitative role. Here EMSA was used in the preliminary confirmation
of binding interactions between recombinant purified proteins and their native nucleic
acid binding partners prior to moving on to the more quantitative methods of surface
plasmon resonance, and biolayer interferometry.
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An additional complication in this non-denaturing assay is the issue of protein charge.
While nucleic acid is always negatively charged and migrates from the negative to the
positive electrode, proteins can be positively charged, negatively charged, or can have no
net charge at their respective isoelectric points complicating migration in non-denaturing
gel electrophoresis. In the case of positively charged proteins in non-denaturing gels the
positively charged proteins will migrate in the opposite direction from the nucleic acid
toward the negative electrode and in some cases can migrate up out of the wells of the gel
and be dispersed into the running buffer.

12.9. Method

In order to qualitatively characterize the interaction between the recombinant Tat chimera
and the TAR RNA an EMSA was performed in which both the full Tat chimera, and
CycT1m-Tat (from which the tag had been removed) were bound to a 27 nucleotide
stem-loop portion of the wild type TAR RNA (Figure 13-1). Two additional proteins
were included in the assay: the MBP tag alone in order to determine whether the tag itself
bound the RNA, and a 13 amino acid arginine rich peptide which is the minimal portion
of the Tat protein found by Weeks et al. 1990 to bind the TAR RNA, and which also
contains the nuclear localization signal (NLS) of the Tat protein.

The concentration of the polyacrylamide gel used for EMSA was determined empirically
to suit the 27-nt nucleic acid, and the various proteins ranging in molecular weight from
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1.7 kDa for the Tat minimal peptide to 60.8 kDa for the full tagged Tat chimera. A 12%
acrylamide non-denaturing gel was pre-run for one hour at ~8°C and 100 Volts in 1 X
TBE buffer at pH 8.0. Nucleic acid was heated for three minutes at 90°C vortexed lightly
and briefly and then cooled on ice briefly before being added to samples. Protein
samples in 20 mM Tris, 0.2 M NaCl, 10 uM ZnCl2, 5 mM BME, and pH 7.4 were
incubated with the wild type TAR RNA stem loop to a final concentration of 500 nM of
the RNA, and 5 and 10 uM of each of three experimental proteins assayed. Glycerol was
added to each of the samples to a final concentration of 5% in order to facilitate loading
on the gel. Once the samples were mixed they were equilibrated at 4°C for 15 min.
Positive and negative control samples of known binding partners HIV-1 SL3 RNA 33-nt
with and without HIV-1 Ncp7 (7 kDa), respectively, were loaded in the first and second s
of each gel. Negative control samples of the wild type TAR RNA alone were loaded in
the third, and negative control samples of each of the proteins in the absence of RNA
were loaded in the final three s (Appendix 16).

The EMSA gel was run for 90 minutes at ~8 °C and 100 Volts, removed from the
apparatus, incubated in Millipore Milli-Q Biocel ultrapure water (Millipore, Billerica, MA)
for 15 minutes, and then stained with SYBR® Gold nucleic acid stain (Molecular Probes,
Inc. Eugene, OR) for one hour. After rinsing the gel with water the RNA was visualized
and photographed with the Kodak Gel Imager equipped with UV transilluminator. The
gel was then incubated in 100 ml of fixing solution comprised of 50% methanol and 7%
acetic acid for 30 minutes two times. The gel was then incubated in 60 ml of SYPRO®
Ruby gel stain solution (Molecular Probes, Inc. Eugene, OR) overnight, and then

- 148 -

visualized and photographed again with the Kodak Gel Imager. The two images were
then superimposed over one another in order to facilitate the interpretation of the pattern
of protein and nucleic acid migration.

12.10.Results: Electrophoretic Mobility Shift Assay

In Figure 13-2 (EMSA) the negative control in one demonstrates the migration of the
free HIV-1 SL3 RNA at 500 nM, and with the addition of 10 uM of Ncp7 the positive
control in two demonstrates the super-shifting of the SL3 RNA as predicted for this well
characterized interaction. The negative control free wild type TAR RNA in three
migrates slightly less than the SL3 as predicted based on the two nucleotide difference
between the two oligonucleotides. In the experimental four the addition of Tat minimal
peptide at 10 uM binds to TAR 500 nM and produces a small shift consistent with
expectations for the low molecular weight (1.7 kDa) peptide. In experimental five a
super-shift appears where the 10 uM recombinant CycT1m-Tat (17.5 kDa) binds the 500
nM TAR RNA. In this interaction the RNA appears to have been completely prevented
from migration into the gel. In six a super-shift appears where 10 uM recombinant full
MBP tagged chimera (60.8 kDa) binds the 500 nM TAR RNA and is indistinguishable
from the shift produced by CycT1m-Tat in the prior. In seven no shift is observed where
10 uM of the MBP tag has been incubated with the 500 nM TAR RNA indicating that the
MBP tag alone does not bind TAR. In s eight, nine, ten, and eleven the previous four s
are repeated albeit with 5 uM of each of the proteins and the same 500 nM TAR RNA
with similar results except for the binding of the minimal peptide where slightly less

- 149 -

shifting is observed. In the same figure lanes twelve, thirteen, fourteen, and fifteen
contain the proteins alone at 10 uM and demonstrate that none of the recombinant
proteins contains any observable nucleic acid contamination.

12.11.Discussion

The results of the EMSA were as predicted for both positive and negative controls, and
for the experimental samples. Shifting of the TAR RNA was minor for the low molecular
weight Tat minimal peptide, and was absent for MBP which is not known to bind TAR.
Super-shifting of the TAR RNA for both the full Tat chimera, and CycT1m-Tat is readily
apparent. The binding affinity of the two samples was almost indistinguishable from the
EMSA experiment alone. However, CycT1m-Tat did appear to bind with slightly higher
affinity than its tagged counterpart.

In Figure 13-2 s 5 and 6, and 9 and 10 for CycT1m-Tat and the full chimera, at 10 uM
and at 5 uM respectively, the nucleic acid is not visible. The large, high molecular
weight, and high affinity complexes formed in these s appear to have super-shifted the
nucleic acid preventing its migration into the gel. In general, conditions known to prevent
visualization of nucleic acid in EMSA are where the nucleic acid has been degraded,
where protein-nucleic acid complexes are too large for the gel system, where protein
aggregation occurs, or where the ratio of nucleic acid to protein is higher than the gel
system can accommodate (144). The appearance of the nucleic acid in both the positive
and negative controls indicates that degradation was unlikely. Lower concentration of
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polyacrylamide in other trials failed to improve resolution (data not shown). Reducing the
ratio of nucleic acid to protein, and the addition of non-ionic detergents or higher
concentrations of glycerol might improve the visualization of the nucleic acid (144).
However, since MBP (43.4 kDa) at identical concentrations did not prevent the migration
of the TAR RNA it could reasonably be concluded that neither the ratio of nucleic acid to
protein nor the concentration of the gel were particularly unsuitable. While aggregation
of the recombinant full chimera and CycT1m-Tat could not be ruled out, the EMSA did
prove to be a successful screening tool for the Tat-TAR interaction as specific binding
was readily apparent (Figure 13-2).

With regard to the free protein samples, at the pH 8.0 of the 1 X TBE buffer the charges
of the Tat minimal peptide, CycT1m-Tat, full MBP tagged chimera, and the MBP tag
alone are +7.5, -0.5, -5.9 and -5.9, and their respective isoelectric points are 12.7, 7.9, 6.6,
and 5.71 (Appendices 2,3,4, and 5). These characteristics along with the fact that in this
non-denaturing system protein migrates based on a combination of size, shape, and
charge and are influenced by a multitude of additional factors including pH, and ionic
conditions could be responsible for the modest migration of the free protein through the
gel.

Although not quantitative, EMSA did prove to be a suitable initial method for screening
binding interactions between the recombinant chimeric proteins and the TAR stem-loop
nucleic acid.

- 151 -

kDa
250
150
100
75
50
37

25 kDa

25
20
15
10

Figure 12-1 Western blot of the Tat chimera and His6-TEV protease.
A Western blot of the Tat chimera and His6-TEV protease from left to right:
1 – ladder

2 – Positope™ control

3 – full chimera control

4 – cleavage reaction

5 – His6-TEV control
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine buffer.
Run condition: 200V, 50 minutes.
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Figure 12-2 SDS-PAGE of the Tat chimera and His6-TEV protease.
The SDS-PAGE analysis of the Tat chimera and His6-TEV protease samples from left to
right:
1 – ladder

2 – Positope™ control,

3 – full chimera control

4 – cleavage reaction,

5 – His6-TEV protease control.
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine
buffer. Run condition: 200V, 50 minutes. The same gel is used in Figure 12-1 Western blot.
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Figure 12-3 Western blot of full chimera and CycT1m-Tat.
A Western blot of the full chimera and CycT1m-Tat samples in various concentrations
and buffers from left to right:
1 – ladder

2 – Positope™

3 – CycT1m-Tat 0.5 mg/ml

4 – CycT1m-Tat 1.0 mg/ml

5 – full chimera

6 – full chimera concentrated

7 – CycT1m-Tat (fluor buffer)

8 – full chimera (Octet buffer)

9 – CycT1m-Tat (Octet buffer)
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine
buffer. Run condition: 200V, 50 minutes.

- 154 -

123 4 56 7 8 9
kDa

60

25

Figure 12-4 SDS-PAGE of full and CycT1m-Tat.
SDS-PAGE analysis of the full chimera and CycT1m-Tat samples from left to right:
1 – ladder

2 – Positope™

4 – CycT1m-Tat 1.0 mg/ml

3 – CycT1m-Tat 0.5 mg/ml
5 – full chimera,

6 – full chimera (fluor buffer)

7 – CycT1m-Tat (fluor buffer)

8 – full chimera concentrated (Octet buffer)

9 – CycT1m-Tat (Octet buffer)

Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine
buffer. Run condition: 200V, 50 minutes. The same gel is used in Figure 12-3.
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Figure 12-5 Diagram of the MALDI-TOF Method of Mass Spectrometry.
In MALDI-TOF a pulsed laser beam ionizes proteins affixed to the surface of the target
plate (bottom right). The mass to charge ratio of the ionized proteins causes the particle to
be deflected. A detector receives the deflected particle, the signal is amplified, and the
mass to charge ratio is recorded and plotted on the x axis, while the intensity of the signal
is plotted on the y axis in what is called a mass spectrum. Reprinted from: “The Next
Generation Technology for Microbial Identification: MALDI-TOF”, Copyright 2011
Accugenix, Inc. with permission from Accugenix, Inc. Accessed online at:
http://www.accugenix.com/microbial-identification-bacteria-fungus-knowledgecenter/micro-id-basics/maldi-tof-method/
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Figure 12-6 Bruker Daltonics flexAnalysis of CycT1m-Tat
The Bruker AutoFlex III MALDI TOF/TOF Mass spectrometer in the Jahn Lab at the
State University of New York College of Environmental Science and Forestry (SUNYESF) was set for the range of 8000 to 50000 Daltons. The molecular weight determined
by two trials is in close agreement with the theoretically calculated molecular weight of
17,481.5 Daltons.
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Figure 12-7 Wild type HIV-1 TAR (27-nt) stem loop structure for EMSA
The wild type HIV-1 TAR (27-nt) stem-loop nucleotide sequence and structure used in
the electrophoretic mobility shift assay (EMSA) for the characterization of the binding
complexes formed with the full MBP tagged Tat chimera, cleaved tag free Tat chimera,
and the Tat minimal peptide.

- 158 -

Figure 12-8 Electrophoretic mobility shift assay (EMSA)
EMSA of wild type HIV-1 TAR (27-nt) RNA complexed with full-length MBP tagged
Tat chimera, CycT1m-Tat, and the Tat minimal peptide (see also, Appendix 16). An
image of gel stained with SYBR Gold (RNA) was superimposed with an image from the
same gel stained with SYPRO Ruby (protein). [SL3] = [TAR] = 500 nM when present.
Lanes are color-coded for the most important analytes, numbered left to right:
1 – SL3 RNA

2 – SL3 + NCp7 protein 10 uM

3 – TAR RNA

4 – TAR + Tat minimal peptide 10 uM

5 – TAR + CycT1m-Tat 10 uM

6 – TAR + MBP tagged chimera 10 uM

7 - TAR + MBP 10 uM

8 - TAR + Tat minimal peptide 5 uM

9 - TAR + CycT1m-Tat 5 uM

10 - TAR + MBP tagged chimera 5 uM

11 - TAR + MBP 5 uM

12 – Tat minimal peptide 10 uM

13 – CycT1m-Tat 10 uM

14 – MBP tagged chimera 10 uM

15 – MBP 10 uM
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Chapter 13 Label-Free Binding Analysis

From its introduction in the 1960’s (152-154), biosensor technology has developed into a
multibillion dollar market utilized by a large and diverse group of industries as well as by
the general public (152). Though many different definitions exist, in general a biosensor
is a device that is used to detect a signal that is produced when a target molecule interacts
with a biological component in close proximity to a transducer (152,155). This label-free
technology is now widely employed, and is the basis of several home diagnostic devices
available to the general public such as: the ClearBlue pregnancy test, and the electronic
blood glucose monitors commonly used by diabetics (152).

For biochemists, biosensors permit the detection and quantitation of interactions between
unlabeled biological components, and facilitate a wide variety of experiments by
obviating the tedious and problematic process of labeling the biological components
under investigation. In addition to the difficulties encountered during labeling, the study
of labeled components is frequently hindered by inefficient labeling, as well as by
interference, or the necessity to rule out interference, caused by the label itself. A wide
array of enzymes, antibodies, and nucleic acids are now assayed by label-free methods
using biosensors that employ electrode, thermistor, or optical transducers to convert the
interaction between biomolecules into a quantifiable signal (152,156).
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13.1. Optical Biosensors

Among optical biosensors surface plasmon resonance (SPR) is at present the most
commonly used affinity-based biosensor technique. Several different manufacturers have
developed equipment that varies widely in price, ease of use, and popularity among
researchers. BIAcore® is currently the market leader, and most of the published research
protocols detail techniques applicable to the BIAcore system (GE Healthcare
Biosciences, Piscataway, NJ). The system in our lab is a GWC Technologies
SPRimager®II (Madison, WI) that, while less popular among researchers, is a more
moderately priced model that is capable of a comparable range of assays. Another
important variant is biolayer interferometry, discussed below in Section 16.6. As of this
writing the bulk of published SPR research still tends to pertain to the investigation of
protein-protein interaction, and a good deal less published work is to be found regarding
the interaction between a protein and a nucleic acid binding partner such as is the subject
of this research.

13.2. Surface Plasmon Resonance

The technology behind SPR affinity-based biosensors is based on the detection of
changes in the refractive index of a solution with a positive real part of the dielectric
constant Re () flowing over an oscillating electromagnetic wave parallel to a metal (Au,
Ag, Cu, Ti, Cr) sensor surface with a negative  (157). Surface plasmons at the metal
surface produce a self-propagating electromagnetic wave called surface plasmon
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polaritons (SPP) when infrared polarized light couples (through a prism-coupling
arrangement) with free oscillating electrons in the metal (156-159).

Coupling must occur at a specific angle known as the angle of incidence. When
biomolecules bind within the sensitive region of 300 nm from the metal surface, incident
light is lost to the metal at the surface and the reduction in light is detected as the angle of
reflection is shifted by the binding event (Figure 14-1) (159). The difference between the
angle of reflection prior to adsorption of the analyte and after binding has occurred is
plotted as response versus time and is displayed in real time on the system’s computer
monitor (Figure 14-2) (156,158,159).

In the typical SPR assay a “bait” ligand, either a protein or nucleic acid, is affixed to a
gold surface over which a solution containing the analyte binding partner is passed. The
interaction between the analyte and the ligand is recorded as intensity of response versus
time in a real-time curve generated by the system software (Figure 14-3). The kinetics of
the reaction, in terms of the on-rate, off-rate, and dissociation constant of the interaction,
are then calculated by fitting the curves of the association and dissociation phases of the
response. The height of the SPR response is related to the mass of material bound to the
sensor surface.
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13.3. Surface Plasmon Resonance Surface Chemistry

When performing binding assays with the GWC SPRimager®II a self-assembled
monolayer (SAM) must be created on the gold spots on the surface of a glass chip prior
to beginning the experiment. The SAM provides the surface chemistry for the attachment
of the ligand to the metal on the chip surface. Several different types of surface chemistry
are available including: amine, streptavidin, or polyethylene glycol (PEG). Deciding
which surface chemistry to use for a specific interaction is most frequently an empirical
process. The preparation of the SAM is performed over the course of two days. Preparing
the chip fresh prior to each experiment is advisable, although regeneration is theoretically
possible results are frequently not reproducible.

13.4. Limitations of Surface Plasmon Resonance

Set-up and execution of the SPR experiment with the GWC SPRimager®II is a relatively
long procedure that is complicated to assemble, and it is generally not possible to recover
sample after the experiment. Accurate determination of the ligand concentration on the
surface is not possible due to the potential for artifacts related to the application of the
surface chemistry to the chip. Ligand may or may not have successfully bound to the
surface chemistry in some regions of the chip surface producing inter-spot or intra-spot
binding heterogeneity (160). Consequently, the concentration of bound analyte cannot be
accurately known if the concentration of bound ligand is unknown.
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13.5. Mass Transport Limitation

In addition to the SPR limitations related to the efficiency of the surface chemistry, are
limitations related to analyte delivery. When attempting to measure the binding affinity
of an interaction with a fast on-rate it is common for the measured rate to be slower than
the true rate according to chemical kinetics. This can occur when the density of the
affixed ligand is so great as to sterically hinder the delivery of the analyte to the binding
site, and also when the on-rate of the interaction is faster than the rate of analyte delivery
that the system can accommodate (160). Further, where the on-rate of the interaction is
fast a local depletion of analyte concentration can occur preventing an accurate
determination of on-rate (160).

Interference with dissociation can occur when the density of the ligand prevents the free
dissociation and diffusion of the analyte. The size and concentration of the analyte must
also be considered, as large proteins can hinder binding at other sites. Thus the potential
effects of mass transport limitation on the determination of binding kinetics in SPR are
not trivial. However, in the evolution of SPR protocols researchers have found that
determining and employing a minimal working ligand concentration, and keeping the
concentration of the analyte well below that of the ligand are prudent approaches to
minimizing the potential for mass transport limitation problems (personal conversation
with Dr. Thomas Duncan, Upstate Medical University, Syracuse NY) (160).
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13.6. Biolayer Interferometry

Improving upon SPR biosensor technology, biolayer interferometry (BLI) is another
label-free optical biosensor detection platform used to study the interaction of
biomolecules. In BLI (Figure 14-4 and 14-5) the interaction of light waves in constructive
and destructive interference produces a wave pattern that is the basis of optical
interferometry technology. Glass fiber-based biosensors, with a variety of available
surface chemistries, bind the ligand and are then dipped into 96 well plates containing the
analyte in solution.

White light travels down the sensor and is reflected back to the detector from two
surfaces within the tip: a reference layer surface, and the interface surface where the
ligand meets the analyte solution (Figure 14-6) (161). At the spectrometer individual
reflected wavelengths that are either in phase or out of phase combine to form an
interference pattern. When binding occurs at the second interface surface of the tip, the
change in the interference pattern of the reflected wavelengths is detected as the intensity
variation by wavelength. The change in intensity is then plotted as response (in
nanometers) versus time (161). The kinetics of the reaction can then be calculated from
the association and dissociation phases of the resulting response versus time curve, as in
SPR.

However, unlike SPR where microfluidics govern the delivery of the analyte through a
flow cell, BLI systems such as the ForteBio’s Octet optical biosensor provide
“microfluidic-free” delivery of the analyte by dipping the fiber optic sensor tip loaded
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with the affixed ligand into an open shaking 96 well microplate rather than flowing the
analyte solution over the chip as in SPR (161). In this manner many of the complications
of microfluidics and analyte delivery are avoided. The ForteBio Dip and Read™
Biosensors are available in a wide variety of surface chemistries and can also be
customized for a specific application. Assays can be performed in crude or purified
analyte solutions, and in many cases it is possible to recover the sample after the
experiment.

13.7. Biolayer Interferometry ForteBio Octet Method

Many attempts to obtain kinetic data for the interaction between the recombinant Tat
chimera and the TAR stem-loop using the GWC SPRimager®II failed to produce
consistent and reproducible results. At the time of the experiments manufacturer
suggestions for ligand density of 1 to 2 mM on the chip surface proved to be too dense
and appeared to contribute to steric hindrance. Results were somewhat more reproducible
when ligand concentrations were reduced, however the three dimensional nature of the
surface chemistry on the chip was also a likely contributor to steric hindrance (personal
conversation with Dr. Thomas Duncan, Upstate Medical University). Hence, BLI was an
attractive alternative for acquiring these data. The Octet Red 96 (Pall FortéBio Corp,
Menlo Park, CA) provides real time data for protein kinetics and quantitation and was
generously made available by Dr. Thomas Duncan of Upstate Medical University in
Syracuse, New York. The streptavidin biosensor tips used with the Octet system affix the
ligand with a surface chemistry that is more two dimensional in nature and less likely to
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contribute to steric hindrance (personal conversation with Dr. Thomas Duncan, Upstate
Medical University).

To begin each experiment the instrument was set at 22°C so that it could be heated to the
experimental temperature of 25°C rather than cooled as this requires more time.
Streptavidin-coated fiber optic tips were incubated in buffer at pH 7.4, containing 20 mM
Tris, 0.2 M NaCl, 10 µM ZnCl2, 0.02% Sodium Azide, 5 mM BME, and 0.5 mg/ml fat
free bovine serum albumin (BSA) for a minimum of 10 minutes prior to beginning the
assay.

The first trial compared the response for ligand concentrations of TAR RNA-27 nt at 0.3
µM, 0.6 µM, 1.25 µM, 2.5 µM, and 5.0 µM in a BLI binding assay with a static CycT1mTat analyte concentration of 1.5 µM (data not shown). From the results of this assay a 0.5
µM ligand concentration was chosen as the working concentration for subsequent trials.
The 0.5 µM ligand concentration was low enough to minimize mass transport limitations,
while high enough to produce the appropriate and characteristic response curve for BLI.

13.8. Non-specific Binding

The second experiment was designed to assess the level of nonspecific binding of the
protein to the streptavidin tips utilizing negative controls. Raw aligned data in figures 147 and 14-8 demonstrates very low level response for the non-specific binding of the
CycT1m-Tat (17.5 kDa) to the streptavidin sensor tips in the absence of 5’ biotinylated

- 167 -

TAR RNA ligand at analyte concentrations of 1.5, 0.5, and 0.2 µM. This response was
similar even at concentration of up to 4.0 µM of CycT1m-Tat (data not shown). The
nonspecific response is approximately 0.05 nm above the background response for the
negative control sensor in the absence of both the RNA ligand and CycT1m-Tat analyte,
and well below the positive control response of 0.5 nm for 1.5 µM CycT1m-Tat bound to
the 0.5 µM 5’ biotinylated TAR stem-loop.

13.9. Tat-TAR Binding Interaction

Eight disposable fiber-optic sensors were used in the third experimental assay. The single
use Dip and Read™ Streptavidin (ForteBio Menlo Park, CA) sensors were incubated in a
solution of 0.5 µM 5’ biotinylated TAR 27-nt stem-loop RNA ligand (10.6 kDa)
purchased from Integrated DNA Technologies, Coralville, IA. Protein analyte solutions
used for the assay were: full Tat chimera (60.8 kDa) 4 µM, CycT1m-Tat (17.5 kDa) 4
µM, 2 µM, 1 µM, 0.5 µM, 0.25 µM, and MBP (42.0 kDa) 4 µM (MBP purchased from
GenWay Biotech, Inc. San Diego, CA.). All samples were prepared in the same buffer
solution containing 0.5 mg/ml fat free bovine serum albumin (ffBSA) to inhibit
nonspecific binding.

A 96 well plate was prepared with buffer solution in rows 1, 3, and 5 (Figure 14-9)
(Table 14-1). The 5’ biotinylated TAR RNA 0.5 µM ligand (in buffer solution) was
loaded in 2. In 4 various analyte solutions (in the same buffer solution) were loaded as
listed in Table 14-1. For the first 300 seconds (step 1) (Figure 14-10) of the experiment
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the streptavidin biosensor tips were incubated in 1 (buffer 1), followed by a 400 second
incubation (step 2) in 2 with 0.5 µM 5’ biotinylated TAR RNA 27-nt affixing the ligand
to the tip. At 700 seconds the tips were incubated in 3 (a fresh buffer solution of the same
composition) (step 3) for 600 seconds to remove unbound ligand. In step 4 the tips were
incubated for 60 seconds in a fresh buffer solution in 5 in order to achieve a stable
baseline in fresh buffer unadulterated by the presence of unbound RNA. In step 5 the
biosensor tips were incubated in the various concentrations of analyte solutions for 900
seconds which was sufficient to achieve saturation. In step 6 the tips were returned to the
unadulterated buffer in 5 for 1800 seconds for the dissociation step. Data were displayed
in real time using the ForteBio Data Acquisition 6.4 software program (ForteBio Menlo
Park, CA) (Figure 14.9).

13.10.Determining the Dissociation Constant of the Tat-TAR Interaction

In the formation of the bound Tat-TAR complex the binding event can be represented as
a two-state process by:

Tat + TAR

Tat-TAR

Thus the corresponding equilibrium dissociation constant Kd is defined as:

Kd = [Tat]·[TAR]
[Tat-TAR]
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where [Tat], [TAR] and [Tat-TAR] represent molar concentrations of the Tat protein, the
TAR RNA ligand and the bound [Tat-TAR] complex, respectively.

The equilibrium of this reaction will be reached when

[Tat]·[TAR] kon = [Tat-TAR] koff
where kon and koff are the on and off rates of the reaction in M-1 s-1, and s-1 respectively.
The equation can then be rearranged

Kd = koff = [Tat]·[TAR]
kon
[Tat-TAR]

The actual concentrations of Tat, TAR, and the Tat-TAR complex cannot be known
during BLI as discussed previously. Therefore the equilibrium constant Kd must be
calculated from the ratio of the off rate to the on rate for the Tat-TAR interaction.

The data calculated by the ForteBio Data Analysis 6.4 reports a response of kobs for the
binding event. The equation for a trend line of the linear regression of kobs versus
concentration is:

kobs = ka[L] + kd

where ka is equal to the on rate of the interaction, L is the ligand concentration, and kd is
the off rate of the interaction in units of per nanomolar per second when reported by Data
Analysis 6.4.
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13.11.Biolayer Interferometry ForteBio Octet Results: Fitting the Data

The measured response was minimal and consistent with expectations for the negative
control MBP protein (the solubility enhancing tag alone) (Figure 14-10, B7). A larger
response, with a rapid onset and early approach to saturation was observed for the full
MBP-Tat chimera (Figure 14-10 A7). The samples of CycT1m-Tat demonstrated the
largest response that increased in proportion to concentration, saturating at about 2-4 uM
for the present conditions. CycT1m-Tat comprises only 29% of the full chimera, so each
binding event for the full protein should carry 3.4 times more mass than for CycT1m-Tat
(60/17.5 = 3.4) if both proteins had the same binding constant and an equivalent number
of binding sites. Figure 14-10 portrays the opposite situation, where the final A7-signal is
less than half of that for C7. While it is possible that the MBP portion of the full chimera
renders its CycT1m-Tat domain less effective in binding TAR, the most likely
explanation is that the MBP portion of the full chimera occludes some of the TAR RNA
sites on the Octet tip. The data are consistent with a high-affinity interaction between
CycT1m-Tat and surface-immobilized TAR RNA.

13.12.Association 1:1 Model Fit

The association and dissociation phases of the binding response versus time curves
(Figure 14-10 steps 5 and 6) were displayed in real time during the experiment.
Excluding the MBP protein and full Tat chimera, the association phase (step 5) for the
five remaining samples of CycT1m-Tat chimera (4.0 µM, 2.0 µM, 1.0 µM, 0.5 µM, and
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0.25 µM) were fit to a 1:1 model. Using ForteBio Data Analysis 6.4 software program
the 1:1 model was selected with settings for global fit and Rmax unlinked by sensor. As
seen visually in Figure 14-11, the data did not fit perfectly to the 1:1 model (the fit is
improved by invoking a second binding class – see next paragraph). The regression
analysis of the 1:1 model to the data in Figure 14-12 for the five concentrations of
CycT1m-Tat gave an R2 value of 0.98 (Figure 14-12).

13.13.Association 2:1 Model Fit

The same data for the association phase of CycT1m-Tat samples fit well to a 2:1 model
(Figure 14-13). A linear regression analysis for the response kobs1 was plotted for all data
points with an R2 value of 0.99 (Figure 14-14). The slope of the trend line for
concentration (nM) versus response is equal to ka, the on rate for the primary binding
event, which accounted for approximately 88% of the response. For the predominant high
affinity species the on rate ka is equal to 2.0 x 10-5 nM-1 s-1 or 2.0 x 104 M-1 s-1.

In the linear regression analysis kobs2 for the second binding event, a minor fraction of the
response, a single data point was removed as an artifact of the software calculations
(Figure 14-15). From the remaining data points the R2 value was 0.92 and from the slope
of the trend line ka is equal to 1.0 x 10-6 nM-1 s-1 or 1.0 x 103 M-1 s-1.
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13.14.Dissociation Fit 1:1 Model

The majority of data for the dissociation step (step 6) fit well to a 1:1 model. The first
200 seconds indicate the presence of a second species which is fast dissociating and did
not fit well to the 1:1 model. These first 200 seconds were excluded from the 1:1 model
fit. The predominant species, however, was slow to dissociate. Only approximately 0.1
nm of the approximately 0.8 nm total response or 12% was attributable to a fast
dissociation by the presence of a second species (Figure 14-16). The average off rate, kd,
for the five cleaved Tat samples was 8.8±0.6 x 10-4 s-1 with a R2 > 0.99.

13.15.Equilibrium Dissociation Constant

The equilibrium dissociation constant KD is a measure of the strength of the binding
interaction between two molecules and is defined as the ratio of the off rate to the on rate
of the interaction:

where kd is the off rate of the interaction in units of s-1, and ka is the on rate of the
interaction in units M-1 s-1.
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Using the ka = 2.0x104 M-1 s-1 for the 2:1 model predominant interaction, and kd =
8.8x10-4 s-1, the KD for the interaction between CycT1m-Tat and the TAR 27-nt stemloop is 44 x 10-9 M (44 nM) indicating a high affinity for the protein-RNA interaction.

For these studies, the CycT1m-Tat protein was not purified to absolute homogeneity and
it takes time to concentrate the protein with appropriate buffer exchanges, during which
time one might expect a small amount of degradation. There could also be a small
amount of the full-length chimera present. Thus, a leading explanation for the Octet
results is that 85-90% of the CycT1m-Tat fusion binds TAR RNA with low nanomolar
affinity, exhibiting fast association and slow dissociation (ka ~ 2104 M-1 s-1 and kd ~ 9
10-4 s-1), while related impurities having reduced affinity for TAR RNA exhibit slower
association and faster dissociation (ka ~ 1104 M-1 s-1 and a larger kd [value not
determined] and accounting for ~12% of the Octet response).

13.16. Biolayer Interferometry Discussion: Non-Ideal Behavior

For the sake of completion, it is useful to formally consider the effects that may occur in
Biolayer interferometry due to imperfect samples. Non-ideal behavior is typically
observed under three circumstances: (1) heterogeneity of the ligand (2) heterogeneity of
the analyte (3) mass transport limitation (4) interactions more complicated than a simple
1:1 binding ratio (ForteBio Product Literature).
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13.17. Heterogeneity of the Ligand or Analyte

From Figure 14-10 step 5 the five Tat samples appear to reach equilibrium in the
association phase, but fail to reach a complete dissociation in step 6. Fitting the data to a
1:1 model demonstrates that a small portion of the dissociation is fast in nature and
deviates substantially from the predominant interaction that dissociates slowly. This may
indicate heterogeneity of the ligand, the analyte, or possibly both.

Heterogeneity of the RNA ligand can result from a variety of causes, among them:
artifacts related to the surface chemistry, dimerization, contamination, and degradation.
Similarly, heterogeneity of the analyte can be caused by a multitude of factors such as:
impurities in the sample, incomplete or improper folding of some portion of the analyte,
contamination, the absence of cofactors, “bridging” (binding more than one ligand
molecule), and degradation. Determining the factors or combination of factors
responsible for the observed heterogeneity could require many additional assays, and
unless the non-ideal behavior is resolved it is possible that the source of the heterogeneity
may remain obscure.

13.18.Non-ideal Behavior and Mass Transport Limitation

Non-ideal behavior in the association phase is often associated with a mass transport
limitation. Since the association phase of the experiment did reach equilibrium a mass
transport limitation is unlikely to be the cause of the observed deviation from ideal
behavior.
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13.19.Non-ideal Behavior with Multiple Binding Sites

Non-ideal behavior is frequently observed when binding events have a stoichiometry
more complicated than a simple one to one ratio. Since the Tat chimera has two zinc
fingers which purportedly bind at two separate regions of the TAR stem-loop (the apical
loop and the tri-nucleotide bulge) it is possible that the binding of the two zinc fingers
may contribute in some manner, as yet unanticipated, to the observed analyte
heterogeneity although in theory, binding of either zinc finger individually should
produce a similar response (personal conversation with Dr. Thomas Duncan). Moreover,
partially or incorrectly folded proteins may be present, and the zinc co-factor may or may
not be present in all zinc finger sites. Either of these conditions present in some fraction
of the analyte solution has the potential to inhibit, mitigate, or even to enhance binding of
the protein resulting in the observance of heterogeneous behavior. Finally, several of
these conditions could be contributing simultaneously to the observed non-ideal behavior.

13.20.Reversibility of the Binding Interaction

Since the dissociation step of the experiment did not continue longer than 1800 seconds,
and complete dissociation was not observed it is not possible to confirm that the
interaction is reversible. Additional experiments with such additives as EDTA (to remove
the zinc ions from the zinc fingers), or mutation experiments could be employed to
disrupt the binding interaction and demonstrate reversibility in future work.

- 176 -

Figure 13-1 Surface plasmon resonance Kretchmann configuration
The surface plasmon resonance (SPR) Kretchmann configuration is the standard design
for most SPR instruments. A soluble analyte solution is delivered to the chip surface
through a flow cell. The interaction between the ligand affixed to the chip surface and the
analyte in solution is detected by an increase in mass at the surface that corresponds to a
shift in the angle of the reflected light. This shift is detected and displayed in real time on
the system’s computer monitor. Reprinted from: Methods in Enzymology, vol. 399
Hartmann-Petersen, R., and Gordon, C., Pages 164-177, Copyright 2005 (158) with
permission from R. Hartmann-Petersen.
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Figure 13-2 Adsorption profile for SPR
A diagram of the adsorption profile for the surface plasmon resonance (SPR) assay. A
shift in the angle of reflection is produced when an analyte in solution binds to a ligand
affixed to the chip surface. The shift in the angle of reflection is detected and plotted as
response versus time in a real time display on the system monitor. Reprinted from:
Methods in Enzymology, vol. 399 Hartmann-Petersen, R., and Gordon, C., Pages 164177, Copyright 2005 (158) with permission from R. Hartmann-Petersen.
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Figure 13-3 A surface plasmon resonance sensorgram.
A surface plasmon resonance sensorgram in which real time data is plotted as response
versus time and displayed on the system monitor. Reprinted from: Methods in
Enzymology, vol. 399 Hartmann-Petersen, R., and Gordon, C., Pages 164-177, Copyright
2005 (158) with permission from R. Hartmann-Petersen.
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Figure 13-4 Biolayer interferometry sensor tip
A diagram of a biolayer interferometry glass fiber-based sensor tip. White light traveling
down the tip is reflected from two points at the tip surface. Changes in the wave patterns
of the reflected light are used to detect binding at the tip surface. Reprinted with
permission from ForteBio.
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Figure 13-5 Constructive, partially constructive and destructive interference
Constructive, partially constructive and destructive interference patterns of white light.
Reprinted with permission from ForteBio.
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Figure 13-6 Interference captured by the spectrometer
Interference captured by the spectrometer reported as relative intensity in nanometers.
Reflected wavelengths are altered by binding at the surface and the thickness of the
optical layer. Reprinted with permission from ForteBio.
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Figure 13-7 Nonspecific binding to Octet biosensor tips
Assessment of the nonspecific binding of CycT1m-Tat to the streptavidin biosensor tips.
Raw aligned data demonstrates a low level of Tat chimera nonspecifically bound to the
streptavidin biosensor tips in the absence of TAR RNA. From left to right:
A (dark blue) – Positive control - 5 uM TAR RNA with 1.5 M cleaved Tat,
E (yellow) – No RNA bound to sensor with 1.5 uM CycT1m-Tat,
F (violet) – No RNA bound to sensor with 0.5 uM CycT1m-Tat,
G (turquoise) – No RNA bound to sensor with 0.2 uM cleaved Tat,
H (red-orange) – Negative control - No RNA bound to sensor and buffer only (No
Protein) analyte solution
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Figure 13-8 Raw aligned nonspecific protein response
Raw aligned nonspecific protein response for streptavidin biosensor tips in the absence of
the RNA ligand:
E (yellow) – No RNA 1.5 uM Cleaved Tat,
H (red-orange) – No protein No RNA.
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Figure 13-9 The experimental set-up of Octet Red 96 well plate
A diagram of the experimental set-up of Octet Red 96 well plate arrangement for the
loading of samples in Table 14-1.

- 185 -

Experiement Set Up
A
B
C
D
E
F
G
H

1
Buffer
Buffer
Buffer
Buffer
Buffer
Buffer
Buffer
Buffer

2
RNA 0.5 uM
RNA 0.5 uM
RNA 0.5 uM
RNA 0.5 uM
RNA 0.5 uM
RNA 0.5 uM
RNA 0.5 uM
RNA 0.5 uM

3
Buffer
Buffer
Buffer
Buffer
Buffer
Buffer
Buffer
Buffer

4
FL Chimera 4 uM
MBP 4uM
Cleaved Tat 4 uM
Cleaved Tat 2 uM
Cleaved Tat 1 uM
Cleaved Tat 0.5 uM
Cleaved Tat 0.25 uM
NO PROTEIN Control

5
Buffer
Buffer
Buffer
Buffer
Buffer
Buffer
Buffer
Buffer

Table 3 The experimental set up for Octet 96 well plate
The experimental set up for Octet 96 well plate from left to right: 1 - buffer at pH 7.4
containing 20 mM Tris, 0.2 M NaCl, 10 uM ZnCl2, 0.02% Sodium Azide, 5 mM BME,
and 0.5 mg/ml fat free bovine serum albumin (BSA), 2 – wild type TAR 27-nt RNA at
0.5 µM in same buffer as 1, 3 – buffer as in 1, 4 – various concentrations of
recombinant proteins, 5 – buffer as in 1, and 3.
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1

2

3

4

6

5

Figure 13-10 ForteBio Octet Sensogram for TAR stem-loop bound to Tat chimera.
A ForteBio Octet Sensogram for the TAR RNA stem-loop bound to the full Tat chimera,
CycT1m-Tat, and MBP. Steps 1 through 6 are delineated by dashed red lines. Samples
from left to right:
A7 (green) – full chimera 4 µM,

B7 (pink) – MBP 4 µM,

C7 (yellow) – CycT1m-Tat 4 µM,

D7 (purple) – CycT1m-Tat 2 µM,

E7 (dingy green) - CycT1m-Tat 1 µM,

F7 (black) – CycT1m-Tat 0.5 µM,

G7 (red) – CycT1m-Tat 0.25 µM,

H7 (blue) – negative control (no protein)
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Figure 13-11 Association phase 1:1 data fit
The association phase data for TAR [0.5 µM] RNA bound to CycT1m-Tat at 4, 2, 1, 0.5,
and 0.25 µM fit to a 1:1 model. The blue line is the actual binding data and indicates a
response in proportion to concentration. The red line is the curve fitting model. The
actual data deviated from the 1:1 model considerably indicating a multiphasic response
and the possibility of analyte heterogeneity.
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5.00E-02
4.50E-02
y = 1E-05x + 0.0013
R² = 0.9804
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4.00E-02
3.50E-02
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2.50E-02
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Figure 13-12 Association phase 1:1 data fit regression analysis.
The association phase 1:1 data fit regression analysis for the TAR-Tat interaction in
Figure 14-11. The slope of the trend line for concentration versus kobs is ka = 1.0 x 10-5
nM-1 s-1 the on rate of the reaction.
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Figure 13-13 Association phase 2:1 data fit.
The association phase data for TAR [0.5 µM] RNA bound to CycT1m-Tat at 4, 2, 1, 0.5,
and 0.25 µM fit to a 2:1 model. The blue line is the actual binding data and indicates a
response in proportion to concentration. The red line is the curve fitting model. The
actual data fit well to a 2:1 model consistent with predictions for the multiphasic response
and analyte heterogeneity.
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Figure 13-14 – Association phase 2:1 data fit regression analysis
The Association phase 2:1 data fit regression analysis for the predominant binding event
kobs1. The slope of the trend line for concentration versus k observed (1/s) is ka = 2.0 x 105

nM-1 s-1 the on rate of the primary reaction.
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Figure 13-15 Association phase 2:1 data fit regression analysis
The Association phase 2:1 data fit regression analysis for the minor binding event kobs2.
The slope of the trend line for concentration versus k observed (1/s) is ka = 1.0 x 10-6 nM1 -1

s the on rate of the reaction.
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Figure 13-16 Dissociation 1:1 fit minus
The dissociation phase for TAR [0.5 µM] RNA bound to CycT1m-Tat at 4, 2, 1, 0.5, and
0.25 µM fit to a 1:1 model. The first 200 seconds have been omitted from the curve
fitting to remove the data for the fast dissociating species. Less than 15% of the response
appears to be attributable to the low affinity fast dissociating species.
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Sensor

Sensor Type

Sample
ID

C7

SA
(Streptavidin)

Cleaved
TAT

D7

SA
(Streptavidin)

E7

Conc.
(nM)

Response

kdis(1/s)

kdis
Error

Dissoc
X^2

Dissoc
R^2

4000

3.838

8.58E-04

3.62E06

0.026

0.999

Cleaved
TAT

2000

3.988

9.43E-04

4.28E06

0.045

0.999

SA
(Streptavidin)

Cleaved
TAT

1000

3.851

9.64E-04

4.29E06

0.046

0.999

F7

SA
(Streptavidin)

Cleaved
TAT

500

3.273

8.37E-04

4.09E06

0.031

0.999

G7

SA
(Streptavidin)

Cleaved
TAT

250

2.193

7.98E-04

3.59E06

0.014

0.999

Table 4 Dissociation phase responses
A table of Octet dissociation data indicating the off rates kd for the dissociation step of
TAR RNA [0.5 µM] bound to five concentrations of CycT1m-Tat (4.0 µM, 2.0 µM, 1.0
µM, 0.5 µM, and 0.25 µM). The average kd was 8.8 ±0.6 x 10-4 s-1.
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Chapter 14 Labeling the Tat Chimera with Stable Isotopes for
NMR

As discussed in Chapter 3, the first NMR structures of a TAR-arginine complex were
reported by Puglisi, Tan et al. 1992. The structure of TAR alone was reported by Aboulela, Karn et al. in 1995, and a 24 residue Tat peptide bound to TAR was reported by Long
and Crothers in 1999 (21,22,40,162). However, these structures did not consider or
contain any portion of the human Cyclin T1 protein, the essential TAR interacting
component of PTEF-b. At present there is still no structural NMR data of the purportedly
essential 261 Cys residue of Cyclin T1 that is believed to complete zinc finger 2 in
concert with three additional cysteine residues Cys22, Cys25, and Cys27 of Tat (Figure
1-5) (15) , and the active domain of Tat remains obscure.

14.1. Structural Detail of the Tat-TAR Interaction

Initially, the Tat-TAR interaction was predicted to occur at the bulge region of the TAR
stem-loop where an arginine rich region of Tat has been shown to interact (21). However,
Garber et al. 1998, and Wei et al. 1998 found, by Western blot, that an additional binding
interaction between zinc finger 2 and the apical stem-loop contributed substantially to the
high affinity of the interaction (15,17). While the crystal structure solved by Tahirov and
Babayeva in 2010 of PTEF-b and HIV-1 Tat was groundbreaking the reported structure
was disordered in this crucial region of hCycT1 and also failed to elucidate the active
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domain of Tat (7). The opportunity then remains to gain insight into this important region
from 2D 1H-15N HSQC spectra that could either support or refute the findings of Garber
and Wei, while providing structural detail to facilitate rational drug design.

Structural information for the folded state of a protein is reported by 2D 1H-15N HSQC
NMR in the form the dispersion pattern, intensity, and number of cross peaks observed,
with most of the cross peaks corresponding to the amide 1H-15N nuclei of individual
residues in the backbone of the protein. The pattern of cross peaks then provides a
diagnostic fingerprint specific to the protein of interest (163). These peaks can then be
assigned to begin the process of determining the structure of the protein.

14.2. Determining the Suitability of the Tat-TAR Interaction for NMR

The results of biophysical techniques discussed previously indicated that recombinant
CycT1m-Tat was comprised of the appropriate sequence and molecular weight, and that
the unlabeled protein could be sufficiently purified and concentrated for structural work.
When expressed in Turbo Broth™ a concentration approaching the requisite 0.6 ml of 0.2
mM protein for 2D 1H-15N HSQC NMR was obtained. However, it is still possible that
heterogeneity of the sample could prove problematic in structural experiments, for
example: by the presence of more cross peaks than residues in the HSQC NMR spectrum.
In addition, the presence of multiple domains, as is the case with Tat, has been cited as a
potential impediment to NMR structural determination (93,164).
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Most of the structures solved by 2D 1H-15N HSQC NMR are less than 30 kDa (164).
Proteins larger than 30 kDa may be candidates for the more recently developed TROSY
technique (165). In general, proteins with multiple domains tend to be more troublesome
subjects for structural study due to difficulties with expression in E. coli, conformational
heterogeneity, and the frequently large size of these proteins (93). Initially however, the
wild type TAR RNA at 10.2 kDa, and CycT1m-Tat 17.5 kDa appear to be within the
acceptable range of size necessary for structural study. Although the CycT1m-Tat
chimera does exceed, by four residues, the approximate 150 residue recommended limit
cited by Edwards, Arrowsmith et al. 2000. It is most likely that fully 15N,13C-labeled
protein and RNA will be used to determine the structure by combination of 2D, 3D, and
4D NMR experiments as was done for determining the structure of the complex between
the HIV-1 nucleocapsid protein and the SL3 RNA stem-loop (166).

14.3. The Expression of 15N Labeled Proteins for NMR
The first step toward obtaining 2D 1H-15N HSQC NMR structural data for CycT1m-Tat is
the production of recombinant protein which is uniformly 15N-labeled. Typically an M9
minimal media formula (Appendix 19) containing the 15N isotope in the form of 15NH4Cl
is used to grow the culture and all other sources of nitrogen are removed thereby forcing
the incorporation of heavy nitrogen. In addition to 15NH4Cl, trace metals, and vitamins
are added to the media to aid the bacterial growth under the sub-optimal and taxing
growth conditions afforded by the M9 minimal media. Frequently, the target protein can
be otherwise expressed with the same protocol as would be used for rich media, but a
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lower yield of the recombinant protein may be reasonably predicted (rich media contain
amino acids with 100% 14N, which would dilute 15N-crosspeaks to an extent that makes
the HSQC spectrum useless).

Since the amount of protein required for NMR experiments is relatively large,
optimization of the growth conditions, cell density, and protein expression is highly
recommended. When expressing 15N labeled proteins, optimization of the growth
conditions is limited considerably by the use of minimal media. High cell density cultures
can be employed to improve protein yield, but efforts in this regard are often hampered
by resulting plasmid loss, reduced pH, and low levels of dissolved oxygen in the growth
medium (165). One attractive approach to increasing the yield of the labeled protein
without altering the medium, or increasing the culture density is to perform a double
colony selection of the expression strain (165). The double colony selection method of
selection can be used for normal or high density cell cultures.

14.4. Double Colony Selection

It is always advisable when embarking on a recombinant protein expression to begin with
a fresh transformation of the plasmid of interest into its intended host. Plasmid loss
occurs over time and during storage due to ampicillin instability and will reduce the
overall yield of recombinant protein expression. In addition to a fresh transformation, it is
also advisable to screen the transformed colonies as genetic differences will cause some
colonies to demonstrate a higher level of target protein production than other colonies.
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Exploiting this fact, in a double colony selection several colonies are selected from a
fresh transformation plate and separately screened for the highest level of protein
expression and, where possible, the lowest level of background expression. The colony
demonstrating the most efficient expression in this first round is then grown and plated,
and several colonies are selected from this second plate and separately screened in a
second round of selection. The colony demonstrating the most efficient expression in the
second round of selection is then employed in a large scale expression and purification
(165). In this way it is possible to substantially improve protein expression yield and
purification without otherwise altering the protocol.

14.5. Method

Following the work of Sivashanmugam, Murray et al. 2009 with minor modifications, a
double colony selection was performed in accordance with their published protocol. A
fresh transformation of the pDEST His-MBP-hCycT1-Tat plasmid into Rosetta Gami B
(Novagen) was performed (Appendix 18). Four colonies were selected from the
transformation plate and grown overnight to an OD600 of approximately 2-3 in 2 ml of LB
media with 100 ug/ml of ampicillin and 35 ug/ml of chloramphenicol at 37 °C. The
culture was then spun down, the cell pellet was resuspended in 5 ml of M9 minimal
media (Appendix 19) with 100 µg/ml of ampicillin and 35 µg/ml of chloramphenicol to
an OD600 = 0.1, and the culture was grown to OD600 = 1.0 at 28 °C. Then the culture was
induced with a final concentration of 1 mM IPTG, and grown overnight at 28 °C.
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14.6. Results: Protein Expression in Minimal Media

Predictably, protein expression in minimal media was reduced when compared with
expression levels in rich media. Despite the lower overall expression however, the third
colony from the first round of selection demonstrated the highest level of expression from
among the four colonies selected (Figure 15-1 lane 3). A 2 ml culture of LB with 100
ug/ml ampicillin and 35 µg/ml of chloramphenicol was then inoculated with colony three
and grown overnight. An aliquot of 100 µl of the overnight culture was plated on LB with
100 µg/ml of ampicillin and 35 µg/ml of chloramphenicol, and four colonies were
selected from the plate after overnight incubation at 37 °C. The expression protocol was
repeated as for the first round of selection above and the expression levels of all colonies
are compared in Figure 15-1. After two rounds of selection the fourth colony (Figure 151 lane 8 - DCS 3.4) from the second round demonstrated the highest level expression of
the target and the lowest level of background expression of all other cellular proteins. A
low level of background expression is desirable when attempting to achieve a high degree
of purity after chromatography. Hence, colony 3.4 was selected for 15N labeled protein
expression.

To assess the effects of IPTG concentration on protein expression a comparison was
made of the effects of increasing concentrations of IPTG from 0.2 mM to 1.0 mM on
both the original glycerol stock Rosetta Gami B strain (RGB), and the DCS 3.4 freshly
transformed high expression mutant. The culture was incubated for 49 hours at 37°C and
reached an OD600 of 0.5 for RGB, and 0.3 for DCS. At 20 minutes prior to induction 1%
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ethanol was added to the minimal media with 100 µg/ml ampicillin and 35 µg/ml of
chloramphenicol and the culture was grown for 42 hours at 28°C.

Comparing the original glycerol stocks of the pDEST HisMBP-hCycT1-Tat plasmid in
Rosetta Gami B to the DCS 3.4 mutant the increased expression of the recombinant
protein by the DCS 3.4 mutant is clear (Figure 15-2). For both the original transformed
colony and the DCS 3.4 1.0 mM IPTG produced the highest level of recombinant protein
production (Figure 15-2 lane 8 and lane 15) when compared to IPTG concentrations of
0.2 mM, 0.4 mM, 0.6 mM, and 0.8 mM. Notably, the DCS mutant produced considerably
more protein despite a lower OD600 at induction.

Increasing the concentration of IPTG above 1.0 mM did not appear to further enhance
recombinant protein expression (Figure 15-3), nor did decreasing the temperature postinduction to 14°C improve yield. In fact, at 14°C the recombinant protein expression was
decreased markedly. While decreasing the post-induction incubation temperature does
tend enhance protein solubility, purportedly by allowing increased time to fold, in this
case the detrimental effects of the lower growth rate at 14°C eclipsed any gain in yield of
the soluble form.

Attempts to improve the expression level of the recombinant protein further by
transferring high cell density starter cultures from rich media to minimal media prior to
induction were also unsuccessful, despite careful attention to the maintenance of a neutral
pH. The cultures required an extraordinarily lengthy incubation to reach an adequate
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OD600 for induction yet increasing the incubation time after induction from 42 hours to 88
hours actually appeared to reduce the level of expressed protein rather than enhance it
both at 28°C and at 14°C (Figure 15-4). This observation is likely due to degradation, and
the buildup of toxic waste by-products that accumulated during the lengthy incubation.

14.7. Protein Expression in BioExpress Cell Growth Media

Since most of the more commonly employed techniques for improving recombinant
protein expression levels in minimal media had been exhausted it became apparent that a
nutrient deficiency could possibly be causing the low level of expression observed for the
recombinant chimera in minimal media. Researchers have observed that some proteins
are particularly “stubborn” or do not express well in minimal media (University of
Connecticut Health Center). In these cases The Gregory P. Mullen NMR Structural
Biology Facility at the University of Connecticut Health Center has succeeded at
increasing recombinant expression levels of 15N labeled protein with the use of
BioExpress cell growth media (Cambridge Isotope Laboratories, Inc. Andover, MA).
However, the downside to the use of BioExpress cell growth media is the high cost of
this media when compared to traditional formulas. Some researchers have circumvented
this drawback, and found that at little as 10% BioExpress formula in the cell growth
media can substantially improve the expression of labeled protein for difficult targets
(167).
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Trials with 100% BioExpress cell growth media were conducted by inoculating a 25 ml
culture of BioExpress cell growth media with lightly spun down cells from 2 ml of an
overnight culture of either freshly transformed RGB cells or the DCS mutant in LB with
100 ug/ml ampicillin and 35 ug/ml of chloramphenicol. After 4 ½ hours of growth the
cultures were induced at OD600 ~0.7 with 1 mM IPTG. Samples of the post-induction
culture were taken after 4 hours and after 18 hours. The target protein expression levels
of samples of the DCS mutant in BioExpress cell growth media were compared to the
target protein expression levels of the RGB strain in LB, Turbo, and BioExpress cell
growth media (Figure 15-5).

The expression levels of the 15N labeled chimera in the DCS mutant (Figure 15-5 lanes
12 and 13) were comparable to the expression levels of unlabeled protein expressed by
the RGB strain in rich media (Figure 15-5 lanes 3,4, 6,7,9 and 10). Of note is the clear
decrease in target protein expression level observed for the DCS mutant in BioExpress
cell growth media after the extended post-induction incubation time of 18 hours when
compared to the expression level after 4 hours (Figure 15-5 lane 13). While a similar
decrease in target protein expression level is apparent for the RGB strain in LB after 18
hours when compared to the expression level after 4 hours (Figure 15-5 lanes 3, and 4),
when expressed in Turbo Media™ the expression level was actually increased after 18
hours. For the RGB strain in BioExpress cell growth media the difference in expression
level between the two time intervals is barely detectible (Figure 15-5 lanes 9 and10).
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Based on these results, and the yield of the cleaved recombinant protein achieved for
unlabeled cultures, it is reasonable to assume that the 2 mg/ml 15N labeled sample
concentration required for NMR HSQC would be obtainable by expressing a 1 or 2 liter
culture of the DCS mutant in BioExpress cell growth media for approximately 4 or
slightly more hours. While typically protein samples might be concentrated for NMR
structural study by such methods as the use of concentrating spin columns, CycT1m-Tat
did not concentrate well by this method and often appeared to either precipitate or bind to
the column material. This loss of protein was evidenced by a concentration which
reduced both counter intuitively and unpredictably after multiple rounds of attempted
concentration. The decrease in concentration was measured by UV detector at 280 nM
with a NanoDrop spectrophotometer (Thermo Scientific Wilmington, DE).
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Figure 14-1 Double colony selection and expression in M9 minimal media
The SDS PAGE comparison of the double colony selection (DCS) and expression in M9
minimal media for the selection of a colony expressing high levels of the full Tat
chimera. The four colonies from the first round of selection appear in s 1-4. The third
colony was selected ( 3) as the highest expressing colony from the first round and then
employed in a second round of selection with colonies from the second round appearing
in s 5-8. From left to right:
Round 1:
1 – colony 1

2 – colony 2

3 – colony 3

4 – colony 4

6 – colony 3.2

7 – colony 3.3

8 – colony 3.4

Round 2:
5 – colony 3.1
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Figure 14-2 Minimal media expression comparison
The SDS PAGE comparison of minimal media expression of the full Tat chimera in the
wild type and double colony selection (DCS) mutant (3.4) with variable IPTG
concentrations after 42 hours of post-induction growth at 28°C. From left to right:
1 – ladder,

2 – uninduced wild type (wt),

3 – induced wt

0 mM IPTG

4 – induced wt

0.2 mM IPTG

5 – induced wt

0.4 mM IPTG

6 – induced wt

0.6 mM IPTG

7 – induced wt

0.8 mM IPTG

8 – induced wt

1.0 mM IPTG

9 – uninduced DCS colony 3.4

10 – induced DCS 3.4

0 mM IPTG

11 – induced DCS 3.4

0.2 mM IPTG

12 - induced DCS

0.4 mM IPTG

13 - induced DCS 3.4

0.6 mM IPTG

14 - induced DCS 3.4

0.8 mM IPTG

15 – induced DCS 3.4

1.0 mM IPTG
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Figure 14-3 An IPTG and temperature comparison for the DCS (42 hours)
An SDS PAGE IPTG induction concentration and post-induction temperature
comparison for the double colony selection (DCS) mutant expression of the full Tat
chimera in minimal media with increasing concentration of IPTG 1.0-5.0 mM at both
28°C and 14°C for 42 hours post-induction. From left to right:
1 – ladder

2 – uninduced

3 – 1.0 mM IPTG 28°C,

4 - 2.0 mM IPTG 28°C

5 – 3.0 mM IPTG 28°C

6 - 4.0 mM IPTG 28°C,

7 – 5.0 mM IPTG 28°C

8 – 1.0 mM IPTG 14°C

9 – 2.0 mM IPTG 14°C,

10 - 3.0 mM IPTG 14°C

11 - 4.0 mM IPTG 14°C

12 - 5.0 mM IPTG 14°C
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Figure 14-4 An IPTG and temperature comparison for the DCS (88 hours)
An SDS PAGE IPTG induction concentration and post-induction temperature
comparison for the double colony selection (DCS) mutant expression of the full Tat
chimera in minimal media with increasing concentration of IPTG 1.0-5.0 mM at both
28°C and 14°C for 88 hours post-induction. From left to right:
1 – ladder

2 – uninduced

3 – 1.0 mM IPTG 28°C,

4 - 2.0 mM IPTG 28°C

5 – 3.0 mM IPTG 28°C

6 - 4.0 mM IPTG 28°C,

7 – 5.0 mM IPTG 28°C

8 – 1.0 mM IPTG 14°C

9 – 2.0 mM IPTG 14°C,

10 - 3.0 mM IPTG 14°C

11 - 4.0 mM IPTG 14°C

12 - 5.0 mM IPTG 14°C
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Figure 14-5 Media comparison for expression of the full Tat chimera
The SDS PAGE media comparison of protein expression of the full Tat chimera from
Rosetta Gami B (RGB) wild type and double colony selection mutant (DCS) in LB media, Turbo
Media™, and BioExpress media. All cultures were induced at OD600 = 0.7 with 1 mM IPTG and
expressed for 4 hours at 28°C. From left to right:
1 – ladder

2 – uninduced RGB in LB

3 – induced RGB in LB, 4 hrs

4 - induced RGB in LB, 18 hrs

5 – uninduced RGB in Turbo Media

6 – induced RGB in Turbo Media, 4 hrs

7 – induced RGB in Turbo Media, 18 hrs

8 – uninduced RGB in BioExpress

9 – induced RGB in BioExpress, 4 hrs

10 - induced RGB in BioExpress, 18 hrs

11 – uninduced DCS in BioExpress

12 – induced DCS in BioExpress, 4 hrs

13 – induced DCS in BioExpress, 18 hrs
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Chapter 15 Conclusions and Suggestions for Further Work
The expression and purification of CycT1m-Tat, at a concentration sufficient for
structural study, proved to be considerably more challenging than was initially
anticipated. The sheer number of options available for modification of expression and
purification protocols requires researchers not working with high throughput screening
methods to make a series of educated guesses in order to achieve reasonable results in an
efficient manner. While such “best guess” conditions may prove to be sufficient to
produce adequate protein concentration and purity for a particular downstream
application it is unlikely that these will be the optimal conditions for the chosen target. If
a substantial quantity of the chimera is to be produced frequently the expression and
purification protocols presented in this work should continue to be tested and optimized
to the greatest extent necessary for the intended application.

In addition to optimizing expression and purification, the activity of the 257-280
hCycT1-Tat chimera must be assessed. The high affinity binding observed between the
re-engineered chimera and TAR is promising, especially with respect to is application
toward the production of a diagnostic tool for drug discovery. However, assessing the
ability of this chimera to produce transactivation is essential. Moreover, future mutation
and deletion experiments modifying key residues of the zinc fingers as well as
modifications to arginine residues suspected of playing important stabilizing roles should
lend much to our understanding of the key features necessary for recognition, binding,
and transactivation
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In this section suggestions will be made for: future improvement to the expression and
purification of the chimera, activity assays, confirming the zinc content of the chimera,
confirming the folded state of the chimera, mutation and deletion experiments, and for
the future structure elucidation of the Cyclin T1-Tat-TAR interaction by NMR

15.1. Alternative Expression Strains

An educated guess was made when selecting the expression strain Rosetta Gami B for the
recombinant production of the MBP-His6-CycT1m-Tat chimera. The hope initially was
not only that the rare codons would be accommodated by Rosetta Gami B but that target
solubility might be enhanced by the “tunable” feature of the strain which permits the
modulation of expression levels with induction by IPTG. Since no increase in expression
level was observed when the concentration of IPTG was varied this feature appears
unnecessary for expression of the MBP-His6-CycT1m-Tat chimera.

An additional feature of the Rosetta Gami B expression strain is the formation of
disulfide bonds in the cytoplasm as opposed to in the periplasm of the cell. It is possible
that the folding of the target protein might in some way be improved by this feature, but
no information could be found on the effect of this feature on zinc finger proteins. It is
also conceivable, however, that this feature could have no effect or could even hinder the
expression of zinc finger proteins which are sensitive to the redox state of the cell (168).
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The choice of this strain imposed limitations on the expression of the Tat chimera in that
it is not possible to use the Rosetta Gami B strain with an auto-induction media. A
comparison could be made between expression and purification in the Rosetta Gami B
strain and the Rosetta strain without the “Tuner” lacZY mutation. If a similar yield is
obtained expression in auto-induction media may improve yield and facilitate expression
by optimizing the induction. Furthermore, it is possible that other strains not considered
here may prove superior to the Rosetta strains in the expression of the Tat chimera. If
large scale expression of the Tat chimera is undertaken it would be worthwhile to
evaluate the performance of several other strains. Ideally, such an evaluation would be
done in a high-throughput manner.

15.2. Alternate Solubility Enhancing Fusion Tags

The MBP fusion tag is highly effective at enhancing the solubility of many recombinant
proteins. However, from the perspective of structural study, MBP is large (43 kDa) and
likely to interfere with many downstream applications; thus its removal is generally
required. As has been demonstrated previously in this work, removal of the tag can be
time consuming and difficult and will inevitably result in a decrease in the final yield. In
addition, removing the fusion tag from less tractable targets frequently and predictably
renders the target insoluble once again. For these reasons it might be advantageous to
explore other smaller but similarly effective fusion tags such as Small Ubiquitin-like
Modifier (SUMO) (12 kDa) which is available with a His6 modification for affinity
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purification. With a fusion tag of this size it may be possible to obtain Tat chimera
structural data by NMR while circumventing removal of the fusion tag entirely.

15.3. Optimizing Reduction of the Tat Chimera

Reducing agents used in the expression of the Tat chimera have been discussed at length
previously. However, in the literature reviewed there was a conspicuous absence of
discussion on the determination of the optimal concentration of reducing agent employed.
While insufficient reduction may permit aberrant disulfide bond formation, potentially
leading to aggregation and insolubility, conversely it is also possible that the excessive
use of reducing agents may alter the secondary structure of the protein and confound
downstream applications and structural determination. Therefore, it would be worthwhile
to examine the effects of a series of reducing agents and concentrations on the binding
affinity of the Tat chimera for the HIV-1 TAR RNA.

15.4. Confirming the Presence of Zinc

Since the native structure of the Tat chimera is dependent on the presence of the two zinc
atoms complexed in the zinc fingers of the chimera it is necessary to confirm the
presence of zinc in the purified recombinant protein. Several attempts were made to
determine the concentration of zinc in the purified samples by a direct spectrophotometric
method. Since Zn2+ itself is spectroscopically silent 4-(2-pyridylazo)resorcinol
(PAR)resorcinol and iodoacetamide were used to measure the presence of Zn2+ (169). In
this reaction 2-iodoacetamide is used as an alkylating agent to covalently bind to the thiol
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group of the cysteine residues in the two zinc fingers of the Tat chimera and release Zn2+.
Free Zn2+ is then complexed to form Zn(PAR)2 (170-172) and the solution changes color
from yellow to orange. A change in absorbance at 490-500 nm can then be measured
spectroscopically and used to calculate the approximate concentration of zinc complexed
in the zinc fingers of the recombinantly produced Tat chimera (171,172).

Method

First a standard curve was calculated using the absorbance measured at 500 nm of ZnCl2
and PAR added to a solution to form Zn(PAR)2 for a range of ZnCl2 from 10 uM to 100
uM. The response for this range was fairly linear (Figure 16-1). Next, following a
protocol by Pfister et al. 2000, a 48.75 ul sample of 48.6 uM Tat chimera was incubated
with 1.25 ul of Proteinase K (2.0 ug/ul) and incubated for 30 minutes at 56 °C (172).
Subsequently, Iodoacetamide (5 mM) and PAR (0.2 mM) were added to a total volume of
100 ul, and the absorbance of the solution at 500 nM was measured by NanoDrop
spectrophotometer (Thermo Scientific Waltham, MA).

Results

The absorbance of two redundant samples ranged from .063 to .151 placing the estimated
concentration of Zn2+ in the Tat chimera samples at between approximately 13 and 30
uM according to the standard curve (Figure 16-1). Since the final concentration of the Tat
chimera should theoretically have been approximately 24.3 uM, but two atoms of Zn2+
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should be present for each molecule of the chimera the predicted concentration of
Zn(PAR)2 would be 48.6 uM with, according to the standard curve, a predicted
absorbance at 500 nm of approximately 0.280. Allowing for approximately 20%
contamination in the sample the actual absorbance measurements of Zn(PAR)2 still fall
short of the predicted value. This deviation from prediction may be attributable to a
variety of factors including: inaccuracies inherent in the nature of the calculation of
extinction coefficients using NMR data, limitations of the NanoDrop spectrophotometer
equipment (especially for absorbance values close to background levels), and pipetting
error. Furthermore, some of this error may be due to misfolded proteins that are missing
either or both Zn2+ cofactors.

15.5. Inductively Coupled Plasma Mass Spectrometry
The determination of Zn2+ concentration by spectrophotometric means continued to be
problematic after many trials. Hence an alternative method of determining the Zn2+
concentration of the Tat chimera, such as might be accomplished by inductively coupled
plasma mass spectrometry (ICP–MS), is desirable in order to confirm the presence of the
zinc cofactor at the appropriate concentration. A generally quantitative instrument, ICPMS has low detection limits in the parts per thousand range and is used for determining
the concentration of a large group of elements including zinc. Such equipment is readily
available for use by our lab. Assessment of the Zn2+ content of the Tat chimera should be
undertaken regularly in this native recombinant expression and purification protocol, and
may offer valuable insight into the efficacy of any future modifications of same.
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15.6. Activity Assay

In order to assess the activity of the recombinant CycT1m-Tat chimera an activity assay
should be conducted. Such an assay might be similar to that performed by Fujinaga et al.
2002 which measured the levels of transactivation produced by the Tat chimera from the
HIV-1 LTR in NIH 3T3 cells (28). However, this assay requires working with
mammalian cells, and as our laboratory is not currently equipped to handle this work
collaboration with another laboratory may be required.

15.7. Confirming the Native Structure and Assessing Folding

Since the data acquired from biolayer interferometry indicates the presence of a (minor)
fast dissociating species it is reasonable to suspect the presence of some partially or
incorrectly folded proteins. One interesting and high-throughput method that has been
useful in assessing protein folding involves the interaction of the promiscuous and high
affinity chaperonin protein GroEL with a purified target protein in biolayer
interferometry experiments (173-176). Here chaperonin is employed as a “kinetic trap”
which binds promiscuously to hydrophobic regions of partially folded proteins. Due to
the fairly large size of chaperonin (802 kDa) a large BLI signal is observed when the
protein binds preferentially to a partially folded target protein (176). Such an assay might
reasonably be used to determine the degree to which the purified Tat chimera sample may
be present in a non-native confirmation, as well as to identify optimal conditions for
target solubility and correct protein folding.
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15.8. Analytical Ultracentrifugation

In addition to determining the binding affinity of the interaction between the CycT1m-Tat
chimera and TAR RNA, accurate quantitative characterization requires a determination
of the stoichiometry of the unbound recombinant protein as well as the stoichiometry of
the protein-RNA complex. A number of matrix-based and matrix-free techniques are
available for the identification of protein aggregates. Among the matrix-based techniques
SDS-PAGE, and size exclusion chromatography (SEC), and among the matrix-free
sedimentation velocity (SV), dynamic light scattering (DLS), and field flow fractionation
(FFF) are most common (177).

Analytical ultracentrifugation (AUC) is one of the most efficacious techniques currently
available for the quantitative characterization of macromolecular associations in solution
(178). The Beckman Coulter ProteomLab XL-A AUC, in the laboratory of Dr. Michael
Cosgrove at Upstate Medical University, is equipped with absorbance optics and
calculates the sedimentation velocity of macromolecules in solution by measuring the
absorbance of monochromatic light passed through a sample cell during high speed
centrifugation (177). Sedimentation velocity data provides information about size
distribution that can be extracting using SEDFIT computer software developed by Peter
Schuck (177,179). The SEDFIT software utilizes Lamm equation solutions to describe
the sedimentation data and from these data oligomeric state can reasonably be determined
(177,179).
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The use of the AUC has generously been extended to us by the Cosgrove lab for our
work on the CycT1m-Tat chimera. A gel filtration polishing step will be added to the
purification protocol to remove residual contaminants that might confound the data from
this sensitive technique. In addition to confirming the monomeric state of the
recombinant chimera, this assay may also yield data about the affinity of the interaction
between CycT1m-Tat and TAR RNA.

15.9. Structural Study

The ultimate goal of this work is to produce a sample of Tat chimera protein of sufficient
concentration and purity to obtain structural NMR data. The yield and purity obtained
from the small scale minimal media experiments indicated that, theoretically, a large
scale expression and purification of the Tat chimera protocol herein should yield
adequate protein for structural work. A few additional trials with fresh solutions, and
perhaps different formulae, of trace minerals and with minimal solutions of BioExpress
media would be helpful toward optimizing the protocol and minimizing expenditures.

15.10. Mutation and Deletion Experiments

Toward improving our understanding of the essential features of the hCycT1-Tat
interaction mutation and deletion experiments substituting or removing key residues are
likely to yield valuable insight into the nature of interaction with TAR. Specifically,
mutation or deletion of residues of the two zinc fingers, mutation and deletion of R251
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and R254 (which have been mentioned as possible stabilizers of this interaction (26)),
and mutation or deletion of key arginine residues in the arginine-rich region of Tat could
offer this much needed structural insight. By minimizing the interaction between the
chimera and TAR to that afforded solely by the two zinc fingers the impact of the zinc
fingers contribution to binding and transactivation can be more clearly demonstrated.

15.11. HIV-1 Drug Discovery

Having produced a high affinity Tat chimera containing the appropriate zinc cofactors,
and after confirming the appropriate biological activity, the production of a Tat-TAR
indicator (Figure 2-1) can then commence. Many small molecule inhibitors with potential
for the treatement of HIV-1 can be simultaneously screened for efficacy by means of
high-throughput methods that detect the compounds ability to disrupt the interaction
between the Tat chimera and the HIV-1 TAR RNA. The Tat chimera recombinantly
produced here offers the great advantage of a secondary structure more closely
resembling the in vivo structure encountered in the disease process where such mimicry is
otherwise prevented by the dissordered nature of the Tat protein independent of the
essential portion of hCycT1.
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Figure 15-1 Standard curve for the formation of Zn(PAR)2 measured at 500 nm.

A standard curve was calculated by measuring the absorbance at 500 nm of ZnCl2 and
PAR added to a solution to form Zn(PAR)2 for a range of ZnCl2 from 10 uM to 100 uM.
The response measured by a Nanodrop spectrophotometer for this range was reasonably
linear.
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Appendix 1 - Full length GST-hCycT1-Tat Chimera Sequence Details

MEGAVLDIRY
LYDALDVVLY
HPPKSDLVPR
EFLEIDPVDM
RRQRRRAPQD

GVSRIAYSKD
MDPMCLDAFP
GSPNRLKRIW
EPVDPNLEPW
SQTHQASLSK

FETLKVDFLS
KLVCFKKRIE
NWRACEAAKK
KHPGSQPRTA
QPASQSRGDP

KLPEMLKMFE
AIPQIDKYLK
TKADDRGTDE
CNNCYCKKCC
TGPTESKKKV

DRLCHKTYLN
SSKYIAWPLQ
KTSEQTMPEQ
FHCYACFTRK
ERETETDPFD

GDHVTHPDFM
GWQATFGGGD
KLISEEDLAM
GLGISYGRKK
L

60
120
180
240
291

Isotopically Averaged Molecular Weight = 33491.1992

Estimated pI = 8.10
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the
isolated residues. For a folded protein this is not valid. However, this rough value can be
useful for planning protein purifications. pKa values for the individual amino acids from
Stryer Biochemistry, 3rd edition.

Estimated charge at pH 7.00 = 5.3
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the
isolated residues. For a folded protein this is not valid. However, this rough value can be
useful for planning protein purifications. pKa values for the individual amino acids from
Stryer Biochemistry, 3rd edition.
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Estimated charge over pH range
pH Charge
4.00

41.8

4.50

30.0

5.00

19.4

5.50

13.5

6.00

10.3

6.50

7.7

7.00

5.3

7.50

3.3

8.00

0.7

8.50

-3.4

9.00

-8.7

9.50

-16.2

10.00 -26.8

WARNING: pI estimate assumes all residues have pKa values that are equivalent to the
isolated residues. For a folded protein this is not valid. However, this rough value can be
useful for planning protein purifications. pKa values for the individual amino acids from
Stryer Biochemistry, 3rd edition.

PROTEIN CALCULATOR v3.3
Chris Putnam
cdputnam@scripps.edu
The Scripps Research Institute
Last Updated: March 28, 2006
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Appendix 2 - Full length MBP-hCycT1-Tat Chimera Sequence Details

MKIKTGARIL
VTVEHPDKLE
DAVRYNGKLI
YFTWPLIAAD
AAFNKGETAM
LAKEFLENYL
QMSAFWYAVR
SEQTMPEQKL
CYACFTRKGL
ETETDPFDLS

ALSALTTMMF
EKFPQVAATG
AYPIAVEALS
GGYAFKYENG
TINGPWAWSN
LTDEGLEAVN
TAVINAASGR
ISEEDLAMEF
GISYGRKKRR

SASALAKIEE
DGPDIIFWAH
LIYNKDLLPN
KYDIKDVGVD
IDTSKVNYGV
KDKPLGAVAL
QTVDEALKDA
LEIDPVDMEP
QRRRAPQDSQ

GKLVIWINGD
DRFGGYAQSG
PPKTWEEIPA
NAGAKAGLTF
TVLPTFKGQP
KSYEEELAKD
QTRITKGANW
VDPNLEPWKH
THQASLSKQP

KGYNGLAEVG
LLAEITPDKA
LDKELKAKGK
LVDLIKNKHM
SKPFVGVLSA
PRIAATMENA
RACEAAKKTK
PGSQPRTACN
ASQSRGDPTG

KKFEKDTGIK
FQDKLYPFTW
SALMFNLQEP
NADTDYSIAE
GINAASPNKE
QKGEIMPNIP
ADDRGTDEKT
NCYCKKCCFH
PTESKKKVER

Isotopically Averaged Molecular Weight = 60850.9727

Estimated pI = 6.60
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the
isolated residues. For a folded protein this is not valid. However, this rough value can be
useful for planning protein purifications. pKa values for the individual amino acids from
Stryer Biochemistry, 3rd edition.

Estimated charge at pH 7.00 = -1.8
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the
isolated residues. For a folded protein this is not valid. However, this rough value can be
useful for planning protein purifications. pKa values for the individual amino acids from
Stryer Biochemistry, 3rd edition.
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Estimated charge over pH range
pH Charge
4.00

57.5

4.50

36.6

5.00

18.1

5.50

8.0

6.00

3.4

6.50

0.5

7.00

-1.8

7.50

-3.6

8.00

-5.9

8.50

-9.9

9.00

-16.5

9.50

-28.6

10.00 -47.9

WARNING: pI estimate assumes all residues have pKa values that are equivalent to the
isolated residues. For a folded protein this is not valid. However, this rough value can be
useful for planning protein purifications. pKa values for the individual amino acids from
Stryer Biochemistry, 3rd edition.

PROTEIN CALCULATOR v3.3
Chris Putnam
cdputnam@scripps.edu
The Scripps Research Institute
Last Updated: March 28, 2006
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Appendix 3 - Cleaved hCycT1-Tat Chimera Sequence Details

GANWRACEAA KKTKADDRGT DEKTSEQTMP EQKLISEEDL AMEFLEIDPV DMEPVDPNLE
PWKHPGSQPR TACNNCYCKK CCFHCYACFT RKGLGISYGR KKRRQRRRAP QDSQTHQASL
SKQPASQSRG DPTGPTESKK KVERETETDP FDLS

60
120
154

Isotopically Averaged Molecular Weight = 17481.4746

Estimated pI = 7.89
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the
isolated residues. For a folded protein this is not valid. However, this rough value can be
useful for planning protein purifications. pKa values for the individual amino acids from
Stryer Biochemistry, 3rd edition.

Estimated charge at pH 7.00 = 2.4
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the
isolated residues. For a folded protein this is not valid. However, this rough value can be
useful for planning protein purifications. pKa values for the individual amino acids from
Stryer Biochemistry, 3rd edition.

- 226 -

Estimated charge over pH range
pH Charge
4.00

23.0

4.50

16.1

5.00

9.9

5.50

6.6

6.00

4.9

6.50

3.6

7.00

2.4

7.50

1.3

8.00

-0.5

8.50

-3.3

9.00

-6.6

9.50

-10.6

10.00 -15.9

WARNING: pI estimate assumes all residues have pKa values that are equivalent to the
isolated residues. For a folded protein this is not valid. However, this rough value can be
useful for planning protein purifications. pKa values for the individual amino acids from
Stryer Biochemistry, 3rd edition.

PROTEIN CALCULATOR v3.3
Chris Putnam
cdputnam@scripps.edu
The Scripps Research Institute
Last Updated: March 28, 2006
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Appendix 4 – Tat Minimal Peptide Sequence Details

RKKRRQRRRP PQG

13

Isotopically Averaged Molecular Weight = 1719.0298

Estimated pI = 12.72

WARNING: pI estimate assumes all residues have pKa values that are equivalent to the
isolated residues. For a folded protein this is not valid. However, this rough value can be
useful for planning protein purifications. pKa values for the individual amino acids from
Stryer Biochemistry, 3rd edition.

Estimated charge at pH 7.00 = 7.9
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the
isolated residues. For a folded protein this is not valid. However, this rough value can be
useful for planning protein purifications. pKa values for the individual amino acids from
Stryer Biochemistry, 3rd edition.
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Estimated charge over pH range
pH Charge
4.00

8.1

4.50

8.0

5.00

8.0

5.50

8.0

6.00

8.0

6.50

8.0

7.00

7.9

7.50

7.8

8.00

7.5

8.50

7.2

9.00

6.9

9.50

6.5

10.00

6.0

WARNING: pI estimate assumes all residues have pKa values that are equivalent to the
isolated residues. For a folded protein this is not valid. However, this rough value can be
useful for planning protein purifications. pKa values for the individual amino acids from
Stryer Biochemistry, 3rd edition.

PROTEIN CALCULATOR v3.3
Chris Putnam
cdputnam@scripps.edu
The Scripps Research Institute
Last Updated: March 28, 2006
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Appendix 5 - MBP (Maltose Binding Protein) Sequence

MKIKTGARIL
VTVEHPDKLE
DAVRYNGKLI
YFTWPLIAAD
AAFNKGETAM
LAKEFLENYL
QMSAFWYAVR

ALSALTTMMF
EKFPQVAATG
AYPIAVEALS
GGYAFKYENG
TINGPWAWSN
LTDEGLEAVN
TAVINAASGR

SASALAKIEE
DGPDIIFWAH
LIYNKDLLPN
KYDIKDVGVD
IDTSKVNYGV
KDKPLGAVAL
QTVDEALKDA

GKLVIWINGD
DRFGGYAQSG
PPKTWEEIPA
NAGAKAGLTF
TVLPTFKGQP
KSYEEELAKD
QTRITK

KGYNGLAEVG
LLAEITPDKA
LDKELKAKGK
LVDLIKNKHM
SKPFVGVLSA
PRIAATMENA

KKFEKDTGIK
FQDKLYPFTW
SALMFNLQEP
NADTDYSIAE
GINAASPNKE
QKGEIMPNIP

Isotopically Averaged Molecular Weight = 43387.5195

Estimated pI = 5.71
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the
isolated residues. For a folded protein this is not valid. However, this rough value can be
useful for planning protein purifications. pKa values for the individual amino acids from
Stryer Biochemistry, 3rd edition.

Estimated charge at pH 7.00 = -4.3
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the
isolated residues. For a folded protein this is not valid. However, this rough value can be
useful for planning protein purifications. pKa values for the individual amino acids from
Stryer Biochemistry, 3rd edition.
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Estimated charge over pH range
pH Charge
4.00

34.6

4.50

20.6

5.00

8.2

5.50

1.5

6.00

-1.5

6.50

-3.1

7.00

-4.3

7.50

-5.1

8.00

-5.9

8.50

-7.4

9.00

-10.8

9.50

-19.0

10.00 -33.1

WARNING: pI estimate assumes all residues have pKa values that are equivalent to the
isolated residues. For a folded protein this is not valid. However, this rough value can be
useful for planning protein purifications. pKa values for the individual amino acids from
Stryer Biochemistry, 3rd edition.

PROTEIN CALCULATOR v3.3
Chris Putnam
cdputnam@scripps.edu
The Scripps Research Institute
Last Updated: March 28, 2006
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Appendix 6 - hCycT1-Tat Site-Directed Mutagenesis Protocol

1. Get template (plasmid with hCycT1-Tat from isolated from XL1)
Start 5 ml LB/Amp liquid culture of XL1-Blue cells containing the plasmids
Do plasmid miniprep using QIAprep Spin Miniprep kit. Elute plasmid with 50ul of H2O.
A 16-hr 5-ml XL1-Blue culture typically gives a plasmid yield of 7.5ug (~150ng/ul).
2. Site-directed mutagenesis (Day 1)
Material:




Stratagene QuikChangeII Site-Directed Mutagenesis Kit (Stored @ -20°C)
Template: dilute to 10ng/μl
Primers: dilute to 10μM (100~150ng/μl)

Primer design: Use QuikChange Primer Design Tool:
https://www.genomics.agilent.com/CollectionSubpage.aspx?PageType=Tool&SubPageT
ype=ToolQCPD&PageID=15
PCR Mix:

PCR Cycle:

5 μl of 10× reaction buffer

1) 95°C 30s

10 μl of dsDNA template (1 ng/ul)

2) 95°C 30s

1.25 μl of forward primer (100 ng/ul)

3) 55°C 1min

1.25 μl of reverse primer (100 ng/ul)

4) 68°C 5 min

1.0 μl of 10mM dNTP mix

5) go to 2) for a total of 18 cycles

1.0 μl of PfuUltra polymerase (2.5 U/μl)

6) hold at 4°C

30.5 μl of nuclease free H2O
final volume: 50 μl
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Note: Make a negative control with no template (add 0.5 μl of nuclease free H2O instead
of template).
3. DpnI digestion (Day 1)
Add DpnI 1.0 μl into each PCR reaction
Incubate @ 37°C for 1hr
4. Check product size on agarose gel (Day 1)
1% gel, 160V, 40min.
Use 5 μl of each sample/control per well, 2.5 μl of 1kb DNA ladder (Promega
Cat# G5711).
Note: Do not proceed to next step until you see successful amplification (single band of
size ~ 5kb).
5. Transform into XL-1 Blue Competent Cells (Day 1)
Material:





XL-1 Blue competent cells(Stratagene), stored @ -80°C
Digested PCR mix
LB+0.4% glucose
LB/AMP plates

Procedure:
1) Estimate concentration of PCR product based on the agarose gel. (UV absorption
won’t be accurate because of dNTPs and free primers.) If you loaded 2.5 μl of 1kb
DNA ladder onto your gel earlier, the four brighter bands are 30ng each, other
bands are 10ng each. Compare your sample band to the ladder and make your best
guess.
2) Use ~5ng of DNA (DNA volume should not exceed 10% of reaction volume, in
this case, 2μl) for each transformation. Add the DNA into a 200μl PCR tube, let it

chill on ice. Use 1 μl of pUC18 control DNA (0.1ng/μl, included in the kit) as
positive control. 1 μl of nuclease free H2O as negative control.
3) Thaw a tube of XL-1 Blue competent cells on ice. Add 20 μl of competent cells
into each tube. If you have competent cells left, make 20 μl aliquots of them and
freeze them on dry ice immediately. These aliquots should be good to use for next
time, but their transformation efficiency will be lower.
4) Incubate the mixture on ice for 30min. In the meantime, warm up a tube of
LB+0.4% glucose @ 42°C.
5) Put the tubes into a thermal cycler. Heat shock @ 42°C for 45s.
6) Immediately put tubes back on ice, incubate for 2min.
7) Add 100 μl of pre-warmed LB+0.4% glucose (42°C), gently mix.
8) Pool the tubes in a falcon tube, shake @ 250rpm in a 37°C incubator for 1hr. Warm
up a few LB/AMP plates during this time.
9) Spread 50 μl of the recovered cells onto each LB/AMP plate. Grow @ 37°C
overnight.
6. Pick single colony from plate (Day 2)
Pick single colony from plate, inoculate a 5ml LB/AMP liquid culture, grow @ 37°C
overnight, shaking @ 220~250rpm.
7. Make glycerol frozen stock and Miniprep (Day 3)
Make permanent glycerol storage culture by adding 350 μl of overnight LB/AMP culture
into 150 μl of 50% glycerol (final glycerol concentration 15%). Freeze immediately on dry
ice. Store @ -80°C.
Do plasmid miniprep using QIAprep Spin Miniprep kit. Elute plasmid with 50ul of H2O.
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Measure UV using Nanodrop, calculate concentration.
Take 200~800ng of each plasmid miniprep as sequencing sample. Store the rest @ -20°C
or -80°C.
8. Sanger Sequencing
Sequencing facility at Upstate Medical University. University Hospital Room 4840
Contact: Vicki Lyle lylev@upstate.edu
Sequencing primers for pGEX-2TK plasmid)
Sample dropped off every day by 11AM will be sequenced on the same day. Results usually
get sent via email the second day.
9. Check sequence for mutation (Day 4)
Use BLAST or ClustalW to check mutated sequence against wildtype.
BLAST: http://blast.ncbi.nlm.nih.gov/ (use bl2seq)
ClustalW: http://www.ebi.ac.uk/Tools/clustalw2/index.html
Note: Do not proceed to next step until you confirm the plasmid has the right mutation
and nothing else.
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Appendix 7 - Invitrogen Protocol for Gateway® Reactions


BP Reaction
Creating a Gateway® entry clone from an attB-flanked PCR product is an easy 1
hour reaction. See below for an overview of the set-up. For more detailed
information, refer to the manual.
1. Add the following components to a 1.5 ml tube at room temperature and
mix:
attB-PCR product (=10 ng/µl; final amount ~15-150 ng) 1-7 µl
Donor vector (150 ng/µl) 1 µl
TE buffer, pH 8.0 to 8 µl
2. Thaw on ice the BP Clonase™ II enzyme mix for about 2 minutes. Vortex
the BP Clonase™ II enzyme mix briefly twice (2 seconds each time).
3. To each sample (Step 1, above), add 2 µl of BP Clonase™ II enzyme mix
to the reaction and mix well by vortexing briefly twice. Microcentrifuge
briefly.
4. Return BP Clonase™ II enzyme mix to -20°C or -80°C storage.
5. Incubate reactions at 25°C for 1 hour.
6. Add 1 µl of the Proteinase K solution to each sample to terminate the
reaction. Vortex briefly. Incubate samples at 37°C for 10 minutes.

- 236 -

Transformation

7. Transform 1 µl of each BP reaction into 50 µl of One Shot ® OmniMAX
™ 2 T1 Phage-Resistant Cells (Catalog no. C8540-03). Incubate on ice for
30 minutes. Heat-shock cells by incubating at 42°C for 30 seconds. Add
250 µl of S.O.C. Medium and incubate at 37°C for 1 hour with shaking.
Plate 20 µl and 100 µl of each transformation onto selective plates. Note:
Any competent cells with a transformation efficiency of >1.0 × 10 8
transformants/µg may be used.
8. Transform 1 µl of pUC19 DNA (10 ng/ml) into 50 µl of One Shot ®
OmniMAX ™ 2 T1 Phage-Resistant Cells as described above. Plate 20 µl
and 100 µl on LB plates containing 100 µg/ml kanamycin, or the
appropriate selection marker for your donor vector.

Expected Results
An efficient BP recombination reaction will produce >1500 colonies if the entire
BP reaction is transformed and plated.



LR Reaction
Transferring your gene from a Gateway® entry clone to destination vector is an
easy 1 hour reaction. See below for an overview of the set-up. For more detailed
information, refer to the manual.
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1. Add the following components to a 1.5 ml tube at room temperature and
mix:
Entry clone (50-150 ng) 1-7 µl
Destination vector (150 ng/µl) 1 µl
TE buffer, pH 8.0 to 8 µl
2. Thaw on ice the LR Clonase ™ II enzyme mix for about 2 minutes.
Vortex the LR Clonase ™ II enzyme mix briefly twice (2 seconds each
time).
3. To each sample (Step 1, above), add 2 µl of LR Clonase ™II enzyme mix
to the reaction and mix well by vortexing briefly twice. Microcentrifuge
briefly.
4. Return LR Clonase ™ II enzyme mix to -20°C or -80°C storage.
5. Incubate reactions at 25°C for 1 hour.
6. Add 1 µl of the Proteinase K solution to each sample to terminate the
reaction. Vortex briefly. Incubate samples at 37°C for 10 minutes.

Transformation
Follow the protocol as indicated for the BP reaction, except use the appropriate
selection marker for the LB plates suited to your destination vector (typically 100
µg/ml ampicillin).
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Expected Results
An efficient LR recombination reaction will produce >5000 colonies if the entire
LR reaction is transformed and plated.

One Tube Format
If you want to transfer your attB-flanked PCR product directly into an expression clone,
you can easily combine the BP and LR reactions using the following protocol. This will
potentially eliminate the transformation and DNA isolation of the Gateway® entry clone.

1. In a 1.5 ml microcentrifuge tube, prepare the following 15 µl BP reaction:
attB DNA (50-100 ng) 1.0-5.0 µl
attP DNA (pDONR™ vector, 150 ng/µl) 1.3 µl
BP Clonase™ II enzyme mix 3.0 µl
TE Buffer, pH 8.0 add to a final volume of 15 µl
2. Mix well by vortexing briefly and incubate at 25°C for 4 hours.
Note: Depending on your needs, the length of the recombination reaction can be
extended up to 20 hours. An overnight incubation typically yields 5 times more
colonies than a 1 hour incubation. Longer incubation times are recommended for
large plasmids (=10 kb) and PCR products (=5 kb).
3. Remove 5 µl of the reaction to a separate tube and use this aliquot to assess the
efficiency of the BP reaction (see below).
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4. To the remaining 10 µl reaction, add:
Destination vector (150 ng/µl) 2.0 µl
LR Clonase™ II enzyme mix 3.0 µl
Final volume 15 µl
5. Mix well by vortexing briefly and incubate at 25°C for 2 hours.
Note: Depending on your needs, the length of the recombination reaction can be
extended up to 18 hours.
6. Add 2 µl of proteinase K solution. Incubate at 37°C for 10 minutes.
7. Transform 50 µl of the appropriate competent E. coli with 1 µl of the reaction.
8. Plate on LB plates containing the appropriate antibiotic to select for expression
clones.

Assessing the Efficiency of the BP Reaction
1. To the 5µl aliquot obtained from “One-Tube” Protocol, Step 3, above, add 0.5 µl
of proteinase K solution. Incubate at 37°C for 10 minutes.
2. Transform 50 µl of the appropriate competent E. coli with 1 µl of the reaction.
Plate on LB plates containing the appropriate antibiotic to select for entry clones.
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Appendix 8 - pRK793 Plasmid Map for TEV Protease S219V Mutant

Map of the pRK793 plasmid for recombinant expression of the Tobacco Etch Virus
(TEV) protease S219V mutant, Addgene #8827, deposited by Principal Investigator
David Waugh, National Cancer Institute, Frederick, MD.
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Appendix 9 - M9 Minimal Media Recipe
M9 Minimal Media 1L
Na2HPO4·7H2O

12.8g

Or
Na2HPO4 (anhydrous)

6g

KH2PO4

3g

NaCl

0.5 g

NH4Cl

1g

Carbon Source

0.2% (v/v)

(glucose, sodium gluconate, or glycerol)
Adjust pH to 7.4 with NaOH
Autoclave prior to adding sterile micronutrients:
Stock [C]

Micronutrient

[C] Final

1M

MgSO4

1 mM

1M

CaCl2

100 M

3 mM

(NH4)6Mo7O24·4H2O

3x10-9 M

400 mM

H3BO3

4x10-7 M

30 mM

CoCl2 ·6H2O

3x10-8 M

10 mM

CuSO4 ·5H2O

1x10-8 M

80 mM

MnCl2 ·4H2O

8x10-8 M

10 mM

ZnSO4 ·7H2O

1x10-8 M

5 mM

FeSO4 ·7H2O§

1x10-6 M

Filter sterilize all micronutrients. Make FeSO4 fresh immediately prior to use
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Appendix 10 - Protocol for Expression of the GST Tat Chimera K. Fujinaga.
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Bio
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Appendix 11 - Tat Chimera Expression Protocol
HISMBP-TEV hCycT1/Tat Chimera in Rosetta Gami B Cells
non-DE3 non-p(lysS) strain
TRIS Buffer

1. Inoculate a 250 ml starter culture of LB media with RGB Mut 5 with 100 ug/ml
ampicillin and 35 ug/ml chloramphenicol and grow overnight at 37°C
2. Autoclave 1 L baffle bottom flasks of Turbo media
3. Inoculate 150 ml of overnight culture into 1 L flask of Turbo media with 1.0 ml of
[100mg/ml] ampicillin.
4. Grow at 37°C until A600 = 0.6-0.7 (~3 hours)
5. At 20 min prior to induction add ethanol to Turbo media to final concentration of
1% for expression of heat shock and chaperone proteins. Add 10 ml of EtOH per
L culture.
6. Take 1 mL uninduced sample (for running gel later) spin down and freeze.
Resuspend in 200 ul 1 X SDS loading buffer
7. Induce culture with 1.0 ml 1M IPTG per 1 L to final concentration of 1.0 mM.
8. Incubate overnight shaking at 200-240 rpm at room temp - 28°C.
9. Take 1 mL induced sample (for running gel later); spin down and freeze.
Resuspend in 100 ul 1 x SDS
10. Collect cells by centrifugation at 2,500 rpm for 25 min.
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11. Weight pellets determine weight of cell paste.
12. Pellet can be frozen at this point.
13. Resuspend the cells (in lysis buffer) completely with no clumps by pipetting in
~46 ml per L cell culture.
14. Incubate on ice for 15-20 min.
15. Optional: Add 4 ml BPER per L and incubate additional 10 min on ice
16.

Sonicate (without inducing foaming) at moderate level in burst of 25 sec followed
by 25 sec on ice four times or until solution changes color and transparency.

17. Precipitate nucleic acids with 2 ml 4% PEI /L (polyethyleneimine) (per Liter of
culture). Add and mix well by shaking or vortexing lightly. This will produce a
visible white precipitate. (Additional guideline is 20-80 ul of 5% per ml crude).
18. Spin in pre-cooled ultracentrifuge tubes (Vti 50.2) at 21,000 rpm for 30 min at
4ºC
19. Remove supernatant and keep supernatant.
20. Syringe filter supernatant.
21. Take a 20 uL sample, add 20 uL 5x SDS sample buffer, and 60 ul dH20; vortex
heat at 90℃ for 10 min. vortex and reserve. As soluble extract sample.
22. Resuspend pellet in 5 ml Insoluble Extraction Solution for Insoluble and prepare
sample as per supernatant above. This is insoluble extract gel sample.
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Lysis Buffer pH 7.4 (s/b 7.5) 100 ml
Tris 20 mM (MW 121.14)

0.242 g

NaCl (MW 58.44) 0.500 M

2.92 g

ZnCl2 (MW 136.31) 10 uM

0.2 ml of 5 mM

Imidazole 20 mM (68.077 g/mol) .136 g
BME 5 mM
Ethylene Glycol 20 %

20.0 ml

HALT protease inhibitor (EDTA free) (10 ul/ml) 1.0 ml
Arginine (MW 174.2) 50 mM

0.87 g

Lysozyme ( Cf ~150 ug/ml in H20)

Insoluble Extract Solution (pH 8.0) 20 ml
Urea (mw 60.06) 8 M

9.61 grams

Na2HPO4 (mw 141.96) 100 mM

283.9 mg

Tris-Cl (121.14) 10 mM

24.2 mg

DTT 10 mM

- 247 -

Appendix 12 – Tat Chimera FPLC Purificiation Protocol with TEV Cleavage
Full Length MBP Tagged Protein Recovery


Turn on UV and warm up 15 min



Pump wash A and B with dH2O



Attach 2 - 5 ml HisTrap column columns in series.



Wash with dH2O 1 ml/min.



Equilibrate column with Tris binding buffer



Clean superloop by removing it from the system and disassembling it. Be sure
to refill the loop and push plunger to top before re-assembling.



Apply Sample: Load supernatant in lysis buffer into superloop and then inject
at 0.2 ml/min (2x5 ml column) during sample application switch to binding
buffer. (Make sure to stop the flow after injecting and returning to load)



Wash with 5 column volumes of binding buffer to remove unbound proteins
until no material appears in the effluent at flow rate of 0.4-0.6 ml/min (2x5
ml column)



Gradient elution with elution buffer (IMAC-B) for 30 min to 100% elution
buffer



Analyze fractions by SDS PAGE and/or Nanodrop and combine purest
fractions for cleavage.



Perform a buffer exchange on the full chimera back into binding buffer
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Pro-TEV Cleavage of HIS MBP Tag
1. Use a ratio of 1/50 grams of TEV per gram of protein to be cleaved.
2. Incubate the cleavage reaction overnight at ~14 ºC

CLEAN THE COLUMN AS PER DIRECTIONS BELOW BEFORE APPLYING
CLEAVAGE REACTION BACK ONTO COLUMN

Re-Application of Cleaved Protein to HisTrap Column for Removal of TEV and MBP
Tag
1. Apply the cleaved supernatant in binding buffer to the superloop and inject onto
column at a flow rate of 0.2 to 0.4 ml
2. Collect Fractions after 7 column volumes of buffer have passed.
3. Determine concentration with Nanodrop
4. Analyze the fractions by SDS PAGE
5. Store Fractions in 20% glycerol at -80 ºC
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Solutions:
Binding Buffer pH 7.4 1 L (1 X)
Tris 20 mM (MW 121.14)

2.42 g

NaCl 0.500 M (MW 58.44 g/mol)

29.22 g

ZnCl2 (MW 136.31) 10 uM

2.0 ml of 5 mM

Imidazole 20 mM (68.077 g/mol)

1.36 g

Sodium Azide 0.02%

0.20 g

BME 5 mM
Glycerol 5%

50 ml

Wash Buffer pH 7.4 1 L (1 X)
Tris 20 mM (MW 121.14)

2.42 g

NaCl 0.500 M (MW 58.44 g/mol)

29.22 g

ZnCl2 (MW 136.31) 10 uM

2.0 ml of 5 mM

Imidazole 60 mM (68.077 g/mol)

4.08 g

Sodium Azide 0.02%

0.20 g

BME 5 mM
Glycerol 5%

50 ml
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Elution Buffer pH 7.4 1 L 1 X
Tris 20 mM (MW 121.14)

2.42 g

NaCl 0.500 M (MW 58.44 g/mol)

29.22 g

ZnCl2 (MW 136.31) 1 uM

2.0 ml of 5 mM

Imidazole 500 mM (68.077 g/mol)

34.0 g

Sodium Azide 0.02%

0.20 g

BME 5 mM
Glycerol 5%

50 ml

Short Term Storage Buffer pH 7.4 1 L (1 X)
Tris 20 mM (MW 121.14)

2.42 g

Glycerol 5%

50 ml

NaCl 0.200 M (58.44 g/mol)

11.68 g

ZnCl2 (MW 136.31) 10 uM

2.0 ml of 5 mM

Sodium Azide 0.02%

0.20 g

BME 5 mM

Octet Buffer pH 7.4 1 L (1 X)
Tris 20 mM (MW 121.14)

2.42 g
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NaCl 0.200 M (58.44 g/mol)

11.68 g

ZnCl2 (MW 136.31) 10 uM

2.0 ml of 5 mM

Sodium Azide 0.02%

0.20 g

BME 5 mM

Column Maintenance:

Stripping and Recharging should be performed after 5 to 7 purifications. It should not be
necessary to perform this procedure after batch purification of the same protein

Stripping Buffer (GE) pH 7.4 100 ml
Sodium Phosphate

20 mM

Monosodium Phosphate, monohydrate

0.0623%

Disodium Phosphate, heptahydrate

0.4149%

NaCl (MW 58.44) 0.5 M

2.922 g

EDTA 50 mM

1. Wash with 5 to 10 volumes of stripping buffer
2. Wash with 5 to 10 volumes of binding buffer
3. Wash with 5 to 10 volumes of dH2O
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0623 g
0.415 g

4. Recharge column with 0.5 ml or 2.5 ml of 0.1 M NiSO4 in dH2O on on HisTrap HP 1
ml and 5 ml column respectively (other salts may also be used).
5. Wash with 5 column volumes of dH2O
6. Wash with 5 column volumes of binding buffer (to adjust pH before storage)
Column can be cleaned or stored at this point
Cleaning
1. Remove ionically bound proteins by washing the column with several column
volumes of 1.5 M NaCl; then wash the column with approximately 10 column
volumes of dH2O.
2. Remove precipitated proteins, hydrophobically bound proteins, and lipoproteins
by washing the column with 1M NaOH, contact time usually 1-2 hours (12 hours
or more for endotoxin removal). Then wash the column with approximately 10
column volumes of binding buffer, followed by 5-10 column volumes of dH2O.
3. Remove hydrophobically bound proteins, lipoproteins, and lipids by washing the
column with 5-10 column volumes 30% isopropanol for about 15-20 minutes.
Then wash the column with approximately 10 column volumes of dH2O.
Alternatively, wash the column with 2 column volumes of detergent in a basic or
acidic solution. Use, for example 0.1-0.5% nonionic detergent in 0.1 M acetic
acid, contact time 1-2 hours. After treatment, always remove residual detergent by
washing with at least 5 column volumes of 70% ethanol. Then wash the column
with approximately 10 column volumes of dH2O.

- 253 -

Storage
Ethanol 20%
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Appendix 13 - Expression and Purification of MBP-His6-TEV (S219V)-Arg5
Plasmid: pRK793
Extinction Coefficient: 32,290 M-1 cm-1
Adapted from (134):

Expression:
1. Inoculate 50-150 ml of LB broth containing 100 ug/ml ampicillin and 30 ug/ml
chloramphenicol in a 500 ml bafflebottom shake flask from a glycerol stock of
pRK793 transformed E. coli BL21 (DE3) CodonPlus-RIL cells (here I will
substitute Rosetta 2 (non-DE3 as per Novagen: do not produce T7 polymerase,
provide more tRNA and possess OmpT and Lon mutations eliminating proteases).
Place in an incubator and shake overnight at 250 rpm and 37ºC.
2. Add 25 ml of the saturated overnight culture to each 1 L of fresh LB broth
containing 100 ug/ml ampicillin, 30 ug/ml chloramphenicol and 0.2% glucose
(glucose should be added separately and not autoclaved in LB because it will
caramelize). Glucose (a/k/a dextrose) should be mixed slowly into a water
solution to prevent clumping. Filter sterilize the glucose solution before adding it
to LB. To ensure that there will be an adequate yield of pure protein at the end of
the process, Tropea et al. grow 4-6 L of cells at a time. (Here we attempt 3
separate 1 L cultures).
3. Shake the flasks at 250 rpm and 37ºC until the cells reach mid-log phase (OD600nm
~0.5); approximately 2 h.

- 255 -

4. Take a 1 ml uninduced sample, spin down, and resuspend in 100 ul 1 x SDS
loading buffer.
Heat sample at 95 ºC for 10 minutes, then spin down at 14,000 rpm for 5 minutes.
5. Shift the temperature to 30ºC and induce the culture(s) with IPTG at a final
concentration of 1 mM (5 ml of 200 mM IPTG stock solution per liter of culture).
Continue shaking at 250 rpm for 4-6 h. Place cultures at 4ºC.
6. Take a 1 ml induced sample, spin down, and resuspend in 100 ul 1 x SDS loading
buffer.
7. Recover the cells by centrifugation at 5,000 x g for 15 min at 4 ºC, and store at
-80ºC. A 6 L preparation yields 30-40 g of cell paste.

Purification:

His6-TEV(S219V)-Arg5 protease can be purified to homogeneity in two steps:
immobilized metal affinity chromatography (IMAC) using Ni-NTA resin followed by
size exclusion chromatography.

1. All procedures are performed at 4-8ºC. Thaw the cell paste from 6 L of culture on
ice and suspend in ice-cold cell lysis/IMAC equilibration buffer (10 ml/g cell
paste).
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2 L Cell Lysis/IMAC Equilibration buffer pH 8.0:

Sodium Phosphate Dibasic 50 mM

14.2 g

NaCl 200 mM

23.38 g

Glycerol 10 %

200 ml

Imidazole 25 mM

3.41 g

Add H2O to 1980 ml
Adjust pH with HCl
Adjust Volume to 2 L with H2O
Re-check pH
Filter through 0.22 um polyethersulfone membrane or equivalent
Store at 4ºC.

2. Lyse the cell suspension and measure the volume using a graduated cylinder. Add
polyethylenimine (PEI) to a final concentration of 0.1% (a 1:50 dilution of the 5%
stock solution at pH 8) and mix gently by inversion. Immediately centrifuge at
15,000 x g for 30 min and filter.

3. Apply the supernatant to two tandem 5 ml HisTrap HP columns equilibrated in
cell lysis/IMAC equilibration buffer. Wash the columns with equilibration buffer
until a stabile baseline is reached and then elute the bound His6-TEV(S219V)Arg5 with a linear gradient to 100% elution buffer over ten column volumes.
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Note: It may be helpful to split up the supernatant into several batches to
accommodate the 10 ml column volume. Also, make sure to sample flow through
to monitor efficiency, and run flow through over column a second time (after
eluting from it) if necessary to recover unbound TEV.

1 L IMAC Elution Buffer pH 8.0:

Sodium phosphate dibasic 50 mM

7.1 g

NaCl 200 mM

11.69 g

Glycerol 10%

100 ml

Imidazole 250 mM

17.02 g

Adjust volume to 750 ml with H2O
Adjust pH to 8.0 using HCl.
Adjust volume to 1 L with H2O
Let cool to room temperature
Re-check pH.
Filter through 0.22 um polyethersulfone membrane or equivalent.
Store at 4ºC.

4. Pool the peak fractions containing the protease and measure the volume. Add
EDTA to a final concentration of 2 mM (a 1:250 dilution of the 0.5 M EDTA, pH
8 stock solution) and mix well. Add DTT to a final concentration of 5 mM (1:200
dilution of the 1M DTT stock solution) and mix well.
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5. Concentrate the sample approximately tenfold using an Amicon ultrafiltration
YM10 membrane. Remove the precipitation by centrifugation at 5,000 x g for 10
min. Estimate the concentration of the partially pure protein solution
spectrophotometrically at 280 nm using a molar extinction coefficient of 32,290
M-1 cm-1. The desired concentration is between 5 and 10 mg/ml.
6. Filter through a 0.2 uM syringe filter, aliquot and flash freeze with liquid
nitrogen. Store at -80ºC.

- 259 -

Appendix 14 - Mass Spectrometry Sample Preparation Protocol

Solutions required for MALDI-TOF:
Acetonitrile
Trifluoroacetic Acid 0.1%
Sinapinic Acid 10 mg
TA solution – 1 Part Acetonitrile to 2 parts Trifluoroacetic Acid 0.1%

1. Prepare a 1.5 ml solution of 0.1% aqueous Trifluoroacetic acid from the ampules
(located in the crisper of the fridge in 215) by adding 1.5 ul of TFA to a total of
1.5 ml in H2O
2. Prepare a solution with 10 mg of Sinapinic Acid in 1 ml of TA solution
3. Allow the solution to dissolve for ~ 30 min then spin down the undissolved SA
briefly
4. Dilute the protein samples for your experiment to ~ 20 uM using TFA 0.1% (if
possible the target sample should be dialyzed into H2O PRIOR to the dilution
with TFA. However, due to precipitation Tris buffer was used in lieu of H20
PRIOR to dilution. Do not use PBS with MALDI-TOF.)
5. Mix the protein sample 1:1 with TA solution (ex.: 10 ul of ~20 uM sample + 10 ul
TA solution)
6. Spot 1 ul of each sample on to MALDI Sample Plate
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Appendix 15 - Western Blot Protocol

For use with the WesternBreeze® Chromogenic Immunodetection Kit
Anti-myc FITC antibody

1. Run SDS page gel with appropriate concentrations of protein, and 10 ul of the
Positope Control Protein in a control .
2. Take gel to iBlot with bottom, top, filter, and sponge.
3. Set up iBlot and run for 7-8 min.
4. Remove the gel and discard all but the membrane
5. Place membrane in a plastic container, cover, and add 10 ml of Invitrogen NC
Blocking Solution.
`
Blocking Solution:
Ultra filtered Water 14 ml
Blocker/Diluent (Part A) 4 ml
Blocker/Diluent (Part B) 2 ml
Total Volume

20 ml

6. Rock the membrane slowly for 30 min (~1 rev/sec).
7. Decant Blocking Solution
8. Rinse membrane with 20 ml dH2O and incubate in dH2O for 5 min; decant and
repeat.
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9. Add 10 ml of Primary Antibody Solution with 2 ul of FITC Myc Antibody
(1:5000 dilution). For nitrocellulose membranes the primary antibody solution is
the blocking solution above. Use remaining 10 ml. Incubate for one hour.
10. Wash membrane in 20 ml of Antibody Wash (Anti-Body Wash provided in kit
is 16 X be sure to dilute before use) for 5 minutes; decant and repeat 3 times.
11. Add 10 ml of Secondary Antibody Solution incubate for 30 min then decant.
12. Wash membrane in 20 ml of Antibody Wash for 5 minutes; decant and repeat 3
times.
13. Wash the membrane with 20 ml dH2O for 2 minutes, decant and repeat 2 times.
14. Add 5 ml of Chromogenic Substrate and incubate until purple bands appear on the
membrane (1-60 minutes).
15. Wash the membrane with 20 ml dH2O for 2 minutes, decant and repeat 2 times.
16. Allow the membrane to dry on filter paper in the open air.
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Appendix 16 – EMSA Sample Preparation

PAGE
Date:
Stain:

Non-Denaturing

6/9/2012
SYBR Gold RNA SYPRO Ruby Protein
Pre-Run
100 V > 1 hr
Gel %:
Native PAGE 12%
SNAP COOL RNA
Voltage:
100 V
85 ⁰C 5 min then Ice 5 min
Run Time
90 min
C initial
Spin down 2 sec then Incubate Samples 4 ⁰C for 15
V initial
Running Buffer:
1 X TBE
Sample Buffer:
Tris 20 mM Binding Buffer 5 mM BME 20 mM Imidazole 10 uM ZnCl2 5% Glycerol
Stock Protein Date:
Date of Gel:
Setup:
Component
Volume (ul)
Lane 1
SL3 Negative Control 500 nM
20
Lane 2
SL3-Ncp7 Positive Control 500 nM/10 uM
20
Lane 3
TAR WT 500 nM
20
Lane 4
TAR WT 500 nM Positive Control Tat Minimal 10 uM
20
Lane 5
TAR WT 500 nM hCyctT1-Tat no tag 10 uM
20
Lane 6
TAR WT 500 nM Full Length MBP tagged chimera 10 uM
20
Lane 7
TAR WT 500 nM MBP 10 uM
20
Lane 8
TAR WT 500 nM Positive Control Tat Minimal 5 uM
20
Lane 9
TAR WT 500 nM hCyctT1-Tat no tag 5 uM
20
Lane 10
TAR WT 500 nM Full Length MBP tagged chimera 5 uM
20
Lane 11
TAR WT 500 nM MBP 5 uM
20
Lane 12
Tat Minimal 10 uM
20
Lane 13
hCycT1 Tat no tag 10 uM
20
Lane 14
Full Length His MBP tagged chimera 10 uM
20
Lane 15
MBP 10 uM
20
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Tat minimal: 1.7 kDa
hCycT1-Tat: 17.481 kDa
Full Length Chimera 60.8 kDa
Ncp7 ~7 kDa

Sample/Lane # 1
RNA

SL3 Negative Control 500 nM
ID
SL3

Initial Conc.(M)
4.00E-06

Vol (uL)
2.5

Final Conc.(M)
5.00E-07

10x

2.0
2.0
11.5
1.0
1.0
20.0

1x

Vol (uL)
2.5
3.6
2.0
2.0
8.9
1.0
20.0

Final Conc.(M)
5.00E-07
1.00E-05
1x

Ck

Ck

Buffer
Tris 20 mM + 10 uM ZnCl2
Glycerol
50%
dH2O
Gel Pilot loading dye
BME

0.1
Total Volume

Sample/Lane # 2
RNA
Protein
Buffer
Glycerol
dH2O
BME

SL3-Ncp7 Positive Control 500 nM/10 uM
ID
SL3
Ncp7
Tris 20 mM + 10 uM ZnCl2
50%

Initial Conc.(M)
4.00E-06
5.50E-05
10x

0.1
Total Volume

Ck

Sample/Lane # 3

TAR WT 500 nM
ID

RNA

TAR WT

Initial Conc.(M)
4.00E-06

Vol (uL)
2.5

Final Conc.(M)
5.00E-07

Buffer
Glycerol
dH2O
BME

Tris 20 mM + 10 uM ZnCl2
50%

10X

2.0
2.0
12.5
1.0
20.0

1x

Vol (uL)
2.5
6.7
2.0
2.0
5.8
1.0
20.0

Final Conc.(M)
5.00E-07
1.00E-05
1x

Ck

Vol (uL)
2.5
6.7
2.0
2.0
5.8
1.0
20.0

Final Conc.(M)
5.00E-07
1.00E-05
1x

Ck

Vol (uL)
2.5
6.7
2.0
2.0
5.8
1.0
20.0

Final Conc.(M)
5.00E-07
1.00E-05
1x

Ck

Vol (uL)
2.5
4.2
2.0
2.0
8.3
1.0
20.0

Final Conc.(M)
5.00E-07
5.00E-06
1x

Ck

0.1
Total Volume

Sample/Lane # 4
RNA
Protein
Buffer
Glycerol
dH2O
BME

TAR WT 500 nM Positive Control Tat Minimal 10 uM
ID
Initial Conc.(M)
TAR WT
4.00E-06
Tat Minimal
3.00E-05
Tris 20 mM + 10 uM ZnCl2
10X
50%
0.1
Total Volume

Sample/Lane # 5
RNA
Protein
Buffer
Glycerol
dH2O
BME

TAR WT 500 nM hCyctT1-Tat no tag 10 uM
ID
TAR WT
hCycT1-Tat no tag
Tris 20 mM + 10 uM ZnCl2
50%

Initial Conc.(M)
4.00E-06
3.00E-05
10X

0.1
Total Volume

Sample/Lane # 6
RNA
Protein
Buffer
Glycerol
dH2O
BME

TAR WT 500 nM Full Length MBP tagged chimera 10 uM
ID
Initial Conc.(M)
TAR WT
4.00E-06
Full Length MBP tagged chimera
3.00E-05
Tris 20 mM + 10 uM ZnCl2
10X
50%
0.1
Total Volume

Sample/Lane # 7
RNA
Protein
Buffer
Glycerol
dH2O
BME

TAR WT 500 nM MBP 10 uM
ID
TAR WT
MBP
Tris 20 mM + 10 uM ZnCl2
50%

Initial Conc.(M)
4.00E-06
2.38E-05
10X

0.1
Total Volume
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Sample/Lane # 8
RNA
Protein
Buffer
Glycerol
dH2O
BME

TAR WT 500 nM Positive Control Tat Minimal 5 uM

ID
TAR WT
Tat Minimal
Tris 20 mM + 10 uM ZnCl2
50%

Initial Conc.(M)
4.00E-06
3.00E-05
10X

RNA
Protein
Buffer
Glycerol
dH2O
BME

RNA
Protein
Buffer
Glycerol
dH2O
BME

Sample/Lane # 11
RNA
Protein
Buffer
Glycerol
dH2O
BME

Final Conc.(M)
5.00E-07
5.00E-06
1x

20.0

TAR WT 500 nM hCyctT1-Tat no tag 5 uM
ID
Initial Conc.(M)
TAR WT
4.00E-06
hCycT1-Tat no tag
3.00E-05
Tris 20 mM + 10 uM ZnCl2
10X
50%
0.1
Total Volume

Sample/Lane # 10

2.5
3.3
2.0
2.0
9.2
1.0

0.1
Total Volume

Sample/Lane # 9

Vol (uL)

Vol (uL)
2.5
3.3
2.0
2.0
9.2
1.0
20.0

Final Conc.(M)
5.00E-07
5.00E-06
1x

TAR WT 500 nM Full Length MBP tagged chimera 5 uM
ID
Initial Conc.(M)
Vol (uL)
Final Conc.(M)
TAR WT
4.00E-06
2.5
5.00E-07
TAR WT 500 nM Full Length MBP tagged
3.00E-05
chimera 5 uM 6.7
1.00E-05
Tris 20 mM + 10 uM ZnCl2
10X
2.0
1x
50%
2.0
5.8
0.1
1.0
Total Volume
20.0
TAR WT 500 nM MBP 5 uM
ID
TAR WT
MBP
Tris 20 mM + 10 uM ZnCl2
50%

Initial Conc.(M)
4.00E-06
2.38E-05
10X

0.1
Total Volume
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Vol (uL)
2.5
8.4
2.0
2.0
4.1
1.0
20.0

Final Conc.(M)
5.00E-07
1.00E-05
1x

Sample/Lane # 12

Protein
Buffer
Glycerol
dH2O
BME

Tat Minimal 10 uM
ID

Initial Conc.(M)

Tat Minimal 10 uM
Tris 20 mM + 10 uM ZnCl2
50%

3.00E-05
10X

0.1
Total Volume

Sample/Lane # 13

Protein
Buffer
Glycerol
dH2O
BME

hCycT1 Tat no tag 10 uM
ID

Initial Conc.(M)

hCycT1-Tat no tag
Tris 20 mM + 10 uM ZnCl2
50%

3.00E-05
10X

0.1
Total Volume

Sample/Lane # 14

Protein
Buffer
Glycerol
dH2O
BME

Full Length His MBP tagged chimera 10 uM
ID
Initial Conc.(M)
Full Length MBP
Tris 20 mM + 10 uM ZnCl2
50%

3.00E-05
10X

0.1
Total Volume

Sample/Lane # 15

6.7
2.0
2.0
8.3
1.0
20.0

Vol (uL)
6.7
2.0
2.0
8.3
1.0
20.0

Vol (uL)
6.7
2.0
2.0
8.3
1.0
20.0

Final Conc.(M)
1.00E-05
1x

Final Conc.(M)
1.00E-05
1x

Final Conc.(M)
1.00E-05
1x

MBP 10 uM
ID

Protein
Buffer
Glycerol
dH2O
BME

Vol (uL)

Initial Conc.(M)

MBP 10 uM
Tris 20 mM + 10 uM ZnCl2
50%

2.38E-05
10X

0.1
Total Volume
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Vol (uL)
8.4
2.0
2.0
6.6
1.0
20.0

Final Conc.(M)
1.00E-05
1x

Appendix 17 - EMSA Protocol

Sample Preparation:
Snap Cool RNA: ~3 min @ 90° C, vortex, incubate on ice.
Pre-run gel @ 100 V for ~ 30 min to 1 hour 30 min 4 ⁰ C.
TBE running buffer (1 x) or other
Run gel @ 100 V
Actual running time: ~1:30 min @ 4 ⁰ C

12% Acrylamide Native Gel
30 ml Total Volume (~ 2 gels)
9 ml Accugel 40%
3 ml 10X TBE
18 ml dH2O
12 µl TEMED
300 µl APS 20% (.2 g/ml)

10 X TBE electrophoresis buffer
Tris Base 108g [Cf] 890 mM
Boric Acid 55 g [Cf] 890 mM
dH2O 960 ml
EDTA [0.5 M] 40 ml
pH 8.0 [Cf] 20 mM
- 267 -

300 µl APS 20% (.2 g/ml)

Nucleic Acid Stain:
Prepare 1X SYBR Gold gel stain:
5 µl SYBR Gold (50,000X) in
50 ml TBE buffer

Remove gel from cast and stain with 1 X staining solution, and gentle agitation for 10-40
min. in a plastic container protected from light.
Wash gel two times in 150 ml dH2O for 10 sec.
Visualize nucleic acid by UV transillumination, take a picture.

Protein Stain:
Quick Protocol

Fix

Reagent

Basic Protocol

Rapid Protocol

50% Methanol,

100 mL

100 ml, 15 min

7% Acetic acid

30 min
100 mL

100 ml, 15 min

30 min
Stain

SYPRO

60 mL

60 ml

Ruby gel

overnight

Microwave 30 sec,

Stain

agitate 30 sec,
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microwave 30 sec,
agitate 23 min
Wash

10% Methanol,

100 mL

7% Acetic acid

30 min

100 mL, 30 min

Hands-on Time

10 min

15 min

Total time

~18 hours

90 minutes

Fix
After electrophoresis, place the gel into a clean container with 100 mL of fix solution and
agitate on an orbital shaker for 30 minutes. Repeat once more with fresh fix solution.
Pour off the used fix solution.

Stain
Add 60 mL of SYPRO Ruby gel stain. Agitate on an orbital shaker overnight.

Wash
Transfer the gel to a clean container and wash in 100 mL of wash solution for 30 minutes.
Transfer step helps minimize background staining irregularities and stain speckles on the
gel. Before imaging rinse the gel in ultrapure water a minimum of two times for 5
minutes to prevent possible corrosive damage to the imager. Visualize protein with the
UV transilluminator; take a picture.
Overlay nucleic acid and protein images with Photoshop.
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Appendix 18 - Novagen Rosetta B Gami Transformation Protocol

Materials:

1. Novagen Rosetta B Gami non-DE3 non-pLys competent cells stored at -80°C
2. Chimera plasmid DNA, dilute to 10ng/μl
3. LB Media
4. LB/AMP/Chl plates

Procedure:
1. Add 1 μl of plasmid (10 ng) to a 200 μl PCR tube, let it chill on ice. Use 1 μl of
pUC18 control DNA (0.1 ng/μl) as positive control Use 1 μl of nuclease free H2O
as negative control
2. Thaw competent cells on ice. Add 20ul of Rosetta Gami B competent cells to
each tube
3. Incubate the mixture on ice for 5 minutes
4. Heat-shock the cell mixture at 42°C for 30 seconds
5. Immediately put tubes back on ice, incubate for 2 minutes
6. Add 80 μl of room temperature SOC, gently mix
7. Recover for 1 hour with light shaking at 37°C incubator for 1 hour
8. Spread 50 μl of the recovered cells onto each pre-warmed LB/AMP/Chl plate
9.

Grow plates at 37°C overnight

10. Pick a single colony from the plate and inoculate a 5-ml LB/AMP/Chl liquid
culture

- 270 -

11. Grow at 37°C overnight, shaking at 220~250rpm
12. Add 50 % glycerol to make a permanent glycerol storage culture
13. Store the frozen culture at -80°C.
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Appendix 19 - Double Colony Selection Expression Level Analysis

1. Streak fresh LB+Amp+Chl plate with old glycerol stock for control
2. Select and mark 3 to 4 different freshly transformed colonies from LB plates and
one colony from glycerol stock plate to inoculate two falcon tubes in 2 ml LB
(can also try turbo) for each colony making a total of 8 tubes
3. Incubate tubes at 37°C until OD600 = 2-3
4. Spin down tubes at 1500 g for 5 min
5. Resuspend the pellets in 5 mL of minimal M9 medium to OD600 between 0.07 and
0.1
6. Save 100 ul from control tube prior to induction
7. Induce each tube at OD600 = 1.0 Induce one tube for each colony with 1.0 mM
IPTG
8. Incubate overnight at 28°C
9. Take OD600 of final culture
10. Collect 250 uL from each tube and spin at 3300g for 5-10 minutes
11. Prepare SDS PAGE sample by resuspending the pellets in 50 ul of 2X SDS
loading buffer
12. Incubate samples for 20 minutes at 70°C and spin down at maximum speed for 20
minutes prior to loading
13. Analyze gel and choose highest protein yielding colony
14. Grow high yield colony O/N in LB or Turbo
15. Plate high yield culture on LB + amp + chl plate
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16. Repeat steps 1 through 13
17. Prepare Glycerol Stock for second high yielding double-colony selected culture
and store at -80°C

Sivashanmugam et al. Optimized high-cell density IPTG-Induction Minimal Medium 1 L
Na2HPO4·7H2O 50 mM (MW 268.07)

13.4 g

KH2PO4 (pH 8.0-8.2) 25 mM (MW 136.1 g)

3.4 g

NaCl 10 mM (MW 58.44)

0.6 g

NH4Cl 0.1 % (MW 53.49)

1.0 g

AUTOCLAVE HERE BEFORE ADDITION OF REMAINING REAGENTS
MgSO4 5 mM (MW 120.36)

0.6 g or 5 ml of 1 M

CaCl2 0.2 mM (MW 110.98)

0.2 g or 1 ml of 0.2 M

Glucose 1.0 %

25.0 ml of 40 %

ZnCl2 0.1 mM

0.5 ml of 0.2 M

Trace Metals

2.5 ml of 1000x Trace Metals

Vitamin Mix

10.0 ml of 100x Vitamin Mix
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Appendix 20 - Expression of Double Colony Selected Mutant

1. Inoculate 1L of turbo media in baffle bottom flask with highest yielding colony
2. Grow at 37°C at 240 rpm until OD600 ~5
3. Save 1 ml uninduced sample and prepare with approximately 500 ul 1X SDS
4. Collect cells by spinning down at 1500 g for 5 min
5. Resuspend cells in 1L of minimal media prepared as above
6. Allow cells to recuperate for 1-1.5 hours at 37°C
7. Add 1% EtOH 20-30 min prior to induction
8. Induce with 1 mM IPTG
9. Grow 24-48 hours
10. Purify as per hCycT1-Tat chimera in rich media
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